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ABSTRACT 
BACKGROUND: Dementia is a neurodegenerative disease of the brain associated with 
cognitive and memory impairments. Despite recognition of several types of dementia, 
the Alzheimer type is the most studied and understood. The cholinergic theory of 
Alzheimer's disease led to the development of licensed drugs based on the inhibition of 
the enzyme acetylcholinesterase. Extracts of Salvia (sage) species have been reported to 
have cholinergic activities relevant to the treatment of Alzheimer's disease. 
AIMS: Lack of information on a chemical fingerprint of the extracts responsible for 
inhibition of the enzymes butyrylcholinesterase and acetylcholinesterase prompted this 
in vitro investigation of sage species for anti-cholinesterase activity. Cholinergic 
receptor binding activity, inhibition of ß-secretase, and a pro-inflammatory cytokine 
suppressive activity of extracts of sage species were also studied as relevant treatment 
targets. 
METHODS: The extracts were obtained by methods of supercritical fluid extraction 
using 1,1,1,2-tetrafluoroethane (Phytosol A) and steam distillation. Dose-dependant 
inhibition of human cholinesterases by the extracts and constituents was determined 
using the method of Ellman, while inhibition of ß-secretase via a fluorometric method. 
The nicotinic acetylcholine receptors binding activity was measured as an amount of 
[3H]-nicotine displaced from human acetylcholine receptors, whereas the muscarinic 
activity was assessed using the displacement of [3H]-scopolamine. Determination of 
interleukin 8 inhibitory activity by the extracts was performed via a quantitative 
sandwich enzyme immunoassay using a commercially available kit. 
RESULTS: Inhibition of butyrylcholinesterase by the Phytosol extracts of S. apiana, S. 
fruticosa and S. officinalis var. purpurea was non-competitive. In contrast, inhibition of 
acetylcholinesterase by S. officinalis var. purpurea oil was competitive. S. corrugata 
extract was the most potent inhibitor of acetylcholinesterase with an IC50 value of 
0.009±0.004 mg ml", while S. officinalis var. purpurea oil was the most active inhibitor 
of butyrylcholinesterase with an IC50 value of 0.015±0.004 mg ml''. Time dependent 
increase in inhibition of butyrylcholinesterase by steam distilled oils of S. fruticosa and 
S. officinalis var. "purpurea" was also evident. IC50 values decreased from 0.15±0.007 
and 0.14±0.007 mg ml-1 with 5 minutes to 0.035±0.016 and 0.06±0.018 mg ml-1 with 90 
minutes incubation time respectively. Phytosol A extracts were more potent than steam 
distilled oils with respect to anti-cholinesterase activity. Minor synergy in inhibition of 
bovine acetylcholinesterase was apparent in 1,8-cineole/a-pinene and 1,8- 
cineole/caryophyllene oxide combinations, whereas a combination of camphor and 1,8- 
cineole was antagonistic. Oil of S. apiana displaced [3H]-nicotine from human nicotinic 
acetylcholine receptors and [3H]-scopolamine from muscarinic acetylcholine receptors 
in a dose dependent manner with IC50 values of 0.02 mg ml" and IC50 0.1 mg ml" 
respectively. This oil also showed a modest suppression of interleukin 8 secretions from 
goblet cells. None of the tested oils and constituents had anti-ß secretase activity. 
CONCLUSION: These findings demonstrate that the cholinergic activity of the extracts 
results from a complex interaction between their constituents. Thus, inhibition of 
acetylcholinesterase is mainly due to the activity of the main constituents with some 
degree of synergy, whereas anti-butyrylcholinesterase activity is down to major 
synergistic interactions and identification of a chemical fingerprint responsible for the 
overall activity is therefore challenging. A synergistic combination of extracts or their 
standardised fractions with multiple activities is may be a candidate for clinical trials in 
Alzheimer's disease. 
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Chapter 1. General Introduction 
Chapter 1. General Introduction 
1.1. Dementia 
I. I. I. Definition 
Dementia is an acquired impairment of intellectual and memory functioning caused by 
disease of the brain, which is not associated with disturbances in the level of 
consciousness (Friedland and Wilcock, 2000). The term is not used in reference to 
individuals with mental retardation who have not acquired an adult level of intellectual 
development. A practical approach to the diagnosis of dementia begins with the clinical 
recognition of a progressive decline in memory as well as defects in other mental 
abilities such as abstract thinking, judgement, personality, language, praxis, and 
visuospatial skills. The deficits must be of sufficient magnitude to interfere significantly 
with work or social activities (American Psychiatric Association, 1994 (DSM-IV)). 
Dementia may have onset before the age of 65 years, known as presenile dementia, or 
after the age of 65 years, known as senile dementia. It is inappropriate to use the terms 
dementia, senile dementia, or presenile dementia as a final diagnosis in the individual 
patient, as they are simply symptomatic classifications similar to the terms headache or 
seizure disorders. It is now recognised that the disease can affect people of any adult age, 
although it is more common in the older age groups (Friedland and Wilcock, 2000). 
The most common forms of dementia are Alzheimer's disease (AD), dementia with 
Lewy bodies (DLB), Vascular dementia (Val)), frontotemporal dementia (FTD), and 
dementia secondary to disease, such as AIDS dementia (Friedland and Wilcock, 2000; 
1 
Chapter 1. General Introduction 
Ritchie and Lovestone, 2002). There are many other forms of dementia which are 
described in detail elsewhere (Bums and Levy, 1994). 
1.1.2. Clinical and pathological diagnosis 
1.1.2.1 Alzheimer's disease 
Alois Alzheimer (1907) reported a case of presenile dementia in a 51-year-old woman 
know as Auguste D. The author demonstrated the neuritic plaques (Figure 1.1) and 
neurofibrillary tangles (Figure 1.2. ) in the brain which today are the diagnostic markers 
of the disease that now carries his name. Neuritic plaques are microscopic foci of extra 
cellular amyloid deposition and associated axonal and dendritic injury, found in large 
numbers in the limbic and associated cortices (Dickson, 1997). Such plaques contain 
extracellular deposits of amyloid ß-protein (Aß) that occur as star-shaped masses of 
amyloid fibrils. Much of the fibrillar Aß found in the neuritic plaques is the species 
ending at amino acid 42 (Aß42), a hydrophobic form that is particular prone to 
aggregation (Selkoe, 2001). Neurofibrillary tangles (NFTs) are intracellular bundles of 
abnormal fibres comprising of paired filaments composed of hyperphosphorylated tau 
proteins and contain no Aß deposits and neuritic plaques (Selkoe, 2001). AD is 
responsible for 50 to 60 per cent of cases of dementia in adults in the United States and 
Europe (Friedland and Wilcock, 2000). 
2 
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Figure 1.2. Silver-stained Alzheimer 
neuritic plaque. neurofibrillary tangles in cerebral cortex 
The NINCDS/ADRDA standardised criteria (McKhann et al., 1984) for the clinical 
diagnosis of AD, have improved diagnostic accuracy, and allowed comparison of results 
from therapeutic trials and other clinical investigations. The criteria establish probable, 
possible and definite AD. The NINCDS/ADRDA criteria for probable AD are 
equivalent to those described in DSM-IV. The reliability and validity of the 
NINCDS/ADRDA criteria for probable AD have been reported (Blacker et al., 1995) 
and were adopted by the Consortium to Establish a registry for Alzheimer's Disease 
(CERAD) for its standardisation and reliability studies of clinical, neuropsychological 
and neuropathological assessments of the disease (Morris et al., 1989; Mirra et al., 
1991). McLean et a!. (1997) have agreed with the guidelines concerning CERAD 
criteria but recommended that immunohistochemistry for beta amyloid (Aß) and tau- 
reactive neurofibrillary changes, in addition to hematoxylin and eosin stains, should 
become the basis for histological diagnosis. Marcon et at. (1997) have noted that for the 
post-mortem diagnosis of AD, both Aß immunoreactivity and hyperphosphorylated tau 
protein immunoreactivity have to be found in the neocortex. 
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Salmon et al. (2002) used Mini-Mental State Examination (MMSE) (Folstein MF et al., 
1975) scores of less than 24 to ascertain the accuracy of the clinical diagnosis of 
individuals with AD. The authors conclude that when comprehensive assessment 
procedures are employed, AD can be accurately diagnosed in mildly impaired 
individuals with the dementia reassessment at least one year later to verify the diagnosis. 
Comparable rates of clinical diagnostic accuracy have been shown by Berg et al. (1998). 
The authors studied differences between subjects with AD and cognitively intact control 
subjects, with respect to brain histological markers of AD. They conclude: (1) that the 
neurocortical neurofibrillary tangles, and to a less degree neurocortical total cored 
plaque densities are related to dementia severity in AD, but biological and 
methodological variability are important, and better histological or biochemical markers 
should be sought for this purpose, (2) Plaque-predominant AD may represent a 
developmental stage in AD, (3) An effect of Apolipoprotein E epsilon 4 as a risk factor 
for AD on senile plaque density is variable and complex, being confounded with age, 
dementia severity and methodological differences, (4) Clinical diagnostic criteria for 
AD, even in the very mild stage, and senile plaque-based neuropathological criteria for 
AD are highly accurate. 
Braak and Braak, (1991) found that the pattern of senile plaque related amyloid 
deposition was subject to too much inter-individual variation and that analysis of 
amyloid in the neocortex was of only limited value in staging AD-related pathological 
changes. They also defined six developmental stages of neurofibrillary pathology during 
AD. The first four, limbic stages, correspond to clinically incipient AD whereas the last 
two, iscortical stages, reveal frank dementia. 
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A conference on diagnostic criteria for AD in 1997 (Terry et al., 1999) following a 
workshop sponsored by the National Institute of Aging and the Ronald and Nancy 
Reagan Institute of the Alzheimer's Association resulted in consensus recommendations 
for improving the neuropathological criteria for the post-mortem diagnosis of AD. The 
conferees concluded that for the routine diagnosis of AD in the post-mortem brain, the 
semi-quantitative method of CERAD (Mirra et al.. 1991) in correlation with the 
Braaks's six stages (Braak and Braak, 1991) should be used. 
ALZHEINMEWS 
Figure 1.3. Normal and demented human brains. The frontal lobe (boxed) responsible 
for reasoning, judgment, personality, movement and speech is shrunk in AD sufferers 
1.1.2.2. Dementia with Lewy bodies 
Friedrich Lewy first described cytoplasmic inclusions in neurons in cases of 
parkinsonism in 1912 (Lewy, 1912) but it was not until 1961 that Okazaki et al. (1961) 
discussed their possible role in association with dementia and 1984 that Kosaka et al. 
(1984) linked the presence of cortical Lewy bodies (Figure 1.4. ) to dementia. Lewy 
bodies (inclusions) in pigmented neurons of the brain-stem appear as dense eosinophilic 
cores surrounded by less densely staining peripheral halos. Neocortical Lewy bodies are 
more subtle and appear in the perikarva of pyramidal neurons in layers V and VI as 
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more subtle and appear in the perikarya of pyramidal neurons in layers V and VI as 
spheric, homogeneous, slightly eosinophilic inclusions lacking a concentric laminar 
structure (Hansen, 1999). Dementia with Lewy bodies (DLB) accounts for 15 to 25% of 
the cognitively impaired elderly, many of whom have received diagnoses of AD during 
life (McKeith et al., 1996). 
r 
" 
g 
Figure 1.4. Lewy bodies 
In 1996, an international consortium in Newcastle upon Tyne published consensus 
guidelines for the clinical and pathological diagnosis DLB (McKeith et al., 1996). For 
the pathological diagnosis, brainstem or cortical Lewy bodies are the only features 
considered essential, although Lewy neuntes, Alzheimer's pathology, and spongiform 
changes may also be seen. Later using the consensus criteria for the diagnosis of DLB 
McKeith et al. (2000) reported that 24 of 29 autopsy-confirmed cases were correctly 
identified antemortem with a sensitivity rate of 0.83 and a specificity of 0.91. These 
finding compared favourably with the corresponding sensitivity and specificity rates for 
Nv kCDS-ADRDh aragnosýs of AD, 0. %I and 0.83 respectively. Although, Lopez et at. 
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low sensitivity (30.7 %) and high specificity (100%) when Lewy bodies coexist with 
pathological abnormalities of AD. McKeith et al. (2003) have also reported in a review 
that although the diagnostic specificity of the criteria is high (range 79-100%, mean 
92%), sensitivity is lower (range 0-83%, mean 49%). The authors conclude that 
improved methods of case detection are therefore required. Lippa and McKeith (2003) 
also reviewed DLB cases with AD overlap pathology, concluding that there is a need 
for continuation to refine clinically applicable, scientifically founded diagnostic criteria 
for DLB that will satisfy clinicians, pathologists, classifiers, regulatory authorities 
including the USA Food and Drug Administration, and pharmaceutical companies 
wishing to tackle this problematic therapy area. 
1.1.2.3. Vascular dementia 
Dementia may have vascular causes (Hachinski, 1992). In Western countries vascular 
dementia (VaD) is responsible for up to 15 to 20% of cases. In another 10 to 15% of 
cases, vascular dementia is found in coexistence with AD (Friedland and Wilcock, 
2000). Many forms of VaD have been described (Fortette et al., 1995): multi-infarct 
dementia, lacunar dementia, Binswanger's subcortical encephalopathy, cerebral amyloid 
angiopathy, white matter lesions associated with dementias, single infarct dementia, 
dementia linked to hypoperfusion and haemorrhagic dementia. These make diagnosis of 
VaD difficult. 
Multiple infarcts (Scheinberg, 1988) and ischaemic white-matter lesions (Roman, 1987; 
Scheinberg, 1988) are suggested vascular causes of dementia, both of which have been 
associated with hypertension (Strandgaard and Paulson, 1994). Hypertension is a 
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powerful risk factor for all forms of VaD with the incidence rates rate ranges from 16 
per 1000 person-years (Fortette et al., 1995). 
Vascular factors may also have a role in late-onset AD, in which white-matter lesions 
often occur (Brun and Englund, 1986; Blennow et al., 1991). Extensive white matter 
lesions may affect cognitive function through a loss of axons, producing a functional 
disconnection of the cortex. The latter can lead to significant reductions in blood flow 
and metabolism in frontal, temporal and parietal cortical areas, which do not show any 
structural damage. 
Until recently, the diagnosis of VaD was made with the assistance of the Hachinski 
Ischaemia Scale (Hachinski et al., 1975) which had its poor rate reliability (O'Neill et 
al., 1995). Most recently, two newer scales have been proposed. These are the State of 
California Alzheimer's Disease Diagnostic and Treatment Centres (ADDTC) criteria 
(Chui et al., 1992) and the NINDS-AIREN criteria (Roman et al., 1993). They require 
the presence of dementia and cerebrovascular disease, and a relationship between the 
two, for example the onset of dementia shortly after a stroke. Despite these 
improvements, there are reports (Holmes et al., 1999; Gold et al., 2002; Knopman et al., 
2003) highlighting problems of imperfect sensitivity and validity of the disease 
diagnostic criteria. As with DLB improved methods of VaD detection are also required. 
1.1.2.4. Mild cognitive impairment and age-related cognitive decline 
The term "mild cognitive impairment" (MCI) has been suggested to describe a 
condition that may or may not eventually lead to dementia (International Statistical 
Classification of Disease, 10th rev. ). It also refers to the clinical state of individuals 
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whose memory is impaired but are otherwise functioning well and do not meet clinical 
criteria for dementia (Flicker et al., 1991; Petersen et al., 1999; Ritchie and Touchon, 
2000). Preliminary studies suggest that the rate of progression to dementia is about 25% 
at two years (Tierney et al., 1996) and perhaps 40% at three years (Grundman et al., 
1996). There are also reports indicating that individuals with MCI are not only at risk 
for developing AD but have neuropathologic AD (Bozoki et al., 2001; Morris et al., 
2001; Ritchie et al., 2001). These results suggest that, for many patients, MCI may 
represent the initial clinical presentation of AD. A current challenge is to distinguish 
those patients with MCI who eventually will progress in dementia severity and thus 
have a high probability of underlying AD from those who do not. Thus, the 
measurement of neuroimaging (Wolf et al., 2003), the ratio of amyloid precursor 
protein (APP) (Padovani et al., 2002) and cerebrospinal fluid (CSF) (Andersen et al., 
2003) may be useful markers for the identification of preclinical AD in patients with 
MCI. 
Age-related cognitive decline is characterised by memory loss without other cognitive 
problems. If memory deficit is present but the other diagnostic criteria for dementia are 
not, a diagnosis other than dementia should be considered (American Psychiatric 
Association, 1994). A disorder similar to age related cognitive decline is described as 
"mild cognitive disorder" in the World Health Organisations ICD-10 classification 
(International Statistical Classification of Disease, 10th rev. ). According to DSM-IV, 
age-related cognitive decline represents cognitive changes that are within normal limits 
given the person's age. Age-associated cognitive decline is characterised by a decline in 
only one of the five neuropsychologic domains associated with dementia: memory and 
learning: attention and concentration; thinking; language; and visuospatial functioning 
(Levy, 1994). According to the International Psychogeriatric Association (Levy, 1994) 
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additional criteria should be met to make a diagnosis of age-related cognitive decline. 
These criteria include the report of cognitive decline from a reliable source, a gradual 
onset of at least six months duration and the Mini-Mental State Examination test 
(MMSE). 
1.1.3. Epidemiology and incidence of dementia 
Epidemiological studies require accurate identification of dementia cases. An agreement 
on acceptance diagnostic criteria for identifying cases of dementia was developed in the 
1980s based on the principals introduced in the third edition of the American Psychiatry 
Association's (DSM III) and its later revisions (DSM III-R and DSM IV) 
Ueda et al. (1992) reported that in Japan VaD represents over 50% of demential, 
whereas in another Japanese study (Asada et al., 1996) of centenaries, 70% were found 
to have dementia, of whom AD was present in 76%. In Europe and North America, 
Alzheimer's disease is estimated to be more common than vascular dementia. (Ritchie 
and Lovestone, 2002). According to Ratnavalli et al. (2002) there are at least 3500 
patients with frontotemporal dementia in the United Kingdom and more than 10.000 in 
the United States. The mean age of the onset of FTD was 52.8 years and it also appears 
to be more common in men. 
In the United States, for healthy people between the age of 75 and 85, new cases of 
Alzheimer's disease are as common as myocardial infarction and more common than 
stroke (Katzman et al., 1989). The study by Evans et al. (1989) of the older population 
of East Boston, US, concluded that over 45% of those aged 85 years or more suffered 
from AD. This figure was confirmed by a Swedish study (Skoog et al., 1993) where 
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44% of a representative sample of 494 85-years-olds were considered to have AD. 
Interestingly, 47% received a diagnosis of vascular dementia. 
In a first Shanghai study (Zhang et al., 1990) it was reported that Alzheimer's disease 
accounted for 65% of all dementias. In the second (Zhang et al., 1998), based on DSM 
III criteria, impact of age and education, a total of 1970 non-demented subjects who 
were the age of 65 years or older in 1987 were re-surveyed after five years, of whom 
114 new cases of dementia were identified. This shows that with each age increase of 
five years for those aged 65 years and over, the likelihood of developing dementia 
increases nearly 74%. The incidence of dementia in total was 1.15% annually, 0.98% 
for males and 1.27% for females. The incidence for Alzheimer's disease, vascular 
dementia and dementia by other causes was 0.74,0.33 and 0.08%, respectively. The 
study also showed that incidence of dementia in the Shanghai cohort is similar to that 
from other countries. Education had a protective effect on the development of dementia. 
The highest rate of 2.02% was found in illiterate individuals. 
Jorm et al. (1987) reported national differences in the relative prevalence of AD and 
multi-infarct dementia (MID). MID was more common in Japanese and Russian studies 
rather than in Finnish and American. They also found that across the studies, AD was 
more common in women but MID in men. 
Hofman et al. (1991) showed that the overall European prevalence of dementia for the 
five-year age groups from 60 to 94 years, were 1.0,1.4,4.1,5.7,13.0,21.6 and 32.2%, 
respectively. In subjects under 75 years the prevalence was slightly higher in men than 
in women; in those aged 75 years or over the prevalence was higher in women. The 
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prevalence figures nearly doubled with every five years of increase in age. 
Evidence suggests that AD may be relatively rare in the Indian sub-continent. Chandra 
et al. (1998) conducted a study to determine the prevalence of AD and other dementias 
in a rural elderly Hindi-speaking population in Ballabgarh in northern India. The 
authors performed a community survey of a cohort of 5,126 individuals aged 55 years 
and older, 73.3% of whom were illiterate. It was found that an overall prevalence rate of 
0.84% in the population aged 55 years and older and 1.36% in aged 65 years and older. 
The overall prevalence rate for AD was 0.62% in the population aged 55 and over and 
1.07% in the population aged 65 and over. Greater age was associated significantly with 
higher prevalence of both AD and all dementias. The authors concluded that the 
prevalence of AD and other dementias was low even with the increased age and was not 
associated with gender or literacy. 
Results from community surveys and autopsy reports (Osuntokun et al., 1992) suggest 
that Alzheimer's disease does not occur in Nigerians. In the survey of 932 elderly 
Nigerians, no subject with dementia as defined by DSM-III-R was found, although there 
was significant decline of cognition with the increasing age. 
Differences in rates of dementia between developing and developed countries are 
difficult to explain, but might be attributable partly to difficulties in dementia diagnosis 
in areas with high rates of illiteracy, and survival bias due to high death rates at all ages 
(Ritchie and Lovestone, 2002). But if this is not the case, it would raise the possibility 
that dietary and/or life style factors may be protective. For example, a widely spread 
habit of chewing Areca catechu (betel nut) in Asia (Yoganathan, 2002) may have a 
protective effect against AD. Betel nut contains arecoline, muscarinic M1 receptor 
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agonist (Ghelardini et al., 2001) and according to Fisher et al. (2003) an M1 agonist 
decreases brain Aß and increases cognition in subjects with AD. 
Studies of risk factors for vascular dementia, the second common cause of dementia, are 
fewer in number than those for Alzheimer's disease, principally because of difficulties 
with the definition of research criteria for this group of disorders (Ritchie and Lovestone, 
2002). In Europe, estimates of vascular dementia prevalence thus vary widely from 10- 
50% of all cases of dementia (Rocca et al., 1991). Main risk factors identified for the 
disease are age, male sex, hypertension, myocardial infarction, coronary heart disease, 
diabetes, generalised atherosclerosis, smoking, high lipid concentrations, and a history 
of stroke (Skoog, 1998; Erkinjuntti, 2000). 
These findings may represent the changing frequencies of dementia and its causes with 
increasing age, but may include biases related different diagnostic criteria and also 
cultural or population differences. Nevertheless, because of the rapid aging of the 
world's population and declining incidence of heart disease and stroke (Friedland and 
Wilcock, 2000), it is clear that dementing illnesses, which already have a devastating 
impact on health-care services (Andersen et al., 2003), may become an increasingly 
important problem in the future. 
1.2. Cholinergic systems 
1.2.1. Normal brain 
1.2.1.1 Cholinergic neurons and axons 
The mammalian brain contains several groups of cholinergic (choline acetyltransferase 
(ChAT)-positive) neurons located within the basal forebrain, striatum and brainstem 
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(Nagai et al., 1983; Mesulam & Geula, 1988; Mesulam et al., 1989; Geula & Mesulam, 
1999). 
The basal forebrain cholinergic system is comprised of the nucleus basalis of Meynert 
(nbM). the horizontal and vertical diagonal bands of Broca (HDBB and VDBB, 
respectively), and the medial septal nucleus (Mesulam, 1996). This neuronal system 
provides the primary cholinergic innervations to hippocampus, limbic neocortex and in 
addition to the thalamus. The nucleus basalis of Meynert provides cholinergic 
innervations to the arnygdala and the rest of the cortical mantle. Neurons situated in the 
medial septal nucleus innervate predominantly the hippocampus, whereas those of the 
vertical and horizontal limb of diagonal band of Broca project into the anterior cingulate 
cortex and olfactory bulb, respectively (Mesulam, 1996). 
Figure 1.5. Human brain cholinergic systems 
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Neuroanatomical identification of cholinergic neurons occurs through the 
immunohistochemical demonstration of ChAT, the enzyme which synthesises the 
neurotransmitter acetylcholine (ACh) (Figure 1.6). A neuron is said to be cholinergic 
when it synthesizes ACh for the purpose of neurotransmission. Non-cholinergic or 
cholinoceptive neurons in the brain, which are ChAT-negative, include the 
glutamatergic. gabaergic. dopaminergic. histaminergic, serotonergic, and noradrenergic 
neurons (Mesulam, 2000), as well as many neuropeptides (personal communication 
with Professor E. K. Perry) 
o 
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Figure 1.6. Acetylcholine (C7H16NO2) 
Based on anatomic location, four groups of cholinergic neurons (Chl-Ch4) have been 
described in the human basal forebrain. These neurons are located around the medial 
septum, the vertical and horizontal limbs of the diagonal band of Broca, and the nucleus 
basalis of Meynert (Nagai et al., 1983; Hedreen et al., 1984; Mesulam & Geula, 1988). 
Among these four groups Ch4 is the most extensive (Geula el al., 1993). The human 
Ch4 can be subdivided further into another six sectors (Mesulam & Geula, 1988). The 
Chl and Ch2 neurons may provide the major cholinergic innervation of the 
hippocampus. the Ch-33 of the olfactory bulb, and the Ch4 of the entire cortical mantle 
and arnygdale (Geula & Mesulam, 1999). 
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Cholinergic cell groups are found in the upper brainstem, the pedunculopontine nucleus 
(Ch5), the laterodorsal tegmental nucleus (Ch6), the medial nucleus of the habenula 
(Ch7), the parabigeminal nucleus (Ch8) (Mizukawa et al., 1986; Mesulam et al., 1989). 
The neurons Ch5 and Ch6 provide the major cholinergic innervation of the thalamus 
(Hallanger et al., 1987). The Ch5-Ch6 can also provide an additional, but minor source 
of cholinergic innervation of the interpenduncular nucleus and the Ch8 neurons project 
mostly to the superior colliculus but also to the thalamus (Hallanger et al., 1987; Hall et 
al., 1989). The Ch neurons of the striatum have almost entirely local connections with a 
lesser cholinergic input from Chl-Ch4 (Geula & Mesulam, 1999). 
Geula & Mesulam (1989,1996) reported that the highest density of cholinergic fibers 
(axons) is found within core limbic areas such as the amygdala and hippocampus. 
Paralimbic cortical areas show the next highest density of cholinergic fibers, whereas 
the primary visual cortex contains the lowest. The cortical structures within the 
temporal lobe show a high density of cholinergic fibers, while within the occipital lobe 
lesser. 
1.2.1.2. Cholinesterases 
1.2.1.2.1. Acetylcholinesterase 
All cholinergic neurons of the human basal forebrain and brainstem contain the 
cholinergic enzymes ChAT and acetylcholinesterase (AChE) (Mesulam & Geula, 1988; 
Mesulam et al., 1989). AChE may also occur in non-cholinergic neurons (personal 
communication with Professor E. Perry). The latter is synthesized in the perikaryon and 
then transported to dendrites, axons and further into the cell membranes (Figure 1.7. ). 
AChE is encoded by a gene on chromosome 3 and belongs to the Type B 
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carboxylesterase gene family (Gnatt et al., 1991; Ballard, 2001). Analysis of the three- 
dimensional structure of AChE (Sussman et al., 1991) and homologous lipase (Cygler 
et al., 1993) indicates that these enzymes have a common fold termed the a/(3 hydrolase 
fold (Ollis et al., 1992), in which a central ß-sheet is surrounded by loops and helices. 
Solution of the 3D structure provided that the cholinesterase (ChEs) contain a catalytic 
triad, albeit with a glutamate in place of the aspartate found in the serine proteases. The 
active site is situated in a deep cleft, being located almost 20 A from the surface of the 
catalytic subunit, at the bottom of a long and narrow cavity. This cavity was named the 
active-site gorge or, since over 60 % of its surface is lined by the rings of conserved 
aromatic residues, the aromatic gorge (Sussman et al., 1991). 
AChE comprises 90% of the total cholinesterases in the temporal cortex of normal brain 
(Perry et al., 1978 a). Moreover, Shinotoh (1999) reported a positron emission 
tomography study of the enzyme activity in the human brain. The author found that 
AChE activity is predominant in the striatum followed by the cerebellum, thalamus, and 
the cerebral cortex. 
In adult human brain AChE is mainly present as the membrane-bound globular tetramer 
G4 form, and the more soluble monomer Gl form, with minor contributions of dimeric 
G2 and other asymmetric forms (Attack et al., 1986). Studies (Ogane et al., 1992 a; 
Ogane et al., 1992 b) on brain fractions suggest that 60-90% of the G4 form is 
intracellular and membrane located while 90% of the GI form is intracellular and 
cytoplasmic. In the cortex and hippocampus however, the G1 form represents 
approximately from 30% to 40% of total AChE (Attack et al., 1986). Meneguz et al., 
(1992) reported that in rats G4 and G1 forms were detected in all the brain areas. Their 
distribution, expressed as G4/Gl ratio, varied in young rats from about 7.5 for the 
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striatum to about 2.0 for the medulla-pons and cerebellum. The age-related changes 
consisted in a significant and selective loss of the enzymatic activity of G4 forms in the 
cerebral cortex, hippocampus, striatum, and hypothalamus, which resulted in a 
significant decrease of the G4/G1 ratio. No such changes were found in the medulla-pons 
or the cerebellum. 
The major role of the AChE is to terminate the action of ACh through catalytic 
hydrolysis (Volkova et al., 1976; Mesulam, 2000) (Figure 1.7. ). Rapid hydrolysis of 
acetylcholine by AChE (EC 3.1.1.7) is essential for cholinergic neurotransmission, the 
main feature involved in cognition. This importance is underlined by the large value of 
catalytic constants Kcat/Km, = 109 M-1-s-1 (Nolte et al., 1980), which ranks as one of the 
highest catalytic efficiencies known (Fersht, 1985) despite the fact that the substrate has 
to reach the active site at the bottom of a narrow, 20 A deep gorge (Sussman et al., 1991) 
by diffusion. Zhou et al. (1998) showed that such enzyme specificity is achieved by 
dynamic configuration of the five aromatic rings of tyrosine (Tyr) amino acids Tyrl21 
and 334 and phenylalanine (Phe) amino acids (Phe290) 330 and 331), serving as the gate, 
where it can rapidly switch between the open and closed states (Figure 1.8. ). One of 
these open states may coincide with the ACh entering state allowing the entrance of the 
substrate with high efficiency. 
Moreover, binding between the acetyl moiety of ACh and catalytic binding site involves 
an interaction with three key amino acid residues. These amino acids are involved in a 
charge relay system within the gorge, which for AChE is centred around a serine (Ser2oo) 
residue, and involves histidine (His447) and glutamate acid (G1u334). In this region of the 
gorge two large amino acids Phe295 and Phe297 may restrict a passage to the active site 
for larger substrates (Greig et al., 2001). 
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Figure 1.7. Cholinergic neurotransmission. The neurotransmitter Ach is synthesised in 
presynaptic cholinergic neurons by choline acetyltransferase (CAT). The process entails 
transfer of an acetyl group from acetyl-coenzyme A to choline (A). Until needed, the 
ACh molecules are stored in discrete vesicles at the ends of the presynaptic neurons. 
Arrival of a nerve impulse triggers the release of Ca2+ ions, which activate actin 
microfilaments that in turn pull the storage vesicles into position for ACh release. In a 
single event the vesicles empty their contents into the synaptic cleft (C). Most of these 
molecules bind to cholinergic receptors on adjacent postsynaptic neurons (D). Any that 
remain unbound are rapidly hydrolysed by AChE (E). The choline released in the 
process is reused in synthesising new ACh. Inhibition of AChE and BuChE increase the 
amount of ACh available for neurotransmission. 
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Figure 1.8. Open and close state of acetylcholinesterase with Tyr and Phe residues at the 
date 
1.2.1.2.2. Butyrylcholinesterase 
Butyrylcholinesterase (BuChE) is encoded by a gene on chromosome 3 and as AChE 
belongs to the Type B carboxylesterase gene family (Gnatt et al., 1991). AChE and 
BuChE share 65% amino acid homology despite being encoded by different genes 
(Soreq and Zaku, 1993). 
The human cerebral neurocortex also contains BuChE-rich neurons (Mesulam et al., 
1995; Darvesh et al., 1998). The number of these neurons is approximately two orders 
of magnitude less than the number of AChE-rich neurons (Mesulam, 2000). In the 
normal brain BuChE, primary located in glial cells, accounts for 20% of ChE activity, 
while AChE accounts for the remaining 80% (Greig et al., 2001). Most cortical BuChE- 
rich neurons are non-pyramidal, lie predominantly in deeper cortical layers, including 
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layer 6 and in the immediately adjacent juxtacortical region (Mesulam et al., 1995). 
Limbic structures such as amygdala, hippocampus, and entorhinal cortex contain a 
slightly higher density of BuChE-rich neurons (Mesulam, 2000). In the hippocampal 
complex, BuChE-rich neurons are located mostly within a white-matter layer. There are 
no BuChE-rich axons in the cerebral cortex (Mesulam, 2000). 
Development of normal cholinergic pathways in AChE knockout mice (Xie et al., 2000; ) 
and the hydrolysis of the ACh surrogate acetylthiocholine by widely spread BuChE, not 
only in the brain of a wide-type mouse (Mesulam et al., 2002 b) but in areas of the 
human brain known to receive cholinergic input (Mesulam et al., 2002 a), suggest that 
ACh is a functional substrate to BuChE (Figure 1.7. ). 
Ekholm and Konschin (1999) summarised structural differences between BuChE and 
AChE. In BuChE a similar channel, an aromatic gorge, as in AChE leading to the active 
site was found, although it was not as narrow as in AChE and it did not contain as many 
aromatic amino acids. Moreover, Phe295 and Phe297 in comparison with AChE are 
replaced with two smaller amino acids-valine and leucine-creating additional space for 
entering large substrates. The space of the active centre in BuChE is greater than in 
AChE. An intra-atomic distance analysis of the active site indicates that two hydrogen 
bonds easily form in AChE but only one in BuChE. The active site in BuChE is 
therefore less rigid than in AChE, allowing the substrate move more freely. 
BuChE, like AChE, also occurs in asymmetric and globular forms where they exist as 
amphiphilic and hydrophilic species in different brain regions. Six major molecular 
forms are recognised, three globular (G1, G2 and G4) and three asymmetric (A4, Ag and 
A12), the latter being associated with a triple-strand collagen like tail (Mesulam, 2000). 
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G4 form is the most abundant form of ChEs in the healthy human brain and is central to 
breakdown of ACh. In contrast, G1 form present in smaller amounts in the healthy 
human brain and plays a relatively minor role in ACh degradation (Attack et al., 1986; 
Arendt et al., 1992). 
The kinetics of BuChE further distinguish it from AChE. AChE is most efficient at low 
substrate concentrations (up to 0.5 mM, personal communication with Professor E. 
Perry) and becomes inhibited by a high level of ACh (above 2 mM, personal 
communication with Professor E. Perry). The mechanism of inhibition caused by the 
excess of ACh has been shown by Shafferman et al. (1992). It is related to a change in 
conformation of Tyr337 amino acid which lines the upper part of the catalytic gorge of 
AChE representing in part the peripheral site overlapping the substrate-inhibitor site. A 
change in conformation of Tyr337 or a mutation in a single amino acid may induce 
allosteric changes in the peripheral site which are responsible fir this inhibition. In the 
case of BuChE in which alanine replaces the tyrosine of AChE no substrate inhibition 
observed (Sussman et al., 1991; Shafferman et al., 1992). 
In contrast, the enzymatic affinity constant (Km) for BuChE makes the enzyme less 
efficient at low concentrations, but very efficient at higher levels when AChE becomes 
substrate inhibited (Silver, 1974). It has been suggested (Giacobini, 2001) that BuChE 
may support the hydrolysis of excess ACh via relationship between glial BuChE, 
synaptic AChE and their differences in Km. 
1.2.1.3. Cortical cholinergic receptors 
Cholinergic signalling is mediated by nicotinic and muscarinic receptors. Nicotinic 
acetylcholine receptors (nAChRs) have been shown to be involved in cognitive 
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functions such as attention and memory and changes in nAChR expression are 
associated with brain development, aging and neurodegenerative diseases such as AD, 
DLB and Parkinson's disease (Jones et al., 1999). 
nAChRs are members of the ligand-gated ion channel family that includes y-amino- 
butyric acid A (GABAA), glycine and 5-HT3 receptors. They are formed by the 
pentameric association of a and 0 subunits, of which at least 12 nAChR subunit genes 
(a2- a10 and ß2-ß4) have been identified to date in the rat and chick nervous system, 
while human a2- a7, a9, a10 and 02-134 nAChR subunits have been cloned (Sargent, 
1993; McGehee and Role, 1995; Lukas et al., 1999; Lustig et al., 2001; ). Different 
combination of subunits generate subtypes of nAChRs with diverse functional and 
pharmacological properties (Chavez-Noriega et al., 1997) which in vivo may have 
selective roles in specific brain pathways (Lena et al., 1999). The main nAChRs 
subtypes in mammalian brain have been shown to be those containing a402 subunits 
which bind nicotine with high affinity or a-bungarotoxin-sensitive a7 subunits 
(Goldman et al., 1986,1987; Gotti et al., 1997; Pacheco et al., 2001). nAChRs act 
presynaptically in the hippocampus to influence the release of various neurotransmitters 
including glutamate (Gray et a1., 1996), GABA (Radcliffe et al., 1999) and 
noradrenaline (Clarke and Reube, 1996), whilst a7nAChRs and a402 may also have a 
postsynaptical role in fast synaptic transmission of the hippocampus (Frazier et al., 
1998). 
The highest density of a4ß2 and a7 receptor subunits is found in the subiculum, 
followed by the thalamus (Rubboli et al., 1994; Jones et al., 1999). Graham et al. (2003) 
reported differential distribution of nAChR subunits on various cell types within the 
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human hippocampus and entorhinal cortex and emphasises their potential role in 
neuronal modulation, astrocyte activity and vascular function. 
Five subtypes of muscarinic cholinergic receptors (ml-m5), localised on both pre- and 
post-synaptic membrane, have been recognised, each the product of a different gene 
(Braun et al., 1993). The receptors couple to multiple G proteins to modulate signal 
transduction pathways. While the ml, m2 and m4 proteins are abundant in the brain, the 
m3 and m5 are expressed only in small quantities (Levey, 1996). The ml-m3 receptors 
refer to the pharmacologically identified M1-M3 (transcribed from the ml-m3 genes) 
subunits (Geula and Mesulam, 1999). In the human brain high densities of muscarinic 
M1 and M4 cholinergic receptors occur within the striatum and, hypothalamus, 
intermediate to high densities in the amygdala, hippocampus, and cerebral cortex, and 
the lowest density in the cerebellum (Lin et al., 1986; Cortes et al., 1987) The M1 
receptor is mainly located postsynaptically (on cholinoceptive neurons and other cells) 
in the cortex, hippocampus and brainstem. The M1 receptors are much more numerous 
than the M2 subtype and display peak densities in almost all limbic and paralimbic 
regions (Kasa et al., 1997). 
In the cerebral cortex, nicotinic and muscarinic receptors are localised predominantly on 
pyramidal neurons in layers III and V and a smaller population on polymorphic neurons 
(Geula and Mesulam, 1999). Approximately 30% of pyramidal neurons display 
reactivity for both muscarinic and nicotinic receptors (Schroder et al., 1989; Graham et 
al., 2003). 
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1.2.2. Demented brain 
1.2.2.1. Alzheimer's disease 
Davies and Maloney (1976), Bowen et al. (1976) and Perry et al. (1977) reported a 
significant loss in levels of biochemically determined ChAT activity in post-mortem 
tissue from cerebral cortex of AD. Since that time the loss of cortical ChAT activity, 
especially within the nucleus basalis of Meynert (nbM) and other regions of the basal 
forebrain complex (Whitehouse et al., 1982), has become established as one of the most 
consistent findings in AD (Geula and Mesulam, 1999). Thus, it has been suggested 
(Bartus et al., 1982) that the degeneration of basal forebrain neurons and the 
accompanying loss of cholinergic projections to the neocortex and hippocampus 
provide an important contribution to emerging cognitive deficits. The greatest cortical 
deficits in acetylcholine occur in those brain areas concerned with memory and 
cognition, the hippocampus and temporal, frontal and parietal cortices (Geula and 
Mesulam, 1996; Perry et al., 1998). There is a strong correlation between cortical 
cholinergic deficits (especially in temporal and parietal lobe) and dementia scores 
(Perry et al., 1978 b). 
In the human cerebral cortex, ChAT is found only in pre-synaptic cholinergic axons, 
whereas AChE is found in cholinoceptive (ChAT-negative) neurons as well as in 
cholinergic axons. AChE, therefore, is a marker for both the presynaptic and the post- 
synaptic component of cholinergic pathways. Some studies (Davies, 1979; Zubenko, et 
al., 1989) reported up to a 90% loss in the activity of cortical AChE in AD. This loss 
was restricted to the membrane-bound detergent soluble G4 form of the enzyme, mainly 
in cortical and subcortical brain regions (Attack et al., 1983; Fishman et al., 1986; Seik 
et al., 1990). The G4 form of AChE is preferentially expressed at cholinergic synapses 
and the G4/G1 ratio is a marker for these sites (Seik et al., 1990). It was noted (Fishman 
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et al., 1986) that the G4/G1 ratio is correlated with the activity level of the presynaptic 
cholinergic marker ChAT in normal human brain. The G4 form of AChE represents 
more than 80% of total AChE activity transported in axons. In severe AD patients, the 
G4 form is decreased in the frontal and parietal cortices by 71% and 45 % respectively 
and in the caudate putamen by 47% as compared with control levels (Giacobini, 2000). 
In contrast, in the brains of patients with AD, the Gl form of BuChE shows a 20% 
increase while the G4 form remains the same as in non-diseased brains (Giacobini, 
2000). As AD progresses, levels of the G1 forms of AChE and BuChE in neuritic 
plaques and neurofibrillary tangles increase according to plaque density (Greig et al., 
2001). Although, the level of collagen-tailed forms is very low in normal brain, A12 and 
A8 forms showed an increase of three- to four-fold in the cortex of AD patients reaching 
about 15 % of the total AChE activity (Younkin et al., 1989). Thus, the cortical 
cholinergic depletion and the concomitant loss of axonal AChE are among the earliest 
and most severe markers of the neuropathology in AD. However, Mesulam, (2000) 
reported that the biochemical determination of AChE is a weak indicator of cortical 
cholinergic innervations because the enzyme is not only found in cholinergic axons but 
also in cholinoceptive neurons. A more accurate assessment of cortical cholinergic 
denervation may require the microscopic analysis of AChE-rich or ChAT-rich cortical 
axons (Geula and Mesulam, 1989). On a basis of this method Geula and Mesulam (1989) 
showed that cortical cholinergic depletion starts even before the onset of clinical 
dementia and that it becomes especially severe in advanced AD. 
Kasa et al. (1997) reviewed evidence that the most affected areas of the cholinergic 
innervation of the diseased brain include the cortex, the entorhinal area, the 
hippocampus, the ventral striatum and the basal part of the forebrain, whereas other 
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areas are less affected. Geula and Mesulam (1996) demonstrated that the areas with the 
greatest loss (greater than 75%) of cholinergic innervation were all in the temporal lobe 
and least pronounced in primary sensory-motor areas. For instance, within the 
hippocampal formation, AChE-rich axons showed reduction in all sectors, whereas fiber 
density in the amygdala was high but relatively preserved in the central nucleus and in 
the entorhal cortex (Emre et al., 1993), showing that the cortical cholinergic denervation 
in AD is selective and not part of general cholinergic deficiency. The loss of axonal 
AChE is also most severe in cortical structures within the temporal lobe (Mesulam, 
2000) and in subcortical areas (Geula and Mesulam, 1999). 
Pilleri (1966) reported a loss of nbM-Ch4 neurons in AD. Later, Whitehouse et al. 
(1982) found a 75% decrease in the number of nbM-Ch4 neurons in AD patients. Later 
reports have produced support for a consistent loss not only of nbM-Ch4 neurons, 
ranging from 30% to 95% but also, ChAT activity in the latter (30-90%) of AD patients 
(Geula and Mesulam, 1999). Moreover, mean mRNA expression per ChAT-positive 
neuron was reduced by 50% in the Ch4 in those with AD (Strada et al., 1992). 
Mesulam (2000) reviewed evidence that histopathological markers of AD, such the 
amyloid plaques, neurofibrillary tangles and vessels with amyloid angiopathy, express 
intense AChE and BuChE activity. The AChE in these lesions displays enzymatic 
properties that differ from that of normal neurons and that are similar to those of glial 
AChE. Furthermore, the AD-related histopathological lesions with BuChE activity tend 
to be more abundant in cortical layers which display higher densities of BuChE-positive 
glia. The AD-related ChEs therefore seem to have a glial origin with a possible role in 
development of the disease. 
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Geula and Mesulam (1999) also reviewed evidence that neuronal loss occurs in 
practically all the basal forebrain cholinergic cell groups and in all nbM-Ch4 subsectors. 
The greater reduction of nbM-Ch4 neurons is consistent with the greater loss of ChAT 
activity within at least the temporal cortex. In addition, Doucette and Ball (1987) 
showed that nbM-Ch4 neuronal loss in AD has no left-right asymmetry. 
Arendt et al. (1984; 1985) reported correlation between the number of neuritic plaques 
in five neocortical areas and loss of neurons in subsectors of the nbM, which give rise to 
the cholinergic innervation of the affected cortical areas. It was suggested that the 
degeneration of cortical cholinergic afferents from the neurons of the nbM is an 
important feature in the pathogenesis of neuritic plaques. A significant relationship has 
been reported between cortical plaques and nbM-Ch4 neuronal loss (Mann et al., 1984; 
Rasool et al., 1986). Many of the reaming nbM-Ch4 neurons have been shown to 
contain neurofibrillary tangles as well as moderate density of amyloid plaques (Arendt 
et al., 1988). However, the relationship between plaques and tangles within the nbM 
and the loss of Ch4 neurons needs further investigation (Geula and Mesulam, 1999). In 
contrast the brainstem Ch5 and Ch6 cholinergic neurons, major innervation for the 
thalamus and minor for the cerebral cortex, show almost no neuronal loss in AD but 
presence of neurofibrillary tangles (Geula and Mesulam, 1999). 
Greig et al. (2001) also reviewed a role of cholinesterases in AD. In advanced AD 
AChE activity may be reduced to 55-67% of normal levels in certain brain areas, while 
BuChE activity increases (Perry et al., 1978 a). Levels of AChE and BuChE GI forms 
have been positively correlated with plaque density and pathogenicity (Arendt et al., 
1992). Both enzymes may also contribute to beta-amyloid peptide (Aß) aggregation in 
plaques formation, as they accumulate within the amyloid plaques and are found in 
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neurofibrillary tangles in AD (Perry et al., 1978 a; Inesterosa et al., 1996). Increasing 
levels of BuChE are also associated with the development of cortical and neocortical 
neuritic plaques (Greig et al., 2001). 
Geula et al. (1998) showed in an in vivo study that fibrillar Aß is toxic to neurons and 
can induce phosphorylation of tau characteristic of neurofibrillary tangles. Injections of 
the fibrillar form of Aß have been shown to cause the degeneration of basal forebrain 
cholinergic neurons (Harkany et al., 1995) and a decrease in ACh release (Abe et al., 
1994). The soluble form of Aß, which is produced by cells under normal conditions 
(Geula and Mesulam, 1999), decreased ACh synthesis in a cell line derived from 
cholinergic neurons of the basal forebrain (Pederson et al., 1996), together with ACh 
release (Kar et al., 1996) and transduction through the muscarinic receptor (Auld et al., 
1998; Geula and Mesulam, 1999). 
Perry et al. (2001) reviewed evidence that reduction of nAChRs, a4 subunit expression 
in the cortex and a7 subunit in the thalamus and in some cases in hippocampus, occurs 
in areas with the pathological changes associated with AD. The a3 and a4 subunits has 
been shown to be reduced in the hippocampus (Guan et al., 2000) and either reduced 
(Guan et al., 2000) or unaltered in the cortex (Martin-Ruiz et al., 1999) in AD. 
Therefore, the receptors are selectively involved in the symptoms and pathological 
changes associated with the disease. Perry et al. (2001) also noted that dementia rating 
has been positively correlated with loss of high affinity nicotinic agonist binding in the 
cerebral cortex. The decline in nAChRs in Alzheimer's disease may be a consequence of 
synaptic or dendritic loss (or loss of both), rather than of neuronal loss, from the 
neocortex. 
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Moreover, there are several different interactions between Aß peptides and nAChRs, 
especially with the a7 subtype (Auld et al., 2002). These interactions may be involved 
in the disruption of normal cholinergic neurotransmission and the possible enhancement 
of sensitivity to Aß neurotoxicity in AD. Wang et al. (2000) reported an interaction 
between Aß and a7 nicotinic receptors and their precipitation in human brain tissue, 
particularly in the AD brain. Especially, Aß1-42 and a7 nAChRs were co-localised on 
cortical neurons and neurotic plaques. In vitro, the formation of A(31-42/a7 nicotinic 
receptor complexes was inhibited by the A012_28 fragment, suggesting that this sequence 
competes for the binding site and is therefore likely to contain the active site (Wang et 
al., 2000). Thus, as with the effects of Aß on ACh release (Kar et al., 1996) and 
synthesis (Pedersen et al., 1996), this sequence of the peptide may be important for its 
effects on the cholinergic system. 
Pettit et al. (2001) provided evidence of a novel physiological role for A0142 as an 
inhibitor of postsynaptic nAChRs in rat hippocampal inter-neurons. In this study API-42 
blocked nAChR-mediated current and reduced open channel probability. The authors 
suggested that chronic inhibition of cholinergic signaling by Aß1.42 could contribute to 
the cognitive deficits and loss of cholinergic function associated with AD. 
Kasa et al. (1997) also reviewed evidence that the M1 receptor, locating post- 
synaptically on cholinergic neurons, binding parameters were generally unaltered in 
brain tissue samples from AD patients, whereas the M2 pre-synaptic receptor density in 
the brain tissues of the diseased patients is significantly decreased in numerous areas of 
the brain, including cortical areas and the hippocampal formation. The authors also 
noted that the densities of muscarinic receptors, and proportions of the M1 and M2 
subtypes, were not significantly different in sections of hippocampal tissue samples 
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between AD and age-matched, non-demented controls. However, most studies report 
robust reductions in G-protein signaling and/or phosphoinositide generation after 
muscarinic receptor stimulation (e. g. with carbachol) in AD brain tissue (Jope, 1996). 
Rodrigues-Puertas et al. (1997) found that M1 and M3 receptors are reduced in severe 
AD in entorhinal cortex and hippocampus, Ml and total mAChRs reduced in visual and 
frontal cortex, with unchanged M3 and M4 receptors. 
Nitsch et al. (1992) suggested that cholinergic neurotransmission may also influence the 
processing of the amyloid precursor protein (APP) through activation of muscarinic 
acetylcholine receptors. They showed in vitro that such stimulation with carbachol 
increased the basal release of APP derivatives through the a-secretase pathway. Geula 
and Mesulam (1999) raised the possibility that AD may be associated with a cycle 
wherein the cholinergic depletion promotes the production of Aß, which in turn, further 
reduces the effectiveness of cholinergic neurotransmission. 
1.2.2.2. Dementia with Lewy bodies 
Oh, call it by some better name. -Thomas Moore 
In DLB cortical cholinergic neurotransmission is compromised to a greater extent than 
in AD and this is thought to contribute to cognitive decline and the neuropsychiatric 
symptoms experienced by these patients (Perry et al., 1978 b; Perry et al., 1990). 
Neuropathological studies have found that up to 60% of the patients with AD can have 
Lewy bodies in the neocortex and brainstem (Lopez, 2003). Nevertheless, the losses of 
ChAT in DLB occur in temporal and parietal neocortex and some thalamic niclei (Perry 
et al., 1998; Ballard et al., 2000). ChAT is also moderatly reduced in striatum (Piggott 
and Marshal, 1996). Perry et al. (1993) also found that hallucinations in DLB are 
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associated with marked cortical cholinergic deficit. Liberini et al. (1996) reviewed 
evidence that the neuronal damage in the nbM of patients with DLB is greater than that 
of AD cases. Moreover, an extensive cholinergic deficit in frontal, parietal and temporal 
cortices, with reduction in ChAT activity is greater than those in AD. Minoshima et al., 
(2001) reported significant metabolic reductions in the occipital cortex, particularly in 
the primary visual cortex, which distinguished DLB versus AD with 90% sensitivity 
and 80% specificity. 
M1 receptors are elevated in temporal and parietal cortex (Ballard et al., 2000). Piggott 
et al., (2003) reviewed reports suggesting that in the cerebral cortex post-synaptic target 
neurons are undamaged in DLB, with severe degeneration of presynaptic cholinergic 
projections provoking upregulation of M1 receptors in cholinoceptive neurons in 
temporal and parietal cortex. Piggott et al. (2003) also reported significant reduction of 
M1 receptors in striatum. Using epibatidine binding assay, Martin-Ruiz et al., (2000) 
found a selective loss of cortical nicotinic receptor a4 subunit but no change in a7 
subunits in DLB. 
DLB can also be suspected clinically on the basis of the early occurrence of a cognitive 
decline resembling a chronic confusional state with fluctuating cognitive sings and 
visual and/or auditive hallucinations in a patient with mild Parkinsonism (Dubois, 2003). 
The main difference between DLB and AD is the increased persistence of visual 
hallucinations in DLB (Ballard, 2003). The rapidly progressive dementia is 
accompanied by aphasis, dyspraxia, spatial disorientation and severe visuospatial 
disorders suggestive of temporopariental dysfunction. The neuropsychological profile 
differs from that of patients with AD: cognitive deficits are more acute, attentional 
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fluctuations more intense, and psychotic features more precocious. Moreover, patients 
with DLB present less severe memory deficits than those with AD (Dubois, 2003). 
1.2.2.3. Vascular dementia 
Mesulam et al. (2003) reported that subcortical ischemic lesions can cause cortical 
cholinergic denervation in the absence of primary nucleus basalis or neocortical 
pathology. The greatest cholinergic loss occurred in the posterior parietal, dorsal frontal, 
and occipital cortices. Even in the areas there were some residual AChE-rich fibers. The 
hippocampus, entorhinal cortex, and much of the temporal neocortex displayed a 
relatively normal density of cholinergic axons. This pattern is the exact opposite of the 
AD pattern where the temporal lobe displays the greatest cholinergic denervation. The 
authors concluded that the physiologic impact of cholinergic denervation is therefore 
likely to differ in VaD and AD. 
Grantham and Geerts (2002) reviewed evidence that in post-mortem studies patients 
with VaD have decreased brain ChAT activity in the cortex, hippocampus and striatum. 
Levels of ChAT are typically reduced when nAChR numbers are decreased leading to a 
general degeneration of cholinergic neurotransmission. Moreover, ACh concentrations 
in cerebral spinal fluid (CSF) correlated with the severity of the dementia, as measured 
using the Mini-Mental State Evaluation and the Hasegawa revised version of the 
Dementia Scale. 
In contrast to DLB, Martin-Ruiz et al. (2000) found no reduction in epibatidine binding 
or immunoreactivity of cortical nicotinic receptor a4 and a7 subunits in Val). Nordberg 
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et al. (1992) reported that M1 and M2 receptors were decreased in multi-infarct 
dementia, while marked loss of nicotinic receptors was observed in cortical tissue. 
1.2.2.4. Mild cognitive impairment 
Volumetric magnetic resonance imaging has shown (Du et al., 2000) that the entorhinal 
cortex and hippocampal volumes are reduced in mild cognitive impairment, and that 
there is loss of entorhinal cortex neurones (Kordower et al., 2001). In PET studies, 
reduction of glucose metabolism in the hippocampal formation has been seen without 
any significant neocortical change (De Santi et al., 2001). Imaging results therefore 
indicate that at a structural and metabolic level the first pathological changes develop in 
the entorhinal and hippocampal areas. Mufson et al. (1999) found in-vitro that 
cholinergic nbM neurons are relatively preserved and the remaining neurons are not 
hyperinnervated by galaninergic fibers in subjects with MCI and mild AD. Padovani et 
al. (2002) demonstrated that alteration in APP metabolism is an early event in sporadic 
AD and that most patients with MIC have undergone such changes. The APP changes 
may predate the onset of clinical dementia and be detected when cognitive impairment 
is barely measurable. In addition, Rinne et al. (2003) reported in-vivo that hippocampal 
acetylcholinesterase activity is only slightly reduced in MCI and early AD. There is also 
a report (O'Brien et al., 2003) that BuChE did not affect attentional performance in non- 
demented individuals with mild cognitive impairment. 
1.3. Current and prospective treatment of dementia 
1.3.1. Cholinergic theraputical agents 
The cholinergic theory of AD, originally derived from post-mortem studies of the brain 
(Davies and Maloney, 1976; Bowen et al., 1977; Perry et al., 1977; Whitehouse et al., 
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1982; Perry 1986), led to the development of licensed drugs based on the inhibition of 
AChE (Thomsen and Kewitz., 1990; Enz et al., 1991; Sugimoto et al., 1995). Treatment 
with such drugs results in a significant improvement in cognitive function (Farlow et al., 
1992; Knapp et al., 1994; Wilkinson, 1997; Rogers et al., 1998; Rosier et al., 1999; 
Raskind et al., 2000) and may also retard progression of the disease (Farlow, 2002; Ott 
and Lapane, 2002) by prolonging the action of ACh at the post-synaptic receptors. 
Numerous cholinesterase inhibitors have undergone development since Perry et al. 
(1978 b) reported that the severity of a cholinergic deficit in AD correlates with the 
degree of cognitive decline. Because of the severe cortical cholinergic denervation in 
DLB (1.2.2.2. ), VaD or mixed AD and VaD (1.2.2.3. ) concomitant with cognitive 
decline, cholinergic therapy may be relevant to these disorders (Giacobini, 2000; Fisher 
and Bowler, 2003). Moreover, individuals with MCI, who are at risk of AD, may also 
represent a suitable target for the therapy (Giacobini, 2000). Patients who develop AD 
start with normal cognitive function and slowly progress to a stage of MCI. In addition, 
Fisher and Bowler (2003) noted that for symptomatic treatment of dementia, a precise 
diagnosis is not essential and that individual responsiveness should determine whether 
treatment continues or not. 
To date, AChE inhibitors approved by the U. S. Food and Drug Administration (FDA) 
for the symptomatic treatment of patients with AD include tacrine, donepezil, 
rivastigmine and galanthamine. There are no FDA-approved treatments for DLB and 
VaD (Giacobini, 2000). 
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1.3.1.1. Licensed drugs 
1.3.1.1.1. Tacrine (Cognes(D) 
Tacrine (Figure 1.9. ) (Shaw and Bentley, 1953) was the first marketed 
acetylcholinesterase inhibitor approved by FDA in 1993 (Thal, 1999). Harel et al. (1993) 
demonstrated that the three-ring structure of tacrine is stacked against the indole 
tryptophan (Trp84) at the aromatic gorge and that the N-methylacridinium forms a 
charge-transfer complex with a tryptophan in the active site of AChE. They also 
reported that in tacrine/ACNE complex, the only residue undergoing significant 
conformational change is phenylalanine (Phe330). Tacrine thus binds between the rings 
of Phe330 and Trp84. The authors highlighted the important role of aromatic groups of 
the enzyme as binding sites for quaternary ligands. 
Figure 1.9. Tacrine (C13H14N2). Synonyms: 9-Amino-1,2,3,4-tetrahydroacridine; 9- 
Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate; Cognex; THA 
Tacrine preferentially inhibits AChE in the hippocampus and cortex (Enz et al., 1993). 
Moreover, Zhao and Tang (2002) reported that tacrine also preferentially inhibits the Gl 
human form of AChE of hippocampal, striatum and cortical origins, exhibiting 
significant differences in Ki values between G4 and G1 forms. The Gl form is 
predominant in the brain of patients with AD. Tacrine is a non-competitive type of 
inhibitor not only with the enzyme but also the G1 and G4 forms. In addition, Pacheco et 
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al. (1995) showed that tacrine readily inhibits both AChE and BuChE in a mixed, non- 
competitive way. Giacobini (2000) also summarised evidence confirming that tacrine is 
a non-selective inhibitor of cholinesterases. 
Increased binding of ["C]-nicotine has been observed in the temporal cortex of AD 
patients treated with tacrine, 80 mg/day for 3 months (Nordberg, 2000). Nordberg (2000) 
also suggested that the restoration of cortical nicotinic receptors, following tacrine 
treatment, may be due to a stimulatory effect of the inhibitor on these receptors via an 
allosteric site which is separately located from ACh binding site. Nevertheless, Prince et 
al. (2002) reported on an in vitro study of tacrine on nAChRs expressed in human adult 
cells. They found that the mean channel open time decreased with increasing tacrine 
concentration in a voltage-dependent manner, suggesting that tacrine acts as an open 
channel blocker. 
Herrera et al. (2001) reported that tacrine acts as an antagonist on rat intestinal smooth 
muscle and it also antagonist to M1 receptor (Snape et al., 1999). Giacobini (2000) also 
noted that 3 months treatment with tacrine in those with AD may cause down-regulation 
of the muscarinic receptors in the temporal cortex, which may be normalised after 10 
months of the treatment. Snape et al. (1999) found using in vivo microdialysis in 
cerebral cortex of rats that orally administrated tacrine produce a marked (at least 30- 
fold) increase in extracellular acetylcholine which remained elevated for more than 2 
hours. 
In addition, Perry et al. (1994) reported that two of the Lewy body cases with extremely 
low cholinergic activity were responders in therapeutic trials of tacrine, whereas Lebert 
et al. (1998) also showed that tacrine increased cognitive performances (verbal initiation 
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and digit span) in 22 patients with DLB out of 31. These data suggest that cholinergic 
therapy may be particularly relevant to patients with LDB. Although, tacrine was 
marketed in 1993, it never achieved widespread use in AD patients because of 
hepatotoxicity. In the pivotal trials, almost half the subjects discontinued therapy 
because of severe side-effects (Thal, 1999). 
1.3.1.1.2. Donepezil (Aricept®) 
In 1996 donepezil (Figure 1.10. ) received FDA approval for marketing (Nightingale, 
1997). Donepezil (E2020) is a member of a large family of N-benzylpiperidine-based 
AChE inhibitors that were developed, synthesized and evaluated by Eisai in Japan 
(Kawakami et al., 1996). 
Kryger et al. (1999) reported that the inhibitor has a unique orientation along the active- 
site gorge, extending from the anionic sub-site of the active site, at the bottom near 
Trp84i to the peripheral anionic site, at the top near Trp279. E 2020 does not interact with 
the catalytic triad (glutamate-histidine-serine or Glu-His-Ser) at the bottom of the gorge 
but binds to the free and the acylated forms of AChE. In the middle of the gorge, Phe330 
may serve as an additional quaternary binding site, midway down the gorge, between 
the peripheral site and the anionic sub-site of the active site. At the top of the gorge the 
indanone ring stacks against the indole ring of Trp279, in the peripheral binding site, by a 
classical Tt-Tt interaction. 
E2020 is a drug with both high affinity and a high degree of selectivity for AChE, as 
opposed to butyrylcholinesterase (Snape et al., 1999), with the BuChE/AChE ratio of 
inhibition is around 1000 (Giacobini, 2000). The high affinity and selectivity results 
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from a fact that Phe330 and Trp279 residues are conserved in AChE, but absent in 
BuChE. 
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Figure 1.10. Donepezil(C24H29N03). Synonyms: E2020, Aricept, (R, S)-1-benzyl-4- 
[(5,6-dimethoxy-1-indanon) 2-yl] methyl piperidine. *C8 is a chiral carbon 
Zhao and Tang (2002) reported that E2020 is more selective for G1 human form of 
AChE in striatum and hippocampus than G4 form. In contrast, in cortex both forms were 
inhibited to similar degree, namely Ki values for G1 and G4 forms were 3.5±1.2x10"9 M 
and 4.0±1.5 x 10-9 M respectively. In addition, E2020, as tacrine, shows non-competitive 
type of inhibition not only with the enzyme but its both forms, indicating that it is down 
to the inhibitor to determine the nature of inhibition, not the molecular form of the 
enzyme or its tissue source. 
Donepezil readily penetrates the blood brain barrier (BBB) in rats (Kosasa et al., 2000) 
and has non-competitive, reversible type of inhibition of AChE (Snape et al., 1999). 
Donepezil, like tacrine, is antagonist to M1 receptor (Snape et al., 1999) with binding 
activity at nicotinic sites in both the hippocampus and prefrontal cortex of aged rats 
(Barnes et al., 2000). Moreover, Takada et al., (2003) showed that the drug protects 
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cortical neurons against glutamate neurotoxicity via a4ß2- and a7-nAChRs and also 
protects apoptotic neuronal death. 
The cholinergic deficits seen in VaD are less pronounced and of a different pattern than 
those of AD (1.2.2.3. ). There is, as yet, no convincing evidence that acetylcholinesterase 
inhibitors have any significant extent in "pure" VaD. A trial of donepezil (Pratt and 
Perdono, 2002) did show a benefit in VaD, but this study used the NINDS-AIREN 
criteria and that the study population probably included many patients with mixed 
dementia 
Lopez-Pousa and Lombardia (1999) also reported that donepezil is a specific, reversible 
AChE inhibitor of close to 100% absorption and a half-life of 70 hours, achieving stable 
concentrations at approximately 3 weeks. AD patients treated with single daily doses of 
5 or 10 mg improve in the ADAS-Cog scale. The medication is initiated with a dose of 
5 mg per day. The drug is administrated once daily and appears to be well tolerated, 
with gastrointestinal side-effects occurring in fewer than 20% of subjects placed on the 
10 mg dose (Thal, 1999). Giacobini (2000) also summarised side-effects caused by 
donepezil treatment. The overall percentage of side-effects was 6-13%, compare with 
40-58% for tacrine. Hepatotoxicity is virtually non-existent with the drug. Longer half- 
life (70 hours) and once-a-day dosing schedule have enabled donepezil to quickly 
surpass tacrine in clinical use. This drug has received widespread acceptance in the U. S 
for AD patients (Thal, 1999). 
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1.3.1.1.3. Rivastigmine (Exelon O) 
Rivastigmine (Figure 1.11. ) is a member of the carbamate class of AChEIs and was 
approved by the FDA in 2000 (Bar-On et al., 2002). Bar-On et al. (2002) reported 
kinetic and structural studies on interaction of ChEs with rivastigmine. They found that 
the carbamvl moiety of the inhibitor is covalently linked to the active site serine (Ser2oo). 
with the leaving group. (-)-S-3-[1-(dimethylamino)ethyl]phenol (NAP), being retained 
in the "anionic" site . ithout causing any conformational changes. 
oýN/ý 
/\\ 
/Ný O 
Figure 1.11. Rivastigmine (C14H22N202). Synonyms: ENA-713, Exelon, (-)-S-N-ethyl- 
3-[(1-dimethyl-amino) ethyl]-N-methylphenylcarbamate hydrogen tartrate 
Reaction with rivastigmine resulted in disruption of the catalytic triad not only within 
Torpedo califoi"nica AChE (TcAChE) but also recombinant human ACNE. Bar-On et al. 
(2002) suggested that this is due to NAP causing a disturbance of His440 away from its 
catalytic triad. Alternatively, the disturbance of His440 may occur by NAP orienting the 
transition state such that the . V-ethylmethv l group crowds the histidine. NAP is a 
competitive inhibitor of AChE but when administrated to rats, no inhibition of brain 
ACNE is detected, probably due to poor BBB permeability and rapid clearance. 
. 
Moreover. Bar-On et al. (2002) found that rivastigmine inhibits recombinant human 
AChE much faster than TcAChE in a slow reversible manner. It was also a more potent 
inhibitor of human BuChE than AChE. The last result contradicts to other reports (Enz 
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et al., 1991; Giacobini, 2000), where rivastigmine had a slight predominance for AChE. 
Bar-On and colleagues (2002) noted that possible differences in molecular structure 
(e. g., degrees of oligomerization and glycosylation) between CSF ACNE and 
recombinant enzymes may be responsible for these differences. Nevertheless, from all 
these reports (Enz et al., 1991; Giacobini, 2000; Bar-On et al., 2002) it is apparent that 
rivastigmine is a non-selective inhibitor of ChEs and has a dual mode of action. Bar-On 
and colleagues (2002) also cautioned that the origin of ChEs may affect the kinetic 
results. 
Zhao and Tang (2002) found that rivastigmine preferentially inhibits the G1 form of 
human brain AChE in cortex, hippocampus and striatum. The G4 form was also 
inhibited in these brain areas but to a lesser degree. The level of G1 form in AD does not 
decline in the cerebral cortex and it found to be present in plaques and tangles (Greig, et 
al., 2001). 
Lopez-Pousa and Lombardia (1999) also found that rivastigmine is a competitive, 
slowly reversible inhibitor of AChE with a half-life of 2 hours and the total of 
approximately 10 hours. They also found that AD patients treated with two daily doses 
of 6 or 12 mg improve in the ADAS-Cog scale. Cutler et al. (1998) demonstrated in- 
vivo that administration of rivastigmine is associated with significant inhibition of 
AChE and BuChE in the CSF and plasma of patients with AD. Moreover, Giacobini et 
al., (2002) reported in-vivo strong and consistent association between the inhibition of 
BuChE in CSF by the drug and improved cognitive performance in subjects with mild 
to moderate stages of AD. Inhibition of BuChE in CSF in healthy young volunteers was 
less apparent. 
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Rosier et al. (1999) reported a clinical trial in 725 patients with mild to moderately 
severe probable AD, which was conducted at 45 centres in Europe and in North 
America for 26 weeks. Data from the trial showed that rivastigmine is a well tolerated 
and effective drug in the treatment of the disease. At doses of 6-12 mg pre day it 
improves cognition, participation in activities of daily living, and global evaluation 
ratings in patients with AD. In another trial, Farlow et al. (2000) reported the efficacy of 
rivastigmine in patients with mild to moderately severe AD in an open-label extension 
of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally 
treated with 6-12 mg per day rivastigmine had significantly better cognitive function 
than patients originally treated with placebo. 
In the largest placebo controlled trial (McKeith et al., 2000) of rivastigmine (12 mg per 
day) in 120 DLB patients over 20 weeks, followed by a 3-week withdrawal period, 
patients taking the drug were significantly less apathetic and anxious, and had fewer 
delusions and hallucinations compared to placebo controls. It was concluded that 
rivastigmine produces statistically and clinically significant behavioural effects in 
patients with DLB, and seems safe and well tolerated if titrated individually. It was 
suggested that cholinesterase inhibitors could be a more rational choice of treatment for 
Lewy-body dementia patients than neuroleptics, both on an efficacy and safety basis. 
1.3.1.1.4. Galanthamine (Reminyl ®) 
Galanthamine (Figure 1.12. ) is a naturally occurring alkaloid in plant species of 
Galanthus and Narcissus (Azoeva et al., 1968; Hanks 2002). It is the most recently 
(February, 2001) FDA approved drug for the treatment of AD (Alzheimer Research 
Forum). Greenblatt et al. (1999) reported that the inhibitor binds at the base of the 
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active site gorge of TcAChE, interacting with both the choline-binding site (Trp84) and 
the acyl-binding pocket (Phe288, Phe290). The tertiary amine group of galanthamine does 
not interact closely with Trp84i rather, the double bond of its cyclohexene ring stacks 
against the indole ring. The tertiary amine appears to make a non-conventional 
hydrogen bond, via its N-methyl group, to Asp72, near the top of the gorge. The 
hydroxyl group of the inhibitor makes a strong hydrogen bond (2.7 A) with G1u199. The 
binding of galanthamine to TcAChE is tight due the rigid chemical structure of the 
inhibitor. 
Figure 1.12. (-)-Galanthamine (C17H21NO3). Synonyms: Reminyl, (4a, 5,9,10,11,12- 
hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a, 3,2-ef] [2]-benzazepin-6-ol 
Galanthamine, like donepezil, is not selective for any cholinesterase iso-forms (Inglis, 
2002). The drug displays 53-fold selectivity for human AChE over BuChE, with IC50 
values of 0.35 pM for erythrocyte AChE and 18.6 mM for plasma BuChE (Thomsen 
and Kewitz, 1990). Interestingly, it displays 10-fold lower potency towards human brain 
AChE than towards the erythrocyte enzyme (Thomsen et al., 1991). Giacobini (2000) 
also showed that galanthamine is more selective for human erythrocyte AChE than for 
human plasma BuChE, with BuChE/AChE ratio of 5.3. 
Moreover, galanthamine is a non-competitive, allosteric ligand for nAChRs (Pereira et 
al., 1993; Storch et al., 1995; Schrattenholz et al., 1996). Samochocki et al. (2003) also 
reported that galanthamine is a potent allosteric ligand of human a3ß4, a4ß2, and a6ß4 
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nicotinic receptors in a range of concentrations from 0.1 µM to 1 [M. This range of 
concentration correlates with the cerebrospinal fluid concentration of the drug at the 
recommended daily dosage of 16 to 24 mg. At concentrations more than 10 µM, 
galantamine inhibits nAChRs. Samochocki et al., (2003) also found that galantamine at 
concentrations up to 100 pM was inactivate on human M1, M2, M3, M4, and M5 
mAChRs. In addition, Wevers et al. (1999) provided evidence suggesting that 
stimulation of nicotinic receptors may help to reduce amyloid plaques in the demented 
brain. 
Scott and Goa (2000) and Corey-Bloom (2003) reviewed evidence that galantamine is 
an effective well tolerated symptomatic treatment for AD which improves cognition, 
function and activities of daily living in patients with mild to moderate AD. The 
cognition benefits are sustained for at least 12 months at baseline levels and apparent 
versus no treatment for at least 24 months. In addition, it delays the development of 
behavioural disturbances and psychiatric symptoms, and reduces caregiver burden (as 
measured by caregiver time). Side-effects associated with galantamine are mainly 
cholinergic, usually mild to moderate in intensity and transient. Galantamine is being 
considered as one of the first-line pharmacological treatments in patients with mild to 
moderate AD (Corey-Bloom, 2003). 
Furthermore, Erkinjuntti et al. (2002) reported a randomised, double-blind, placebo 
controlled 6-month trial where 24 mg per day galanthamine was assigned to individuals 
with probable VaD and AD combined with cerebrovascular disease (CVD). They found 
that the drug significantly improves cognition, activities of daily living, behaviour, and 
global function in these individuals. Regarding Erkinjuntti et al. (2002) study, Fisher 
and Bowler (2003) noted that mixed dementia-i. e., the coexistence of CVD with AD- is 
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now well recognised form of dementia. Both the NINDS-AIREN criteria for possible 
VaD and NINCDS-ADRDA criteria for possible AD were prepared before the mixed 
dementia was widely recognised. The authors suggested that the trial probably does not 
verify the true demented state of the individuals and in reality the theraputic effect of 
galanthamine may be attributed to mixed dementia They also emphasised the 
importance of early identification of cases with vascular characteristics in cognitive 
decline, as these individuals are candidates for preventative therapy rather than just 
symptomatic treatment. They conclude that for symptomatic treatment, a precise 
diagnosis is not essential and that is individual responsiveness should determine 
whether treatment continues or not. 
1.3.1.2. Unlicensed plant derived drugs 
The prototypical inhibitor of AChE physostigmine (Figure 1.13. ) (Holmstedt, 2000), 
together with huperzine A (Figure 1.14. ) are naturally occurring chemicals in plant 
species of Physostigma venenosum (Jobst, 1863), Huperzia serrata (Liu et al., 1986) 
respectively. 
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Figure 1.13. Physostigmine 
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Figure 1.14. Huperzine-A 
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Severe adverse effects observed in the clinical trials of physostigmine (Brufani and 
Filocamo, 2000) led for the development of its synthetic or semi-synthetic analogues for 
the possible treatment of AD, i. e., MF201 and MF286 (Perola et al., 1997), phenserine 
(Al-Jafari et al., 1998) and tolserine (Kamal et al., 2000). Physostigmine is a non- 
competitive inhibitor of AChE (Perola et al., 1997) and it is more selective for human 
erythrocyte AChE than for human plasma BuChE, with a BuChE/AChE ratio of 6.5 
(Giacobini, 2000). It shows no AChE form selectivity in any brain region (Zhao and 
Tang, 2002) and has less affinity for muscarinic as well as for nicotinic receptors than 
tacrine (Svensson and Giacobini, 2000). 
Huperzine A is a non-competitive (Zhao and Tang, 2002), slow reversible inhibitor of 
AChE (Liu et al., 1986). It inhibits mammalian AChE more than BuChE with a 
BuChE/AChE ratio of 908 (Giacobini, 2000). It also inhibits the G4 form of human 
AChE more than the GI form in cortex with Ki values of 7.0±3.5 x 10"9 M and 
3.5±1.5 xlOM respectively, whereas in hippocampus and striatum this selectivity is 
less apparent (Zhao and Tang, 2002). 
Ashani et al. (1994) reported that the inhibition of AChE by huperzine A occurs through 
association with residues located inside the active site gorge, rather than at the rim of 
the gorge. Tyrosine at position 337 (Y337) is essential for inhibition of recombinant 
human AChE by huperzine A (Ki = 26 nM). Lack of the aromatic side chain in the 
position homologous to Y337 explains the poor inhibitory potency of huperzine A 
towards human BuChE (Ki > 20,000 nM). 
The synthesis and pharmacological evaluation of a series of compounds that combine 
the structural skeletons of (-)-huperzine A and tacrine have been reported (Camps et al., 
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2000). Certain hybrids display more powerful anti-AChE activity than either tacrine or 
(-)-huperzine A. These hybrids were named huprines (Camps et al., 2000), and huprine 
X the most powerful of the series, inhibited human AChE with an inhibition constant, K;, 
of 26 pM, being 40-fold more potent than donepezil, 180-fold more potent than (-)- 
huperzine A, and 1200-fold more potent than tacrine (Camps et al., 2000). 
Sun et al. (1999) found that orally administrated 100 pg of huperzine A for one month 
enhances the memory and learning performance of adolescent students. Moreover, 
Zhang et al. (2002) reported results of a clinical trial of huperzine A on 202 patients 
with probable mild to moderate AD. They found that the drug is safe and effective. It 
significantly improves the cognition, behaviour, activity of daily life, and mood of AD 
patients. Mild and transient adverse events such as edema of bilateral ankles and 
insomnia were observed in 3% of huperzine A treated patients. 
1.3.1.3. Cholinergic anti-inflammatory pathway 
There is evidence (Arkiyama et al., 2000; Selkoe, 2001) of a profound inflammatory 
processes in limbic and associated cortices in AD. The inflammatory cytopathology is 
thought to represent a secondary response to the early accumulation of Aß in the brain. 
This innate immune response leads to the accumulation of pro-inflammatory mediators 
such as tumour necrosis factor a (TNF-a), interleukin 1 (IL-1), IL-6, free radicals and 
microglia activation. Microglia are involved in the Aß-mediated pathogenic cascade, 
because they represent monocyte/macrophages-derived cells in the nervous system 
(Weiner and Selkoe, 2002). Clinical studies suggest that anti-inflammatory drugs may 
delay or slow the progression of AD (Arkiyama et al., 2000). 
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Exposure of human macrophages to nicotine or ACh inhibits the release of pro- 
inflammatory cytokines TNF, IL-1 and IL-18 but not anti-inflammatory cytokine IL-l0 
(Tracy, 2003). Tissue macrophages produce most of the TNF that appears during an 
ongoing inflammatory response (Tracey, 2003). Moreover, the mechanism that 
regulates inflammation has been advanced by identification that the nAChR a7 subunit 
of macrophages is essential for cholinergic suppression of TNF (Wong et al., 2003). 
Thus, anti-ChE agents with agonistic properties for a7 subunit may not only inhibit the 
release of TNF but increase a level of ACh which also suppresses the cytokine. 
1.3.1.4. Salvia. From ethnobotany to clinical trials 
1.3.1.4.1. Basis for the use of plants as medicine 
The origin of plant medicine lies in the evolution and ecological interactions in which 
animals, plants and their ancestors have participated. Plants are sessile organisms and 
flight from predators is not an option (Wake, 2001). Plants that synthesise and store 
molecules, which are distasteful and/or toxic to animals, will have an evolutionary 
advantage over those, which do not. These molecules may disrupt the normal activity of 
animal nervous and other metabolic systems (Farnsworth, 1990; Schmeller et al., 1997). 
There are also reports (Gnagey et al., 1987; Marcel et al., 1998) that ChEs in 
invertebrates of Drosophila melanogaster and Caenorhabditis elegans may exist in an 
intermediate form, which is able to hydrolyse both acetyl and-butyryl-cholines. This 
form may share some characteristics with both human ChEs, Le., AChE and BuChE. 
Plants which use bioactive molecules intervening in herbivore biochemical pathways as 
enzyme inhibitors or neuroreceptor activators or blockers, may use less energy and 
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resources for defence than those which relay on structural defences such as lignification, 
production of spines and adhesive lattices (Balick, 1996; Wake, 2001). 
1.3.1.4.2. Ethnobotanical outlook 
Plant families throughout history supplied the fundamental materia medico for human 
cultures (Farnsworth, 1990). A plant, rejected as food because of objectionable taste or 
undesirable physiological effects after ingestion may have been looked for other 
potential uses such as in religion or medicine (Schultes and Raffauf, 1990). Such plants 
are likely to have entered early pharmacopoeias first and the great medicines of ancient 
times, such as the Solanaceous drugs, stimulants, sedatives and pain-killers such as coca 
and opium, and the hallucinogens found in the Cactaceae, Malpighiaceae and 
Convolvulaceae are all of this type (Balick, 1996). More than a hundred of these 
prototype drugs or unmodified compounds from them are still used in allopathic 
medicine (Farnsworth, 1990). 
Many tribal cultures have no tradition of writing or only a small number of people in the 
group may be literate. Medicinal knowledge of plants, which often overlaps with ritual 
information, may therefore only be passed verbally to the next generation. 
Westernisation of the tribal cultures may lead to a decline in young people being 
apprenticed to the tribal healers and if the adept does not pass that knowledge further, 
the corpus of it is lost. Deforestation may also lead to the extinction of useful plant 
species forcing indigenous groups to seek alternative materials for use as medicines. 
Thus, plant species containing compounds of therapeutic potential may be lost before 
anything is known about them (Wake, 2001). 
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Salvia (sage) is one of the most numerous genera within the family Lamiaceae which 
grows in many parts of the world. Salvia comes from the Latin salvare meaning to save. 
Dweck (2000) summarised sayings which emphasise the value of the plant throughout 
the last twelve centuries, namely "why should a man die, if sage grows in his garden? ", 
"he that would live for aye, must eat sage in May", "for a ripe old age, in May you eat 
sage", "sage helps the nerves and by its powerful might, Palsy is cured and fever put to 
flight", "sage is singularly good for the head and brain, it quickeneth the senses and 
memory, strengtheneth the sinews, restoreth health to those that have the palsy, and 
taketh away shakey trembling of the members". The plant has the reputation as one 
which wards off evil spirits and increase the fertility of women. It helps against snake 
bites and was used by country women in church not to fall asleep. 
Dweck (2000) also reviewed traditional use of Salvia species. Thus, S. officinalis L. or 
"common sage" is said to be anti-inflammatory in small doses. Its suggested uses 
included those as a general treatment to enhance "head and brain" functioning, improve 
the memory, quicken the senses, and delay age associated cognitive decline (Perry et al, 
1999). A tea made of either the dried or fresh leaves and drunk in small doses may 
reduce perspiration. It is known as a carminative, spasmolytic, antiseptic and is used for 
treatment of oral inflammation. The use of the plant has been recommended for varicose 
veins and ulcers, as well as warts on the legs. Infusion of sage has been used as a hair 
tonic and also in cases of alopecia, hair loss. 
The Native American tribes of south-western USA and northern Mexico believe that as 
little as a tablespoon of the seed of S. columbariae Benth. known as "Golden Chia" 
would sustain a tribesman for a day on a laborious march. A hot water extract of S. 
coccinea. Juss. ex Murr. is used in South America for treating blood clots and 
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varicosities. The root of S. miltiorrhiza or "Danshen" which is native to northern China 
has been used as a tonic for at least to the first millennium B. C. to stimulate the blood 
circulation and regulate the menses, relieve abdominal pain, depression and insomnia. S. 
plebeia (Brown) has been used in the Indo-Chinese region to relieve toothache and also 
treat cholera and dysentery. The seeds of S. plebeia have long been used to in native 
medicine of Asia to treat gonorrhoea and menorrhagia. In China S. plebeia is known as 
a detoxifier, diuretic, blood cooler, haemostatic, and for the reduction of swelling. S 
sclarea L. or "Clary sage" has been used by the native Jamaicans to treat inflammation 
of the eyes. A decoction of the leaves boiled in coconut oil is beneficial for the stings of 
scorpion. The dried roots of Clary sage, crushed and powdered, are used to clear the 
head and ease a headache (Dweck, 2000). 
S. africana-lutea L. known as "golden African sage", has been used in South Africa for 
cold and is said to be diaphoretic. The Nama, north Americans, use a decoction of the 
plant for coughs, cold and female ailment. Traditional medicine practitioners in the 
Western Cape Province use infusion of the leaves to treat headache, fever and digestive 
disorders (Watt and Breyer-Brandwijk, 1962). S. apiana (Jepson) or "white sage" has 
long been used as important ceremonial incense by many Native Americans for ritual 
purification and cleansing. The smoke is said to smell wonderful and has a soothing 
effect (Epling, 1947). A hot water extract of S. transsylvanica Schur ex Griseb. has been 
used in central parts of Europe to treat inflammation of the throat (Prokopenko and 
Litvinenko, 1982). An infusion of dry or fresh leaves of Sfruticosa Mill. or "Greek 
sage" is used as spasmolytic, hypoglycaemic, diuretic, choleretic and also for treatment 
of common cold (Bellomaria et al., 1992). In Ethiopia and Eritrea the fruits of S. 
schimperi Benth. are used locally for treatment of liver disorders (Tadesse and 
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Demissew, 1992) and S. divinorum is used by the Mazatec people of Oaxaca in Mexico 
to induce visions (Valdes, 1994). 
1.3.1.4.3. CNS activities relevant to dementia 
Botanical descriptions with plant images and biological activities of extracts from 
Salvia species are included in the Salvia database (Appendix 1). The database can also 
be accessed via MPRC web-site, i. e., http: //www. ncl. ac. uk/medplant. 
As mentioned above, the classical inhibitor of AChE, physostigmine (1.3.1.2), together 
with huperzine-A. (1.3.1.2. ) and galanthamine (1.3.1.1.4) are naturally occurring 
molecules in plants. The search for other plant derived inhibitors of ChEs has 
accelerated in view of the benefits of these drugs not only in the treatment of AD but 
other forms of dementia, such as dementia with Lewy bodies (Perry et al., 1994), 
vascular dementia (Erkinjuntti et al., 2002) and Down's syndrome (Kishnani et al., 
1999). 
Howes and Houghton (2003) reviewed CNS activities of S. miltiorrhiza Bung. (Dan 
Shen) which are relevant to memory and cognition. The root of the plant may inhibit 
neuronal cell death by inhibition of presynaptic glutamate release. Glutamate may 
induce neuronal degeneration by overstimulation of NMDA receptors. Memantine, an 
NMDA receptor antagonist, treatment leads to functional improvement and reduces care 
dependence in severely demented patients. Dan Shen also inhibits nitric oxide formation, 
which may be involved the effects of excitatory amino acids, including their effects on 
brain development, learning and memory. Zhang et al. (1994) showed that the plant 
may protect neuronal cell damage in the hippocampus after brain injury. Ji et al. (2000) 
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reported that Dan Shen increases coronary blood flow and scavenges free radicals in 
ischemic diseases, leading to improvement of heart functions. Ji et al. (2000) also 
reported that Dan Shen is effective against stroke, which is a common feature in VaD or 
mixed dementia (1.1.2.3. ), while Hong et al. (1997) showed its anti-AChE activity. 
Thus, the plant may have dual mode of action in the treatment of VaD, inhibition of 
AChE and protection against stroke. 
Du et al. (2000) demonstrated that salvianolic acid B (Figure 1.15. ), a constituent of 
Dan Shen root, ameliorates learning and memory impairments induced by cerebral 
transient ischemia in mice. Moreover, salvianolic acid B may not only prevent the P- 
amyloid peptide toxicity in vitro (Zheng and Juntian, 2000) by decreasing nitric oxide 
release in a dose dependent manner but also inhibit its aggregation and fibril formation 
(Tang and Zhang, 2001). 
Tanshinone I (Figure 1.16. ) and Tanshinone II (Figure 1.17) are the major lipid soluble 
constituents of the dried root of Salvia miltiorrhiza used in traditional Chinese medicine 
for the treatment of cerebrovascular diseases including stroke (Lam et al., 2003). Lam et 
al. (2003) showed that Tanshinone 11 (16 mg kg'') readily penetrates the blood brain 
barrier in mice and reduces brain infarct volume after middle cerebral artery occlusion. 
The authors concluded that tanshinones may have potential for further development as 
neuroprotective drugs. Moreover, Liu and Wu (1999) demonstrated that 20 mg kg-1 of 
Tanshinone II improved learning memory in mice. Howes and Houghton (2003) also 
reviewed anti-inflammatory and anti-oxidant properties of Tanshinones which are 
relevant to the treatment of dementia. 
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Perry et al. (1996) reported that essential oil of S officinalis inhibits human brain AChE 
in a dose dependent manner. An IC50 of the oil was 0.07 mg ml-1. Moreover, 
Akhondzadeh et al. (2003 a) reported a double blind, randomised and placebo- 
controlled clinical trail of 45% EtOH extract of Salvia officinalis in individuals with 
mild to moderate stages of AD. The study showed that 4 months administration of 60 
drops of the extract a day significantly enhance cognition and may reduce agitation in 
those with the disease. 
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Figure 1.16. Tanshinone I (C18 H12 03). Figure 1.17. Tanshinone II (C19H18o3). 
Essential oil of S. lavandulaefolia Vahl. (Spanish sage) showed (Perry et al., 2000) to 
exhibit human erythrocyte anti-AChE activity with an IC50 value of 0.03 µl ml-1 
(approx., 0.04 mg ml-1). Perry also reported et al., (2002) that in vivo essential oil of 
Spanish sage inhibits the rat brain AChE. There was a decrease in AChE activity in the 
O Me 
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striatum and hippocampus, though not in the cortex, at doses of 20 pl and 50 µ1 
suggesting that orally administrated constituents of the oil or their metabolites reach the 
brain and inhibit AChE in select areas. The inhibition of the enzyme seen in the striatum 
may be of relevance to AD as this part of the brain is thought to participate in emotional 
and motivational behaviour and AD patients experience behavioural dysfunction 
(Seldon et al., 1994). One of the symptoms of AD is short-term memory loss and the 
hippocampus that is severely affected in the disease plays a major role in short term 
memory (1.2.2.1. ). Furthermore, the improvements in mood and performance were 
apparent in healthy young volunteers after oral administration of 50 pI dose of Spanish 
sage oil (Tildesley et al., 2003). Essential oil of Spanish sage lacks thujone-a toxic 
component (Hold et al., 2000) of S. officinalis, hence Spanish sage may be a more 
appropriate species to investigate for dementia treatment. Some of the major individual 
constituents of essential oil Salvia species such as 1,8-cineole (Figure 1.18), a-pinene 
(Figure 1.19) were also reported (Perry et al., 2000) in-vitro to inhibit human 
erythrocyte AChE with IC50 values of 0.67 mM and 0.63 mM respectively. 
N 
Figure 1.18. a-pinene: C1oH16 
(1 S)-2,6,6-Trimethylbicyclo[3.1.1 ]hept-2-ene) 
Figure 1.19.1,8-cineole: C1OH180 
(1,3,3-trimethyl-2-oxabicyclo[2.2.2. ] octane) 
Wake et al. (2000) reported nicotinic and muscarinic activities of 80% EtOH extracts of 
Salvia coccinea Juss. ex Murr., S. verticillata L. and S. elegans var "Scarlet Pineapple". 
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The genus also has other properties relevant to dementia therapy, namely 
antiinflammatory (Moretti et al., 1997; Hosseinzadeh and Yavary, 1999; Baricevic et al., 
2001), antioxidant (Lionis et al., 1998; Mantle et al., 2000; Zupko et al., 2001), 
oestrogenic (Bartram, 1995) and glutamergic activity (Kuang and Xiang, 1994). 
Volatile constituents of essential oils of Salvia species are likely to readily cross the 
blood brain barrier (Perry et al., 2002) due to their small molecular size and 
lipophilicity. Their volatile nature may also enable their administration as inhaled 
vapour avoiding the alimentary system with its attendant denaturing of active molecular 
species. 
In addition, another plant of the family Lamiaceae, Melissa officinalis (lemon balm) 
showed in vivo to improve cognitive performance and mood in young people at single 
doses of 600,1000 and 1600 mg encapsulated dried leaf. Ethanol extract of the dried 
leaf plant in vitro showed no inhibition of human AChE but was able in-vitro to 
displace [3H]-(111)-nicotine and [3H]-(111)-scopolamine from human nicotinic and 
muscarinic receptors, with IC50 values of 0.18 mg ml-1 and 3.47 mg ml" respectively 
(Kennedy et al., 2003). In a four month double blind, randomised, placebo controlled 
trial 60 drops a day of 45% EtOH extract of lemon balm significantly improved 
cognitive function, using ADAS-cog and CDR diagnostic criteria, and reduced agitation 
in patients with mild to moderate AD (Akhodzadeh et al., 2003 b). 
Thus, the genus Salvia (family Lamiaceae) is a warranted candidate in endorsing herbal 
medicine as treatment of age related disorders. 
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1.3.1.4.4. Guidelines for clinical trials of botanicals 
Current USA guidelines for clinical trials of botanicals were highlighted by Berman 
(2003 a) at a three day conference on medicinal plants and their uses at Imperial College, 
London. According to the speaker, botanical agents are characterised by the FDA 
according to their use, not their composition. If the intended use is to "promote health" 
and preserve the "structure and function" of the body, the agent is viewed as a dietary 
supplement. If the intended use is to treat or prevent a disease, the agent is considered to 
be a drug. Botanical agents used as dietary supplements are regulated by the FDA under 
the Dietary Supplement health and Education Act of 1994 (DSHEA). In contrast, 
botanical agents used as drugs are regulated by the FDA's centre for Drug Evaluation 
and Research (CDER). 
Botanical drugs have two unique characteristics compared with to conventional agents. 
Firstly, they are mixtures of uncharacterised constituents whose therapeutic effect 
occurs through likely synergistic interaction of unknown constituents with the known 
ones. Such interaction may provide more efficacy than by the known constituent along. 
Nevertheless, being a mixture is a disadvantage in that it is challenging to assay a 
product for quality if the active ingredients are unknown. Secondary, they have had 
substantial prior human use to formal clinical trials. Prior human use is an advantage as 
it gives some assurance that the product may be safe and effective. 
For botanical drugs in-vitro information, although encouraged, is not absolutely 
required. As far as clinical data are concerned neither phase 1,2 nor 3 trials should be 
omitted in a product evaluation program. Phase 3 trials should not be undertaken until 
dose optimisation with respect to safety and efficacy has been accomplished in prior 1 
and 2 trials. 
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1.4. Neuroactive phytochemical project 
Despite the strong ethnobotanical reputation of sage as a plant with memory enhancing 
properties not enough has been studied towards establishing the clinical potential of the 
genus. There are no reports on anti-BuChE, anti-secretase and pro-inflammatory 
cytokines suppressive activities of sage, although nicotinic and muscarinic binding 
properties of ethanol extracts were reported (Wake, 2001). 
This Ph. D project was designed as a follow up of previous positive findings on anti- 
acetylcholinesterase activity of Spanish sage oil (Perry et al., 2000). In vitro activities of 
non-polar extracts of Salvia species relevant to current and prospective treatment of 
neurodegenerative disorders have been evaluated. Studies on chemical interactions of 
low molecular weight compounds have also been included, as these add to 
understanding of a pharmacological mechanism of interaction and may contribute 
towards standardisation of bioactive extracts for clinical trials. 
The main question to be addressed is: could a multiple drug therapy for treatment of 
dementia be based on a standardised herbal preparation comprising a number of 
synergistically interactive molecules with multiple activities relevant to treatment of 
dementia? 
1.5. Aims of the project 
i) To screen a range of non-polar extracts of Salvia species and their individual chemical 
compounds for anti-AChE, anti-BuChE and anti-ß secretase activities. 
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ii) To develop and standardise a novel supercritical fluid extraction process based on the 
proprietary solvent Phytosol A for the purpose of isolation of bioactive extracts which 
could be applied clinically for treatment of dementia. 
iii) To investigate and characterise chemical interactions of single compounds present in 
sage species towards inhibition of AChE, hence to conclude if the activity of a single 
compound accounts for the activity of a whole extract. 
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Chapter 2. Materials and Methods 
2.1. Steam distillation. Anti-cholinesterase activity of oils of Salvia species 
2.1.1. Chemicals 
Acetylcholinesterase (EC 3.1.1.7; ) from human erythrocytes (Ott et al., 1975), 
acetylthiocholine iodide (ATChI), butyrylcholinesterase (EC 3.1.1.8) from human 
serum, butyrylthiocholine (BTChI), 5: 5-dithiobis-2-nitrobenzoic acid (DTNB), diethyl 
ether (Analar, boiling point 34-35 °C), physostigmine, quinidine, anhydrous magnesium 
sulphate and ethanol (Analar) were purchased from Sigma, U. K. 
2.1.2. Plant material 
Aerial parts of Salvia officinalis L. "purpurea" were harvested at flowering (6/02) and 
vegetative (9/02) stages from Jesmond Dene garden, Newcastle upon Tyne, U. K. Fresh 
leaves of the plant were steam distilled on the day of harvest. 
Aerial parts of Salvia officinalis L. (broad leaf sage) were collected on 19th August, 
2002 (8/02) from Dilston Physic Garden, Corbridge, Northumberland. Fresh leaves of 
the plant were steam distilled on the day of harvest. 
Air-dried, aerial parts of Salvia lavandulaefolia Vahl. (Spanish sage) were supplied and 
verified by Advanced Phytonics Ltd., U. K. The plants were harvested in the wild in 
October, 2001 in Granada, Spain. Leaves of the plant were used in steam distillation. 
Air-dried, aerial parts of Salvia fruticosa Mill. "Greek sage" were supplied and verified 
by Advanced Phytonics Ltd., U. K. The plant, growing wild, was harvested in the 
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Troodos area of Cyprus in August, 2002 (8/02). The material contained no seeds or 
floral remains. Leaves of the plant were used in steam distillation. 
Aerial parts of Salvia fruticosa Mill. were also harvested in the Troodos region of 
Cyprus in late July, 2001 (7/01). The plant was verified by Dr Djakouri in Cyprus and 
sent to U. K as dried material. Leaves of the plant were used in steam distillation. 
Verified voucher specimens of each plant (001; 002; 003; 004; 005; 006 as listed above) 
were deposited in the herbarium of Medicinal Plant Research Centre, University of 
Newcastle, U. K. 
2.1.3. Extraction process 
The essential oils were extracted for 2.5 hours by a method of steam distillation in an 
all-glass apparatus (Houghton and Raman, 1998). Nine parts of diethyl ether was used 
to separate oil from one part of water-oil phase in a three batch extraction process. 
Anhydrous magnesium sulphate was added to the diethyl ether-oil mixture to a 
saturation level in order to absorb any remaining water. The oil-ether phase was filtered 
and the ether evaporated at room temperature using a rotary evaporator to obtain the oils, 
which were stored in sealed amber glass vials under oxygen free nitrogen at 5 °C for 
less than one month before analyses. 
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2.1.4. Assays 
2.1.4.1. Acetylcholinesterase activity 
2.1.4.1.1. Human erythrocyte AChE 
Assessment of human AChE inhibition was carried out using the method of Ellman et al. 
(1961) as modified by Nostrandt et al. (1993). A typical run consisted of 5 µl of AChE 
solution, at a final assay concentration of 0.03 U/ml; 200 pl of 0.1 M phosphate buffer 
pH 8; 5 pl of DTNB, at a final concentration of 0.3 mM prepared in 0.1 M phosphate 
buffer pH 7 with 0.12 M of sodium bicarbonate; and 5 µl of a sample solution (oils) in 
53% ethanol (EtOH). The reactants were mixed in a 96-well, flat bottom polystyrene 
microtiter plate. The mixture was pre-incubated at 30 °C over a range of times. The 
reaction was initiated by adding 5 µ1 of ATChI at a final concentration of 0.5 mM. Each 
sample was assayed in triplicate. 
A measurement of the hydrolysis was started after 6 minutes maintenance time. This 
time was necessary to overcome the problem with the inhibition of the human enzyme 
by EtOH (see below: EtOH interference). As a control 5 µ1 of the inhibitor solution was 
replaced with 5 µl of 53% ethanol. The control was also assayed in triplicate. To 
monitor any non-enzymatic hydrolysis in the reaction mixture two blanks for each run 
were prepared in triplicate. One blank consisted of 205 µl buffer (replacing 5 µl 
enzyme), 5 µl DTNB, 5 µl 53% EtOH and 5 µl substrate. A second blank also had 5 µl 
enzyme, 205 µl buffer (replacing 5 µl substrate), 5 µl DTNB and 5 µl 53% EtOH. A 
kinetic run absorbance at 412 nm was measured on a Titertek Multiskan MCC/340 
microplate reader for a period of six minutes at 30 °C with a Genesis-Lite Windows 
microplate software (Labsystem International). 
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The thiocholine, formed during hydrolysis of ATCh, rapidly reacts with DTNB and 
releases a yellow 5-thio-2-nitrobenzoic acid anion (Figure 2.1. ). The production of this 
coloured anion was recorded at 412 nm over 6 min run. Any inhibition of AChE by an 
inhibitor would reduce the release of such anion, as a result of binding to the enzyme, 
and that would result in reduction of hydrolysis of the enzyme. The spectrophotometer 
reads the changes in releasing of the acid anion and expresses it as a change of 
absorbance per minute (abs/min) in a slope value. A percentage of the inhibition was 
calculated as: 
abs/min with no inhibitor - abs/min with inhibitor 
Inhibition =x 100% 
abs/min with no inhibitor 
ham" 
!! 
" 
'ý^4Pt£ý. ý 
Figure 2-1. Release of a yellow 5-thio-2-nitrobenzoic acid anion in 96-well plate 
2.1.4.1.2. Bovine erythrocyte AChE 
A measurement of hydrolysis of bovine AChE was carried out as described in 2.1.4.1.1. 
with a final concentration of the enzyme at 0.008 U/ml. There was no six minutes 
maintenance time as the enzyme was not inhibited in the assay by 1.9% EtOH (see 
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below: EtOH interference) and 84% EtOH was therefore used in preparation of inhibitor 
stock solutions. 
2.1.4.1.3. Butyrylcholinesterase activity 
Assessment of BuChE (human serum) inhibition was performed as described in 
2.1.4.1.1 with the exception of. a final enzyme concentration of 0.01 U/ml; BTChI was 
used at a final concentration of 0.5 mM; the enzyme was not inhibited by 1.9% EtOH in 
the assay, thus 84% EtOH was used in preparation of inhibitor stock solutions; there 
was no 6 minutes maintenance time (see below: EtOH interference). 
2.1.5. Ethanol interference 
Reports (Haboubi and Thurnham, 1986; Baker and Chen, 1989; Dudek et al., 1995) 
indicating that EtOH may inhibit human AChE were confirmed in this study. An assay 
concentration of 1.9% EtOH significantly inhibited (53±2.6%) human AChE. Using 
1.2% EtOH in the assay and maintaining the mixed reagents in the plate for 6 minutes 
before running the assay prevented the inhibition of human AChE by EtOH. Such a low 
concentration of EtOH restricted the solubility limits of plant extracts and their 
individual constituents. 1.9% EtOH did not however inhibit bovine erythrocyte AChE 
or human BuChE. 
Because of a low solubility range of monoterpenoids and sesquiterpenoids in 53% 
EtOH solution the initial screening was performed using bovine AChE and chemicals 
showing activity were re-analysed using human AChE. 
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2.1.6. Dose-response curves and equations 
Each inhibitor was tested in triplicate over a range of concentrations. A triplicate of 
each concentration was equivalent to n=1. Using a Microsoft Excel software dose- 
response curves were fitted to the data points. There were six triplicate sets for the oils 
(n=6), resulting in the same number of dose-response equations, which were used for 
statistical analysis. 
A concentration of the compounds which gave 50% inhibition of the enzymes was 
expressed as an IC50 value. The concentration of compounds which did not achieve 50% 
inhibition was expressed as the percent inhibition, i. e. maximum inhibition of the 
enzymes within the solubility limit of a chemical. 
2.1.7. Gas Chromatography-Mass Spectrometry (GC/MS) 
GC/MS analysis of aromatic compounds was performed on Hewlett-Packard 6890 GC 
with a split/splitless injector (280 °C) linked to a Hewlett-Packard 5973 mass selective 
detector (electron voltage 70eV, filament current 220 uA, source temperature 230 °C, 
quad temperature 150 °C, multiplier voltage 2400V, interface temperature 300 °C). Data 
acquisition was controlled by a HP Kayak xa pc chemstation computer, initially in full 
scan mode 35-550 amu/sec for greater sensitivity. The total peak areas were calculated 
on the basis of 1% of the major peak. 
A sample (1µl) in dichloromethane (Analar) was injected by an HP6890 auto sampler 
and the split opened after one minute. Separation was performed on Zebron (ZB) ZB-5 
(30m x 0.25mm ID x 0.25pmdf) capillary column coated with 5% phenyl polysiloxane. 
The GC was temperature programmed from 40-300 °C at 4 °C per min and held at a 
final temperature for 20 minutes with Helium as the carrier gas at flow rate of Iml/min 
(initial pressure of 50 kPa, split at 30 mis/min). 
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2.2. Supercritical fluid extraction. Anti-cholinesterase activity of extracts of 
Salvia species 
2.2.1. Chemicals/materials 
Phytosol A (1,1,1,2-tetrafluoroethane) and a hand-set extraction kit (Figure 2.2. ) were 
provided by Advanced Phytonics Ltd., U. K. Acetylcholinesterase (EC 3.1.1.7; ) from 
human erythrocytes (Ott et al., 1975), acetylthiocholine iodide , butyrylcholinesterase 
(EC 3.1.1.8) from human serum, butyrylthiocholine , 5: 5-dithiobis-2-nitrobenzoic acid 
(DTNB), physostigmine, quinidine, hexane (analar) and ethyl acetate (analar) were 
purchased from Sigma, U. K. 
2.2.2. Plant material 
Aerial parts of S. africana-lutea Linn. (syn. S. aurea), S. apiana Jepson "white sage", S. 
argentea Linn. (silver sage), S. atrocyanea, S. confertiflora, S. corrugata Vahl., S. 
discolor Kunth., S. divinorum Epling (Pipilzintzinti), S. glutinosa Linn. (hardy sage), S. 
haematodes Linn., S. involucrata Cav., S. Jamensis var. la luna, S. keerlii Benth., S. 
longistyla Benth., S. microphylla var. neurepia Epling, S. napifolia Jaquin., S. sclarea 
Linn. (clary sage), S. stenophylla Burch. ex Benth., S. verbenaca Linn., S. verticilata 
Linn., were harvested in June, 2002 (S. yunnanensis June, 2001) from Chelsea Physic 
Garden, London, U. K. Freeze-dried material, which had no seeds or floral remains, 
were used to prepare the extracts. The freeze-drying was performed on the day of 
harvesting. 
Aerial parts of S. officinalis Linn. "purpurea" were harvested at flowering stage 
(18/07/02) from Jesmond Dene garden, Newcastle upon Tyne, U. K. The material 
contained no seeds or floral remains. Freeze-dried leaves were used in the extraction 
process. 
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Aerial parts of S. officinalis Linn. (broad leaf sage) were collected in July, 2001 from 
Dilston Physic Garden, Corbridge, Northumberland. The material contained no seeds or 
floral remains. Freeze-dried leaves were used in the extraction process. 
Aerial parts of S. lavandulaefolia Vahl. (Spanish sage) were supplied and verified by 
Advanced Phytonics Ltd., U. K. The plants were harvested in the wild in October, 2001 
in Granada, Spain. Freeze-dried leaves were used in the extraction process. 
Air-dried, aerial parts of S. fruticosa Mill. "Greek sage" were supplied and verified by 
Advanced Phytonics Ltd., U. K. The plant, growing wild, was harvested in the Troodos 
area of Cyprus in August, 2002. The material contained no seeds or floral remains. 
Freeze-dried material were used in the extraction process 
2.2.3. Extraction process using Phytosol A 
A batch extraction process was performed using a hand-set extraction kit provided by 
Advanced Phytonics Ltd., U. K (Figure 2.2). One part of ground plant material was 
mixed with eight parts of the solvent (Kusova and Vetrov, 1987) at room temperature 
and left for lhour and 15 minutes (consistent shaking) in a pressurised plastic/rubber- 
free extraction vessel (Figure 2.2. a). After the time elapsed, the extraction vessel was 
inverted and connected to a vertically positioned evaporation vessel (Figure 2.2 b). The 
solvent-extract phase was filtered using a plastic/rubber free filter (Figure 2.2. d) into an 
evaporation vessel (Figure 2.2. b) by opening valves of each of the vessels (Figure 2.2. 
c). It may be necessary to release some of the positive pressure from the evaporator 
during the filtration to allow full transportation of the solvent-extract phase from the 
extractor to the evaporator. After the filtration process, the valves were closed and the 
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vessels detached. The solvent was boiled off by carefully opening the valve of the 
vertically positioned evaporator. leaving a plant extract. 
a 
c. A lid to the extraction and cv aporation 
vessels. It consists of a valve which controls 
a pressurised flow of the solvent and a filter 
which prevents plant material passing 
through from the extractor to the evaporator. 
b. 1 iltering the solvent-extract hhasc from 
the pressurised extraction vessel (top) into 
a glass evaporation vessel (bottom). 
Glass Wool 
{ 
Large Gauze 
Small Gauze 
'O'R7ng & Retainer---%dd 
d. Parts of the filter. Cotton wool was 
used instead of the glass wool. The "O" 
ring was made of polytetrafluoroethylene 
(PTFE) to avoid a cross contamination 
with plasticizers. 
Figure 2.2. A hand-set extraction kit. 
The plant extract was collected using a glass Pasture pipette into an eppendorf tube and 
centrifuged on an Eppendorf 5417R centrifuge machine for 30 minutes at 5 °C with a 
speed of 1200 rpm. After the centrifugation process, the extract was visually examined 
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for its possible separation. namely a solid residue and oil (or resin). The oil part was 
carefully pipetted off and stored in sealed amber glass vials under oxygen free nitrogen 
at 5 °C. 1 ml of hexane was added to the residue (only three residues were analysed; S. 
argentea. S. napifolia. S. yunnanensis) to dissolve non-polar traces of the oil. The 
mixture was sonicated in Decon F5 minor sonication bath for 15 min and then 
centrifuged for 10 minutes at 5 °C with a speed of 1200 rpm. After that a supernatant 
was pipetted off and new 1 ml hexane was added. The process was repeated three times. 
At the end of the process, remained hexane was dried off with oxygen free nitrogen and 
the residue stored at 5 °C. 
2.2.4. Assays 
Inhibition of human AChE and human BuChE by Phytosol A extracted botanicals were 
carried out as described in 2.1.4.1.1. and 2.1.4.1.3. respectively. 
2.2.5. Gas Chromatography-Mass Spectrometry (GC/MS) 
Analysis of chemical composition of extracts of Salvia species was performed as 
described in 2.1.7. 
2.2.6. Extraction with ethanol 
3 grams of air dried plant (ground) were mixed with 30 ml 70% EtOH for 5 days in a 
dark with constant gentle shaking. After this the liquid part was filtered off and 
centrifuged (14000 rpm. 10 min x 2) using Eppendorf an centrifuge machine (5417 R). 
1 ml of the supernatant was transferred into an eppendorf (3 tubes to calculate the mean) 
and freeze-dried at -55 
°C, 0.5 mBar to a constant weight (+0.05% variation). 
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2.3. Anti-cholinesterase activity of terpenoids present in extracts of Salvia 
species 
2.3.1. Chemicals/Reagents 
As in 2.1. with addition of. 
(1S)-(+)-3-carene, manool, sclareol, (-)-guaiol, (R)-(+)-limonene were purchased from 
Aldrich Chem. Co., U. K. (-)-globulol, (-)-alpha-copaene, (-)-bornyl acetate, (-)-(3-pinene, 
(-)-trans-caryophyllene. (-)-alpha-thujone were obtained from Fluka, U. K. and Neryl 
acetate. alpha-terpineol from Acros Organics, U. K. Sabinene was purchased from Apin 
Chem. Ltd.. U. K. (+)-a-pinene, 1,8-cineole, (IR)-(+) camphor, (±)-linalool, (-)-borneol, 
caryophyllene oxide, a-caryophyllene (a-humulene) from purchased from Sigma, U. K. 
2.3.2. Assays 
2.3.2.1. Acetylcholinesterase activity 
2.3.2.1.1. Bovine erythrocyte AChE 
As described in 2.1.4.1.2 
Lack of inhibition of the enzyme activity by 1.9% EtOH allowed initial screening of 
single chemicals, present in species of Salvia, for their anti-AChE activity at high 
concentrations at five minutes incubation time. Those compounds showing marked 
potency were further analysed using the human enzyme. 
2.3.2.1.2. Human erythrocyte AChE 
As described in section 2.1.4.1.1. 
2.3.2.1.3. Butyrylcholinesterase activity 
As described in section 2.1.4.1.3. 
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2.3.3. Dose-response curves and equations 
As described in section in 2.1.6. 
There were four triplicate sets of concentrations for individual compounds (n=4) 
resulting in the same number of dose-response equations, which were used for statistical 
analysis. 
2.4. Synergistic and Antagonistic Interactions of Anticholinesterase Terpenoids 
in Salvia lavairdu/aefolia Essential Oil 
2.4.1. Chemicals/Reagents 
Acetylcholinesterase (AChE; EC 3.1.1.7) from bovine erythrocytes, acetylthiocholine 
iodide (ATChI), 5: 5-dithiobis-2-nitrobenzoic acid (DTNB), (+)-a-pinene, (-)-(3-pincne, 
1.8-cineole. (1R)-(+) camphor, (±)-linalool, (-)-borneol, (-)-bornyl acetate, 
caryophyllene oxide (car., oxide), ethanol (Analar), disodiurn hydrogen phosphate 
(Na2HPO4). sodium dihydrogen phosphate (NaH2PO4). sodium bicarbonate (NaHCO3) 
were purchased from Sigma. UK. 
Salvia latiandu/aefolia (fresh leaves) steam distilled oil was purchased from Baldwins & 
Co., London, UK. 
2.4.2. Bovine erythrocyte AChE 
A measurement of hydrolysis of bovine AChE was carried out as described in section 
2.1.4. I.?. 
2.4.3. Dose-response curves 
Each inhibitor was tested over a range of concentrations in triplicate to obtain mean 
inhibition data. Using a Microsoft Excel programme a dose-response curve was fitted to 
72 
Materials and Methods 
the data points. There were four replicate sets of concentrations for each inhibitor (n=4), 
consequently producing four dose-response equations, which were used for calculations 
and statistical analysis of individual compounds and their combinations (Appendix 4). 
A concentration of an inhibitor corresponding to 50% inhibition of AChE (IC50 value) 
was calculated using the dose-response curve equations. A concentration of each 
inhibitor was substituted into the dose-response curve equation of each inhibitor as X 
(concentration). Hence Y would represent inhibition, i. e., an IC50 value or the activity of 
an inhibitor at its particular concentration (Appendix 4). 
2.4.4. Calculation of expected inhibition of combined chemicals 
The method used is described by Berenbaum (1985) and based on an assumption that 
the agents in a combination do not interact, producing a zero-interactive response. This 
is expressed in the following equation: 
n d; 
E=1 (1) 
i=1 D; 
where n is a number of agents in a combination with i=1,2,3,..., n; d; is the actual dose 
(concentration) of the individual agents in a combination and D; is the dose 
(concentration) of the agents that individually would produce the same effect as the 
individual compounds in the combination. 
If equation 1 gives a value of more than 1, >1 - synergy effect, if less than 1, <1 - 
antagonism occurs. For a combination of two agents equation (1.1) can be written as: 
da/Da + db/Db =1 (1.1) 
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Where da and db are known and represent values of final concentrations of two agents 
in a combination. On a graph of the dose-response curves of agents A and B, a 
horizontal line intersects these two curves at points corresponding to Da and Db (X-axis 
co-ordinates). Da, Db and the combination (da, db) are isoeffective (Equation 1.1). 
Therefore, a solution is to find the horizontal, isoeffective straight line, which would 
determine doses of A (Da) and B (Db) to satisfy equation 1.1. This line must have one 
value on the Y-axis and two on the X-axis. A value on the vertical axis (Y) represents 
an inhibition and values on the horizontal axis (X) represent concentrations. These 
concentrations are expressed as Da and Db. It is therefore a matter of finding which 
isoeffective Y value, inserted into the dose-response curve equations of each agent, 
produces values of its corresponding concentrations (X) for Da and Db, which satisfy 
equation I. I. The horizontal isoeffective line locating these values indicates the 
response of the combination if there is no interaction, and represents the value of the 
expected inhibition of a non-interactive combination. If a calculated value of the 
combination is significantly less than obtained experimentally, synergy can be inferred, 
if more - antagonism. The same approach can be applied to any number of agents in a 
combination (Equation 1). The method is illustrated in Appendix 5. 
2.4.5. Calculation of the interaction index of a combination 
The value of observed inhibition of a combination, comprising a number of compounds, 
was inserted into the dose-response curve equations of each individual compound as Y 
(vertical axis for an inhibition) to calculate the corresponding value of X (horizontal 
axis for concentrations), Da and Db in equation (2). If the equation for zero-interaction 
response resulted in a value significantly less than 1, synergism was inferred, if more 
then antagonism. The calculation of the interaction index is shown in Appendix 5. 
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2.4.6. Statistics 
The data was presented as mean ± standard deviation of the mean. Group comparisons 
was analysed using a two sample Student's t-test with a probability value of < 0.05 as 
the level of statistical significance. 
2.5. Extracts of Salvia species in relation to ß-secretase, interleukin 8 and 
cholinergic receptor activities 
2.5.1. ß-secretase assay 
2.5.1.1. Materials 
Secretase activity kit and BACE-1 was purchased from R&D systems Europe, LTD. 
UK. The EDANS/DABCYL substrate corresponds to the amino acid sequence 
associated with ß-secretase cleavage of amyloid precursor protein (aa 668-675) and 
includes substitution of Asn and Leu for amino acids Lys670 and Met671 known as the 
Swedish mutation. 
Recombinant human BACE-1 (ß-secretase): 
A cDNA sequence encoding the ectodomain (amino-acid residues 1-460) of the 
recombinant human ß-secretase was expressed as secreted protein with a COOH- 
terminal His tag in a murine myeloma cell line, NSO. Purity > 90%. 
Extracts of S. fruticosa, S. officinalis var. purpurea and S. apiana were obtained using 
Phytosol A (2.2.3. ). 1,8-cineole and 3-carene were purchased from Sigma Co., U. K. and 
Fluka Co., U. K. respectively. 
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2.5.1.2. Method 
Principle of the test: 
Cleavage of the substrate, conjugated to the reporter molecules EDANS and DABCYL, 
by BACE-1 separates the EDANS and DABCYL allowing the release of a fluorescent 
signal. The level of secretase enzymatic activity is proportional to the fluorometric 
reaction. A measurement of fluorescence was performed on a Tecan SPECTRAFluoro 
Plus fluorometer using Magellan software. 
BACE-1 preparation: 
Reconstitute 100 gg of product in 1000 µl distilled water to make a stock solution 1 
[100pg/ml]. Take 187.5 pl from stock 1 and add 1312.5 µl distilled water to prepare a 
stock solution 2 [18.75 µg BACE/1.5m1 or 0.0125 µg/µ1]. This is a working stock 
solution. Using 40 µl of the stock for the assay or 0.5 pg BACE per well would make 
4.8 µg/ml BACE final concentration. 
Assay procedure: 
40 µl BACE-1 were mixed with 50 µl reaction buffer (supplied) and 10 µl test solution 
(proposed inhibitor). The mixture was incubated over 30,60,90 and 120 minutes in 
dark at 37 °C. 5 pl substrate were added after a period of incubation time. A 96 flat 
bottom micro titter plate was read on a fluorescence microplate reader in endpoint mode 
at an excitation wavelength of 360 nm and emission at 535 nm. 
Negative control: as above with the exception that 10 µl test solution was replaced with 
the 10 µl 84% EtOH (8% EtOH in the assay). Run in triplicate. 
Blank 1 as above with the exception that 10 µl inhibitor was replaced with the 10 
µ1 water. Run in triplicate. 
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Blank 2 as above with the exception that 40 µl BACE were replaced with 40 µl 
distilled water and 10 µl 84% EtOH (8% EtOH in the assay) were used 
instead of inhibitor. Run in triplicate. 
Blank 3 as above with the exception that 5 µl substrate were replaced with 5 µl 
distilled water and 10 µl 84% EtOH (8% EtOH in the assay) were added 
instead of inhibitor. Run in triplicate. 
2.5.2. Neuroinflammation as a target in the treatment of AD 
2.5.2.1. Materials 
Pelikine Compact Human IL-8 ELISA kit and IL-8 was purchased from Research 
Diagnostics Inc. HT29-MXT cell line was supplied Dr. Smirnova (Mucin research 
group, School of Cell and Molecular Bioscience, University of Newcastle). Dulbecco's 
modified Eagle medium (DMEM), fetal bovine serum (FBS), phosphate buffer saline 
(PBS), sulphuric acid (H2SO4) and 96-well polysterene plates was purchased from 
Sigma Co, UK. Universal microplate spectrophotometer mQuant (Bio-Tek Instrument 
Ink). 
2.5.2.2. Method 
2.5.2.2.1. Media and sample preparation 
Oils of S. apiana and S. fruticosa have been tested on the HT29-MXT cell line. The 
HT29-MXT cell line, a well characterised human mucin-secreting cell subpopulation of 
polarised goblet cells (Lesuffleur et al., 1991; Lesuffleur et al., 1993) secretes a 
constitutive level of the secondary pro-inflammatory cytokine IL-8 (m: ý0.3 ng m1"1) 
(Smimova et al., 2002 a). 
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Cells were seeded (5x105 cells/well) in 6-well plates and grown in 4ml of Dulbecco's 
modified Eagle medium supplemented with 10% heat-inactivated fetal bovine serum at 
37 °C in a 10%CO2/90% air atmosphere for 7 days to the pre-confluent stage. Before 
exposure to oils, cells were pre-incubated for 24 hours in serum-free medium to 
stabilise the stage of cell growth and washed twice with PBS at room temperature. 
9 mg oils were diluted in 100 µl 40% EtOH to make a stock solution. After 1 hour (h), 
4h and 24h exposure to oils (a final concentration of 0.9 mg ml-1) the cell culture media 
was subjected to IL-8 immunoassay. Level of IL-8 secretion in oil treated cells was 
measured against control (EtOH treated) cells. 
2.5.2.2.2 IL-8 immunoassay 
Measurements of IL-8 in cell culture media were performed by a quantitative sandwich 
enzyme immunoassay using a commercially available "Pelikine Compact Human IL-8 
ELISA kit" (Research Diagnostics Inc). In brief, the monoclonal anti-human IL-8 
antibody was coated onto the 96-well polystrene plates and 100µ1 of cell culture media 
(or standard) was added to the wells and incubated for one hour at room temperature. 
After one hour plates were washed four times with phosphate buffer saline (PBS), 
containing 0.005% Tween 20. The secondary biotinylated (colour reagent) monoclonal 
anti-human IL-8 antibody was added and incubated for one hour at room temperature. 
After washing plates (as described above) horseradish peroxidase (HRP) conjugated 
streptavidin, (serving as a substrate) was added. After 30 minutes of incubation at room 
temperature plates were washed four times with PBS. A colour reaction was developed 
with 3,3', 5,5'-tetramethylbenzidine (TMB) peroxidase (enzyme hydrolysing biotinyl- 
streptavidin complex) solution and stopped with addition of 0.5 M H2SO4. Absorbance, 
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using universal microplate spectrophotometer mQuant, was read at 450 nm. A standard 
curve was constructed using an IL-8 standard from the "Human IL-8 ELISA kit". The 
IL-8 standard was calibrated against WHO interim International Standard, 1 pg of IL-8 
standard is equivalent to 0.56 pg of the WHO standard. The sensitivity of the IL-8 assay 
was 50 pg ml-1. 
2.5.3. Oil of S. apiana in relation to nicotinic and muscarinic receptors 
2.5.3.1. Preparation of brain neuron membranes for receptor assay 
(Court et al., 1994) 
Membrane homogenates were prepared by paring grey matter from human occipital 
cortical tissue (supplied by the Brain Bank at the Medical Research Council's 
Neurochemical Pathology Unit, Newcastle General Hospital). The tissue was 
homogenised in Na/K phosphate buffer, 50 mM, pH 7.4 (1 g tissue per 10 ml buffer), on 
ice, using an Altratuttax® in a biological safety cabinet. The homogenate was 
centrifuged at 20000 rpm for 20 minutes at 4 °C, the supernatants discarded and the 
membrane pellets re-suspended and centrifuged twice more in similar volumes of ice- 
cold buffer to remove cytoplasmic elements from the membranes. The membranes were 
then re-suspended in a similar volume of buffer and aliquots of 1 ml of the suspension 
were pipetted into 1.5 ml Eppendorf tubes which were centrifuged at 5000 rpm for 10 
minutes to pellet the membranes. All supernatants were removed and discarded after 
treatment with sodium hypochlorite, and the membrane pellets stored at -70 
°C until use. 
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2.5.3.2. Nicotinic receptor displacement assay 
2.5.3.2.1. Materials 
Buffer was prepared as; 
Tris-hydroxymethyl methylamine (Sigma, U. K), 50 mM (60.55g) 
Calcium chloride hexahydrrate (Sigma, U. K), 8 mM (17.58 g) 
Adjust pH to 7.4 with concentrated HCL (Sigma, UK) 
Distilled water: bring the total volume to 1 litter. 
Radioligand; L-(-)-N-methyl-[3H]-nicotine (DuPont, specific activity 81.5 Ci/mM), 
Carbachol (carbamylcholine chloride), Ultima Gold MV (Canberra-Packard) 
scintillation fluid, and 6x 30cm strips of Whatman GF/C filter sheets were purchased 
from Sigma Co., U. K. 
Oil of S. apiana was obtained as described in section 2.2.3. 
2.5.3.2.2. Method 
Pelleted human occipital cerebral cortical cell membranes bearing nicotinic 
acetylcholine receptors as prepared in 2.4.3.1. were used. Each membrane pellet, 
contained in a 1.5 ml Eppendorf tube, was suspended in 1.2 ml of ice cold assay buffer 
and 50 µl of membrane suspension was added to each assay tube. Carbachol, a displacer 
for assessment of a non-specific binding, was prepared as a1 mM solution. The samples 
were run in triplicate and displacement values were calculated from the mean of these 
triplicates. 
A run for the assay; 
i. 350 µl buffer + 50µ1 of the membrane suspension, vortex mix for 10 seconds 
ii. 50 µl carbachol (or oil), vortex mix for 10 seconds 
iii. 30 minutes incubation at 25 °C in a water bath 
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iv. 50 µ1 L-(-)-N-methyl-[3H]-nicotine, vortex mix for 10 seconds 
v. 60 minutes incubation at 25 °C 
The membranes were then filtered from the reaction mixture onto 6x 30cm strips of 
Whatman GF/C filter sheet which was priory soaked in 0.2% polyethylene imine 
solution overnight, using a Brandel Cell Harvester and washed 3 times with cold buffer. 
The filter sheet was then removed from the harvester and the discs, which held the 
harvested membranes, were separated from the filter sheet with forceps. After that the 
discs were transferred to `Pony' brand plastic scintillation vials and 2 ml of Ultima Gold 
MV (Canberra-Packard) scintillation fluid was added. The vials were allowed to stand 
for 2 hours art room temperature (22 °C) and the assays were then counted for 
decomposition per minute (dpm) in a Canberra Packard 1900 CA Tri-carb LSC Counter, 
5 minutes per vial. Dose response curves were plotted for dilution series using 
Microsoft Excel 2000 computer software. 
Controls for the assay; 
Control 1 
i. 400 µl buffer + 50µ1 the membrane suspension, vortex 10 seconds 
ii. 50 µl L-(-)-N-methyl-[3H]-nicotine, vortex mix for 10 seconds 
Control 1 values on the scintillator print-out represent the dpm count of non-specific 
bindings of L-(-)-N-methyl-[3H]-nicotine to the membranes. 
Control 2 
i. 350µ1 buffer + 50µ1 the membrane suspension, vortex 10 seconds 
ii. 50µ1 the non-specific radioligand and 50µ1 the specific displacer, vortex 10 
seconds 
Control 2 dpm values represent the portion of the total bound ligand which is occupying 
sites other than the nicotinic receptor. A dpm value for all nicotinic receptor sites 
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available for radioligand binding (control 3) was calculated as dpm values of control 1 
minus the dpm values of control 2. 
A percentage of displacement produced by oil was calculated as 
dpm control 3- dpm sample x 100% 
dpm control 3 
2.5.3.3. Muscarinic receptor displacement assay 
2.5.3.3.1. Materials 
As in section 2.5.3.2.1. except that the assay buffer was HEPES, containg 10 mM 
MgC12 and 100 mM NaCl, pH 7.4. The radioligand was 1 nM L-methyl-[3H]- 
scopolamine (Dupont specific activity 84.5 Ci/mM, Sigma Co., U. K), atropine and 6x 
30cm strips of Whatman GFB filter sheets (Sigma Co., U. K) were used. 
2.5.3.3.2. Method 
Muscarinic displacement was measured using a similar protocol to that described in 
section 2.5.3.2.2. (Court et al., 1994). Non-specific binding was defined in the presence 
of 1 µM atropine. 
Controls for the assay; 
Control 1 
iii. 400 µl buffer + 50µl the membrane suspension, vortex 10 seconds 
iv. 50 pl L-methyl-[3H]-scopolamine, vortex mix for 10 seconds 
Control 1 values on the scintillator print-out represent the dpm count of non-specific 
bindings of L-methyl-[3H]-scopolamine to the membranes. 
Control2 
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iii. 350µ1 buffer + 50µ1 the membrane suspension, vortex 10 seconds 
iv. 50µ1 the non-specific radioligand and 50µ1 the specific displacer (atropine), 
vortex 10 seconds 
A percentage of displacement produced by oil was calculated as in section 2.5.3.2.2. 
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Chapter 3. Steam distillation. Anti-cholinesterase activity of 
oils of Salvia species 
3.1. Introduction 
S. fruticosa, S. officinalis and S. lavandulaefolia are some of the most common species 
of the genus widely growing throughout the Mediterranean and Middle East (Giannouli 
and Kintzios, 2000; Appendix 1). The plants have aromatic leaves and have been used 
for production of essential oils. The oils of sage are chemically complex mixtures, often 
containing more than 100 individual components that can be grouped into volatile and 
non-volatile fractions. A volatile fraction constitutes 90-95% of the whole oil and 
contains monoterpenoids and sesquiterpenoids hydrocarbons and their oxygenated 
derivatives along with aliphatic aldehydes, alcohols and esters. A non-volatile residue 
contains fatty acids and carotenoids (Waterman, 1993; Giannouli and Kintzios, 2000). 
In addition to flavouring foods, the oils act as antioxidants and preservatives against 
food spoilage, while a broad range of application in aromatherapy and health care has 
been observed during the last fifteen years (Hay and Waterman, 1993). 
Gas chromatography, combined with mass spectrometry, is used to analyse the chemical 
composition of oils. The major constituents of oil of S. lavandulaefolia are a-pinene, 
1,8-cineole, camphor (Marcos et al., 1988) whereas oil of S. officinalis is abundant in 
thujone, camphor, 1,8-cineole, borneol, and a/ß pinenes (Holla and Vaverkova, 1993; 
Bellomaria et al., 1992) and oil of S. fruticosa is rich in 1,8-cineole, camphor, borneol, 
ß-caryophyllene and aJß pinenes (Bayrak and Akgul, 1987). The chemical profile of oils 
within a particular species may vary. Thus, according to Perry et al. (1999) a content of 
thujones and camphor in oil of S. officinalis at the flowering stage is the minimum but 
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the amount of ß-pinene and 1,8-cineole is the maximum. Stems have low oil contents in 
comparison with leaves and flowering parts of the plant. Moreover, Langer et al. (1996) 
reported that oils of aged leaves of S. officinalis and S. fruticosa contain less a-thujone 
but more camphor. Bellomaria et al. (1992) reported that oil of S. fruticosa may contain 
42% camphor and 20% 1,8-cineole if collected in the Troodos area of Cyprus but 55% 
1,8-cineole and 6% camphor if harvested in the Anglisidhes and Stavros areas of the 
island. Oils of S. fruticosa from western Crete contain low amounts of camphor and 
high of 1,8-cineole, while the oils from the central part of Crete are equally abundant in 
camphor and 1,8-cineole (Karousou et al., 2000). In addition, Venskutonis (1997) 
reported that drying fresh leaves of S. officinalis at 30 °C does not affect the total 
contents of volatile compounds, as compared with freeze-drying, whereas drying at 60 
°C gives losses of 31%, mainly of non-oxygenated monoterpenoids. Fadel and El- 
Massry (2000) also reported that the yield of monoterpene hydrocarbons increases after 
drying, while monoterpene esters decreases from 24.8% in fresh leaves to 1.8% in dry 
leaves. 
Oils of the plants exhibit a wide range of bioactivities (Appendix 1) including those of 
CNS relevant to treatment of dementia (1.3.1.4.4. ). A role of acetyl-and butyl- 
cholinesterases in the normal and demented brain has been described in Chapter 1 
(1.2.1.2.; 1.3. ). The Chapter (1.3) also explains the significance of inhibition of 
cholinesterases in the treatment of the disease. As there are no reports on anti-BuChE 
activity of any species of Salvia, the purpose of this study was to determine in vitro 
whether essential oils of the genus contribute to inhibition of BuChE. Parallel AChE 
inhibitory activity was also investigated. 
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3.2. Results 
Anti-BuChE activity of the oils over a range of pre-incubation times (5 to 90 minutes) is 
shown in Table 3.1. Quinidine, a selective inhibitor of BuChE used as a positive control, 
inhibited BuChE (5 min incubation) with an IC50 value of 6.8x 10-4 mg ml" (0.9µM). 
Table 3.1. Anti-butyrylcholinesterase activity of oils of Salvias in relation to incubation 
time 
Oil IC50, mg/mla or Incubation, 
mean±SD (n=6)C 
5 min 30 min 60 min 90 min 
S. fruticosa (7/01) 
S. fruticosa (8/02) 
S. officinalis 
"purpurea" (6/02) 
S. officinalis 
"purpurea" (9/02) 
S officinalis L. 
S. lavandulaefolia 
0.15±0.0071 0.06±0.0lt 0.04±0.01 0.035±0.016t 
10±4 (0.3 mg/m)ý 14±5 (0.3 mg/ml)x 17±4 (0.3 mg/ml)$ 21±8 (0.3 mg/m1)$ 
3513 (0.3 mg/ml): 0.22t0.015t 0.24t0.02t 0.2t0.017t 
0.14±0.007t 0.09t0. Olt 0.074±0.015t 0.06±0.0181 
0.3310.01t 0.24t0.014t 0.21±0.0171 0.23t0.02t 
26±5 (0.2 mglml)t 23±4 (0.2 mg/ml)= 26±5 (0.2 mg/ml)= 18±6 (0.2 mg/ml)x 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. bInhibitory activity of oils which did not reach 
50% enzyme inhibition. The percent activity corresponds to the solubility limit of oil. 
`Each oil was tested in triplicate. Mean of triplicate was designated as n=1. Standard 
deviation (SD) was calculated on a basis of six sets of triplicate using a dose response 
equation of each triplicate. i-corresponded to a. $-corresponded to b. 
There was an increase in the potency of oils during this period. The ICso value of S. 
fruticosa oil (7/01) decreased from 0.15±0.007 mg/ml with 5 minutes incubation to 
0.035±0.016 mg/ml with 90 minutes incubation, whereas S. fruticosa oil (8/02) had no 
marked activity. The potency of oil of S. officinalis var. "purpurea" (9/02) increased 
from 0.14±0.007 to 0.06±0.018 mg/ml at 5 and 90 minutes respectively. Oil of S. 
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officinalis var. "purpurea" (6/02) reached 50% inhibition after 30 minutes of incubation. 
Oils of S. officinalis and S. lavandulaefolia showed no increase in inhibition during any 
period of pre-incubation tested. Extracts of S. fruticosa (7/01) and S. officinalis var. 
"purpurea" (9/02) had the most obvious time dependent increase in inhibition of the 
enzyme as compared with other extracts. Anti-AChE activity of the oils over a range of 
incubation time is shown in Table 3.2. Physostigmine, a selective inhibitor of AChE 
used as a positive control, inhibited the enzyme (5 min incubation) with an IC50 value of 
1.4x10"5 mg ml" (0.04 µM). 
Table 3.2. Human anti-acetylcholinesterase activity of oils of Salvias in relation to 
incubation time 
Oil IC50, mg/mla mean±SD (n=6)b 
5 min 30 min 60 min 90 min 
S. fruticosa (7/01) 0.05±0.005 0.06±0.004 0.05±0.008 0.06±0.013 
S. fruticosa (8/02) 0.04±0.003 0.055±0.006 0.06±0.01 0.06±0.015 
S. officinalis 
"purpurea" (6/02) 
S. officinalis 
"purpurea" (9/02) 
S officinalis L. 
S. lavandulaefolia 
0.1±0.006 
0.04±0.008 
0.07±0.0 1 
0.14±0.01 
0.03±0.01 
0.05±0.014 
0.053±0.007 0.06±0.01 
0.18±0.01 
0.02±0.01 
0.065±0.01 
0.08±0.013 
0.24±0.02 
0.03±0.015 
0.08±0.02 
0.12±0.023 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. "Each oil was tested in triplicate. Mean of 
triplicate was designated as n=1. Standard deviation (SD) was calculated on a basis of 
six sets of triplicate using a dose response equation of each triplicate. 
Oils of S fruticosa (7/01) and S. officinalis var. "purpurea" (9/02) had apparent dual 
cholinergic activity, namely they were active on both enzymes within the incubation 
time, while the duality of oil S. officinalis was less apparent (Table 3.1 and 3.2). 
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In contrast to inhibition of BuChE, there was no increase in inhibitory activity within 
these periods although the oils of S. officinalis var. "purpurea" (6/02) and S. 
lavandulaefolia showed apparent decrease from 0.1±0.006 and 0.053±0.007 mg/ml at 5 
minutes to 0.24±0.02 and 0.12±0.023 mg/ml at 90 minutes incubation respectively. Oil 
of S. officinalis var. "purpurea" (9/02) had the lowest IC50 values throughout the course 
of incubation. 
Table 3.3. Chemical composition of oil of Salvia species 
S. fruticosa S. officinalis S. ofcinalis S. lavandu 
Compounda RTb, % in oil° purpurea, L. laefolia 
min % in oils % in oils % in oils 
7/01 8/02 6/02 9/02 
a-pinene 12.61 -- 2.4 -- -- -- -- 
Camphene 13.2 -- 5.0 -- -- 1.2 -- 
ß-pinene 14.42 -- 1.6 0.5 1.2 3.5 -- 
ß-mycrene 15.16 0.6 1.5 -- -- 0.8 -- 
D-limonene 16.66 1.2 3.6 -- -- 0.8 2.7 
1,8-cineole 16.78 17.6 21.5 2.7 2.8 5.4 17.4 
(+)-4-carene 18.81 -- 2.2 -- -- -- -- 
trans-säbinenehydrate 19.6 -- -- 0.4 -- -- -- 
Thujone, isomers 19.8 -- -- 8.4 12.7 6.2 -- 
Unidentified 21.17 -- -- -- -- -- 5.9 
Camphor 21.29 49.2 49.3 4.8 12.3 11.0 42.5 
Bicyclo (3,1,1) heptan-3-one, 
2,6,6, -trimehtyl -2a; Sa 21.92 -- 2.0 3.1 1.0 -- 
Borneol 22.1 4.6 1.7 3.7 3.2 8.7 6.1 
3-cyclohexen-1-ol, 4 methyl- l- 
(1-methylethyl)-, (R) 22.55 -- -- -- -- -- 2.1 
a-terpineol 23.05 -- -- -- -- -- 2.1 
Unidentified 25.36 -- -- -- -- -- 1.2 
Bornyl acetate 26.45 2.8 1.5 2.4 2.3 3.1 1.0 
Unidentified 26.68 -- -- -- -- -- 4.3 
(+)-2-carene 28.59 -- -- -- -- -- 8.8 
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a-cubenene 28.62 -- -- 0.7 -- -- -- 
Ylangene 29.36 -- -- 0.4 -- -- -- 
Copaene 29.51 -- -- 1.0 -- -- -- 
1-H-cycloprop(e)-azulene, 1a, 2, 
3,4,4a, 5,6,7b-octadydro-1,4,7-tetra 
methyl-, [laR-(laRa... )] 30.63 -- -- 1.0 -- 1.1 -- 
Caryophyllene 30.95 11.9 6.6 3.0 2.6 2.4 1.0 
Germacrene D 31.24 -- -- 1.3 1.0 1.3 -- 
1 H-cycloprop(e)-azulene, deca- 
hydro 1,1,7-trimethyl-4-methylene 31.56 2.8 1.1 2.0 1.4 5.3 -- 
-, (1a, a) 
a-caryophyllene 32.02 0.8 -- 32.5 24.2 23.2 -- 
Naphthalene: 1,2,3,4,4a, 5,6,8a- 
octahydro-7-methyl-4-methylene- 
1-(1-methylethyl)-(la., 4a. a., 8a. a) 32.8 -- -- 2.8 2.3 2.1 -- 
1 H-cycloprop(e) azulene, 1 a, 2,3,5, 
6,7,7a, 7b-octahydro- 1; 1,4,7-tetra 
methyl-, (laR-(la. a, 7a, 7aD, 7ba) 33.3 1.2 -- 2.3 1.8 3.5 -- 
Naphthalene: 1,2,3,4,4a, 5,6,8a- 
octahydro-7-methyl-4-methylene- 
1-(1-methylethyl)-( la., 4aß., 8a. a) 33.87 -- -- 1.4 1.0 1.0 -- 
Naphthalene: 1,2,3,5,6,8a, -hexa 
hydro -4,7-dimethyl-l-(1- 
methylethyl)-, (1S-cis)- 34.14 -- -- 3.9 3.0 2.7 -- 
Caryophyllene oxide 34.95 -- 0.6 -- -- -- 
4aH-cycloprop(e)azulene-4a-ol 35.51 -- -- 2.1 1.6 1.4 -- 
(-)-Spathulenol 35.79 0.8 -- 1.0 -- 1.0 -- 
Ledol (isomers) 36.2 -- -- 9.4 6.8 1.5 -- 
Guaiol 36.4 1.2 0.7 -- -- -- 
Unidentified 48.18 -- -- 3.4 2.1 0.8 -- 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
`Relative percentage as calculated from a total area of peaks on a basis of 1% of a 
major peak 
-- not detected 
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Table 3.3 shows the chemical composition of essential oils of Salvia species obtained 
by steam distillation. The major constituents of the oils of S. fruticosa from different 
origins were 1,8-cineole, camphor and caryophyllene. Oils of S. officinalis var. 
"purpurea" had a-caryophyllene (a-humulene), camphor and thujone as the main 
constituents. Oil of S. officinalis was also rich in a-caryophyllene, camphor, borneol and 
thujone, whilst camphor, 1,8-cineole and 2-carene were abundant in oil of S. 
lavandulaefolia. 
3.3. Discussion 
3.1. Anti-cholinesterase activity of oils 
The main finding of the present study was that oils obtained from species of Salvia 
inhibit BuChE in a time dependant manner. Anti-BuChE activity of the oils differed 
among the species investigated. Oils of Salvia fruticosa (7/01) and Salvia officinalis var. 
"purpurea" (9/02) showed an apparent increase in the inhibition of BuChE during the 
course of time. Their potencies increased four and two folds respectively. Volatility and 
thermo-instability of the oils restricted the course of incubation time at 30 °C, although 
Ogura et al. (2000) reported that rivastigmine, a non-volatile chemical, reached its 
maximum inhibition of BuChE after six hours. 
Perry et al. (2000 b) reported in vitro uncompetitive, reversible inhibition of erythrocyte 
AChE by essential oil of S lavandulaefolia and Perry et al. (2002) also showed in-vivo 
that the oil inhibits brain AChE in rats. This study confirmed that the oils of Salvia 
species readily inhibit human AChE. The activity of the oils did not significantly 
change in the course of the incubation times with the exception of oils of S. 
90 
Steam distilled oils 
lavandulaefolia and S. officinalis var. "purpurea" (6/02) for which inhibition declined 
within the time. In contrast, physostigmine increases inhibition of AChE within this 
period of incubation time (Perola et al., 1997; Ogura et al., 2000). Molecules of the oils 
may not only dynamically modulate accessibility of the substrate to the active site 
(McCammon and Northrup, 1981) but also cause steric and/or allosteric effects on the 
latter (Tai et al., 2002). 
The presence of dual anti-cholinesterase activity in plants may be explained as a 
defensive mechanism against herbivores (Schmeller et al., 1997). Li et al. (2000) 
demonstrated that BuChE is not a minor but an abundant cholinesterase in mammalian 
tissues. Gnagey et al. (1987) and Marcel et al. (1998) also reports that the ChE in 
invertebrates of Drosophila melanogaster and Caenorhabditis elegans may exist in an 
intermediate form, which would resemble some characteristics with both human 
cholinesterases. 
Extracts with preferential cholinergic activity could potentially be used therapeutically 
according to severity of AD. Thus, oils of S. fruticosa (7/01) and S. officinalis var. 
"purpurea" (9/02), which have dual anti-ChE activity, may be appropriate to patients 
with those forms of the disease, where the level of AChE has not yet significantly 
declined (Davies et al., 1999) but a possibility that BuChE could hydrolyse ACh exists 
(Mesulam at al., 2002 b), i. e., a moderate stage. The oils of Salvia lavandulaefolia and 
Salvia officinalis "purpurea" (6/02) may have potential for therapeutic use by dementia 
patients with mild stage of the disease, where Km of ACh is low enough to keep BuChE 
inactivated. 
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A double blind, randomised and placebo-controlled clinical trail of 45% EtOH extract 
of S. officinalis showed improvement in cognition and agitation in patients with mild to 
moderate AD (Akhondzadeh et al., 2003). Moreover, Perry et al. (2002) reported in- 
vivo that essential oil of S. lavandulaefolia inhibits brain AChE activity in the striatum 
and hippocampus in rats at doses of 20 pl and 50 µl. Thus, if the effect of the trial is 
attributed to inhibition of cholinesterases then dual cholinergic activity of the oils may 
become clinically relevant. 
3.3.2. Species variation 
Anti-BuChE activity of oils of S. fruticosa (7/01) and S. fruticosa (8/02) differed 
significantly, although anti-AChE activity did not. The GC/MS analysis of chemical 
composition of these oils shows lack of certain monoterpenoids, namely a-pinene, 
camphene, ß-pinene and (+)-4-carene in the oil of the plant collected in July, 2001. Oil 
of S. fruticosa, as confirmed in this study, may contain 42% camphor and 20% 1,8- 
cineole if the foliage is collected in the Troodos area of Cyprus (Bellomaria et al., 1992). 
The amounts of these major constituents were similar in both oils. The structural 
differences of the enzymes (1.2.1.2.; 1.3) allow the suggestion that anti-BuChE activity 
of S. fruticosa (7/01) oil is attributed to synergistic interactions between its minor 
constituents rather than camphor or 1,8-cineole only, while anti-AChE activity may be 
down to one of these molecules alone. This suggestion can also be supported by the fact 
that oil of S. lavandulaefolia did not inhibit BuChE, despite being abundant in camphor 
and 1,8-cineole, but AChE. 
Oils of S. officinalis and S. officinalis var. "purpurea" (6/02) and (9/02) were rich in a- 
caryophyllene (syn., a-humulene) but had evenly less camphor and 1,8-cineole than oils 
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of S. fruticosa and S. lavandulaefolia. The GC/MS analysis of these oils shows no 
striking differences in their chemical profiles. Dual anti-ChE activity of oil of S. 
offrcinalis var. "purpurea" (9/02), but not the others, may also be explained via 
synergistic interactions of its minor constituents. Anti-AChE activity of all three oils, 
despite a low amount of one of the main compounds of Salvia species camphor and 1,8- 
cineole (Karousou et al., 2000; Appendix 1, Salvia's database), may be explained via 
abundant presence of a-caryophyllene. In addition, all oils of S. officinalis contained 
from 6.2% to 12.7% toxic thujone isomers. ß-thujone is regarded as less toxic than a- 
thujone (Hold et al., 2000). Hold et al. (2000) reported that a-thujone acts as a non- 
competitive agonist to the y-aminobutyric acid type A (GABAA) receptor in mice. 
Nevertheless, the International Organisation for Standardisation allows 18-43% a- 
thujone in oil of S. officinalis (ISO, 1997). 
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Chapter 4. Supercritical fluid extraction. Anti-cholinesterase 
activity of extracts of Salvia species 
4.1. Introduction 
Traditional methods of extraction of essential oils such as steam distillation and organic 
solvent extraction have several limitations. Organic solvents are flammable, toxic and 
environmentally unfriendly, while steam distillation requires conditions where some 
components may be lost through thermal degradation, hydrolysis or volatilization 
(Luque de Castro et al., 1999). Misharina et al. (2003) showed that storage of steam 
distilled oil of Majorana hortensis M. in the light causes chemical transformation of 
terpenoids. This transformation may be initiated by high temperature during the 
extraction process and further supported via photo-oxidation. The implementation of 
new extraction techniques which may reduce the risk of biodegradation of terpenoids 
during the extraction and storage is therefore warranted. 
4.1.1. Principle of supercritical fluid extraction 
Alterations in temperature and pressure change the physical state of a substance 
between solid, liquid and gases; these states have marked differences in their densities. 
However, at a certain temperature and pressure (the critical point), there is no difference 
in density between the liquid and gaseous forms of the substance and it exists as a fluid 
that does not condense or evaporate. This is termed a supercritical fluid. The critical 
temperature and pressure above which supercritical fluids are formed vary with the 
substance and with its purity. For water the values are 374 °C and 220 atmospheres 
respectively, while for carbon dioxide the corresponding figures are 31 °C and 74 
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atmospheres respectively (Houghton and Raman, 1998). The use of carbon dioxide for 
the separation of compounds was suggested more than 60 years ago (Pilat and 
Godlewicz, 1940) but it was not applied before Stahl et al., (1980) demonstrated that the 
supercritical stage of the gas can be used to extract natural products. Later Kusova and 
Vetrov (1987) used dichlorodifluoromethane (Freon 12), with the boiling point of -29 
°C, in supercritical fluid extraction to obtain oil of Elaeagnus angustifolia L. with 
wound healing properties, while supercritical CO2 was used to remove caffeine from tea 
and coffee (Corr, 2002). 
F 
F- C- CH 2- F 
I 
F 
Figure 4.1.1,1,1,2-Tetrafluoroethane. 
Other names: 1,2,2,2-Tetrafluoroethane; AK 134a; Arcton 134a; Ecolo Ace 134a; F 
134A; FC 134a; Forane 134a; Freon 134a; Fron 134a; HC 134a; HCFC 134a; HFA 
134a; HFC 134a; Khladon 134a; Norflurane; R 134a; Refrigerant R 134a; SUVA 134a; 
TG 134a 
1,1,1,2-tetrafluoroethane (Figure 4.1) has been developed as a substitute for fully and 
partially halogenated chlorofluorocarbons and hydrochlorofluorocarbons 
(trichlorofluoromethane Freon 11 and Freon 12), which have been showed to contribute 
to the stratospheric ozone layer depletion (Mayer et al., 1995) and climate forcing. 
Degradation of 1,1,1,2-tetrafluoroethane occurs mainly in the troposphere by reaction 
with hydroxyl radicals leading to production of trifluoroacetic, formic, hydrofluoric 
acids and carbon dioxide. The gas has a global warming potential of 0.3 comparative to 
a reference value of 1.0 for Freon 11 (Mayer et al., 1995). It is a non-flammable, 
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colourless, benign gas with a boiling point of -26.2 
°C and a faint ethereal odour 
(Advanced Phytonics Ltd., chemical safety data sheet). Industrial and research 
applications of 1,1,1,2-tetrafluoroethane have recently been reviewed Corr (2002). 
4.1.2. Extraction with Phytosol® 
Wilder (1994) showed that extraction of botanicals with 1,1,1,2-tetrafluoroethane 
(Phytosol A) at <_40 mbar (under pressure and at room temperature the gas liquefies and 
exhibits solvent properties) results in a higher yield of natural fragrant oils and a lower 
cost of production in comparison with steam distillation, solvent and carbon dioxide 
extractions. Thus, Rodrigues et al. (2003) reported that the best extraction rates which 
give a maximum yield of oil of Pimpinella anisum Linn., using supercritical carbon 
dioxide are 180 bar at 30 ° C. From the economical point of view such differences in 
pressure requirements are in favour of Phytosol A. While supercritical CO2 can produce 
high quality extracts with minimal solvent residues, the cost is prohibitive for many 
products due to the high capital cost of equipment rated for the high operating pressures 
(Corr, 2002). 
Due to the relatively low polarity of Phytosol Aa range of botanicals (e. g., nitrogen 
containing molecules) extracted from a plant material may be restricted. Nevertheless, 
Nicola (1998) suggested that a combination of Phytosol A with a polar co-solvent 
enables extraction of at least one relatively polar component. A mixture of the 
hydrofluorocarbon and carbon dioxide may also increase the polarity of the supercritical 
medium (Abbot et al., 2000). In addition, Advanced Phytonics Ltd., U. K., produces 
Phytosol A in a combination with butane/isobutene (Phytosol B) and dimethylether 
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(Phytosol D). Although, the three Phytosols® have some polarity differences, they are 
essentially designed for the extraction of non-polar materials. Extraction of Salvia 
miltiorrhiza with Phytosol A, B and D provided extracts with 0.031%, 0.029% and 
0.033% of Tanshinone IIA (Appendix 1, database of active principals of Salvia) 
respectively and it was an equivalent to that obtained via supercritical carbon dioxide 
extraction, namely 0.031% (Dean et al., 1998). 
Moreover, Cerny (2000) reported that extract of Rosmarinus officinalis L. obtained 
using Phytosol A has a characteristic rosemary-like odour. The author also noted that 
plant waxes and triglycerides are not soluble in the solvent. In addition, in a six weeks 
pilot open-label study involving oral administration of Salvia lavandulaefolia oil, 
obtained by Phytosol A extraction, to patients with AD there was a statistically 
significant reduction in neuropsychiatric symptoms and an improvement in attention 
without adverse effects with the exception of increased blood pressure in two patients 
(out of eleven) with a history of hypertension (Perry et al., 2003). 
Evaporating Phytosol A as a solvent from a plant material at - 26.2 
°C under a modest 
pressure may facilitate optimal extraction of molecules with cholinergic activities 
relevant to dementia therapy. In contrast the use of steam distillation may involve the 
loss of such molecules through hydrolysis or thermolysis and further photo-oxidation 
during storage (Misharina et al., 2003). Furthermore, an anaerobic environment created 
by supercritical fluid extraction minimises the effects of oxidation and rancidity (Con, 
2002). 
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The purpose of this study was to investigate in vitro cholinergic activity of extracts of 
Salvia species (24 extracts) obtained via Phytosol A extraction and to analyse the 
bioactivity of the extracts in relation to their chemical compositions in order to identify 
a possible chemical fingerprint associated with maximum cholinergic activity. 
Monitoring changes in a chemical profile of the extracts during storage and comparing 
it with the activity of the latter may also help to identify such fingerprint which can be a 
useful marker in the quality control. In addition, the kinetic studies were conducted to 
describe a level of affinity and the biding mechanism between the extracts and both 
cholinesterases. 
4.2. Results 
4.2.1. Anti-cholinesterase activity and chemical composition of Salvia extracts 
Extracts of twenty four species of sage were screened for anti-BuChE and anti-AChE 
activities and analysed for their chemical compositions. Quinidine, a selective inhibitor 
of BuChE, inhibited the enzyme with an IC50 value of 6.8 x 10-4 mg ml" (0.9µM), while 
physostigmine, a selective inhibitor of AChE, reached this value at 1.4 x 10"5 mg ml-1 
(0.04µM). For the convenience of reading this Chapter contains information only on 
major constituents of the extracts, while Appendix 3 shows their whole chemical 
profiles. 
4.2.1.1. Effects of storage time 
Effects of storage time (Chapter 2, stored in sealed amber glass vials under oxygen free 
nitrogen at 5 °C) on the inhibitory activity of extracts of S. apiana, S fruticosa, S. 
officinalis var. purpurea and S. corrugata were also investigated. Table 4.1 shows that 
anti-BuChE activity of S. apiana oil increased 6 times, from IC50 values of 0.18±0.035 
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mg ml-1 to 0.03±0.002 mg ml", during 70 days of storage, while anti-AChE activity did 
not significantly change. Increases in anti-BuChE activity of oils of S. fruticosa and S. 
officinalis var. purpurea were both 2.5 times but anti-AChE activity was reduced 2 
times and 2.5 times respectively during the storage. In contrast, S. corrugata extract was 
a selective inhibitor for AChE with an IC50 value of 0.009 mg ml" in 30 days of 
extraction and 0.02 mg ml-1 in 100 days of extraction (Table 4.1). In the extract anti- 
AChE activity was two-fold reduced. 
Table 4.1. Anti-cholinesterase activity of Salvia extracts in relation to storage time 
IC50° mg m1" or Inhibition, 
Extract Yiel mean±SD (n--4 )f 
d 30 davsg 100 days 30 davsg 100 davs 
% BuChE I BuChE 
S. apiana 1.4 0.18f0.035TJ 0.03t0.002tj 
(light amber oi1)a (1.8) 
S. fruticosa 1.0 b 0.05f0.01tj 0.02f0.001tj 
(amber oil)a (1.25) 
S. officinalis 0.53 b 0.037f0.003ä 0.015±0.004tj 
var. purpurea (0.57) 
(amber oil with a 
tint of green)a 
AChE I AChE 
0.04f0.005' 0.03±0.01 
0.018±0.00lt 0.043±0.008t 
0.02±0.004t 0.05±0.004t 
S. corrugata 0.5 b 16±2.4% 20±3.6% 0.009±0.0041 0.02±0.0061 
(reddish resin)a (0.5) [0.05 mg m1-']$k [0.05 mg mil 
:k 
aAppearance of extract (inhibitor). Yield of extract based on one batch extraction. Total 
yield of the extraction, which is in some cases comprised oil and a precipitated residue, 
is shown in brackets. 'Final concentration of inhibitors required for 50% enzyme 
inhibition, as calculated from the dose response-curve equations. dInhibitory activity of 
extracts which did not reach 50% enzyme inhibition. The percent activity corresponds 
to the solubility limit of oil. fEach oil was tested in triplicate. Mean of triplicate was 
designated as n=1. Standard deviation (SD) was calculated on a basis of four sets of 
triplicate using a dose response equation of each triplicate. 930 days old extracts. '100 
days old extracts. t-corresponded to C. 1-corresponded to d. tiStatistically significant 
(P<0.05). t, tkStatistically insignificant (P>0.05). 
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An analysis of the chemical composition of oils of S. apiana and S. fruticosa revealed 
no significant changes between major constituents during the same storage time and 
conditions (Table 4.2), although changes were apparent among minor constituents 
(Appendix 3). For example, the amount of limonene in 30 days old oil of S. apiana was 
5% but after the storage the compound became undetectable, while an unidentified 
minor constituent (2.2%) with the retention time of 16.4 minutes was present in 100 
days old oil (Appendix 3). Moreover, ß-pinene (0.7%) and caryophyllene oxide (1.1%) 
were only found in 100 days old oil of S. fruticosa, while benzene, 1-methyl- 2-(1- 
methylethyl) (1%) was detected only in 30 days old oil. 
Table 4.2. Major constituents° of extracts of Salvia species and effects of storage time 
S. apiana, S. fruticosa, S. officinalis S. corrugata 
% in oil' % in oils var. purpurea, % in oil' 
E %inoilc 
Compounds E-ý 30 100 30 100 
dayd dayf days dayf 30 dayd yd 30 da 
1,8-Cineole 16.59 34.4 32.6 12.5 13.6 
Camphor 21.09 38.6 38.5 60.8 58.5 
a-caryophyllene 31.84 46.5 
Unidentified 71.15 20.6 
Unidentified 72.28 66.7 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
cConstituents with no less than 10% in extracts as calculated from a total area of peaks 
on a basis of 1% of a major peak 
dExtracts with 30 days shelf-life 
fExtracts with 100 days shelf-life 
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Freshly prepared S. fruticosa oil was used to analyse the effect of storage time after 7 
and 37 days of extraction. Table 4.3 shows changes in anti-cholinesterase activity of oil 
and 70% EtOH extract of S. fruticosa during 30 days of storage time. After this period 
anti-BuChE activity of the oil increased 5 times, while the activity of ethanol extract did 
not change. The oil, after 30 days of storage, also showed a two times decrease in anti- 
AChE activity, whereas a change in the activity of ethanol extract was not significantly 
apparent. Anti-BuChE activity of the oil after 37 days of extraction, with an IC50 value 
of 0.02±0.03 mg ml", was similar to that of 100 days, namely 0.02±0.001 mg m1"' 
(Table 4.1). Anti-AChE activity of 37 days old S. fruticosa oil, with an IC50 value of 
0.045±0.002 mg ml-1, was also alike to that of 100 days, i. e., 0.043±0.008 mg ml" 
(Table 4.1). 
Table 4.3. Anti-cholinesterase activity of S. fruticosa extracts in relation to seven and 
thirty seven days of storage time 
IC50a mg m11, mean±SD (n=4)b 
Method of 
extraction 
7 
Phytosol A° 
70% EtOH" 
AChE 
0.023±0.002 
U. 1f0.005g 
37 days 
0.045±0.002 
0.09±0.01 g 
BuChE 
7 days I 37 days 
0.1±0.011 0.02±0.03 
0.05±0.0059 0.054±0.0029 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. 'Each oil was tested in triplicate. Mean of 
triplicate was designated as n=1. Standard deviation (SD) was calculated on a basis of 
four sets of triplicate using a dose response equation of each triplicate. °Phytosol A 
extraction provided amber colour oil. dEthanol extract, as a source of more polar 
compounds than the oil, was used for a comparison purpose. fStatistically significant 
(P<0.05). gStatistically insignificant (P>0.05) 
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4.2.1.2. Analyses of thirty days old extracts 
Table 4.4 shows anti-cholinesterase activity of the oils of sage which reached 50% 
inhibition of both cholinesterases within their solubility limits. The chemical 
composition of constituents with no less than 10% in the oils is shown in Table 4.5, 
while the whole chemical profile of the oils is demonstrated in Appendix 3. Oils of S. 
apiana, S. fruticosa, S. officinalis var. purpurea (Table 4.1), S. microphylla var. 
neurepia, S. africana-lutea, S. officinalis, S. involucrata, S. argentea and S. divinorum 
(Table 4.4) had potent dual anti-cholinesterase activity, whereas anti-BuChE activity of 
S. lavandulaefolia oils was less apparent. In addition, Table 4.5 shows no obvious 
pattern between major compounds present in the oils and their dual activity. 
Table 4.6 shows the extracts with less apparent dual anti-cholinesterase activity. 
Constituents with no less than 10% in these extracts are shown in Table 4.7, while the 
whole chemical profile is demonstrated in Appendix 3. S. confertiflora oil, with an IC50 
value of 0.03±0.005 mg ml", was a selective inhibitor for AChE. Oils of S. glutinosa 
and S. napifolia inhibited BuChE with IC50 values of 0.04±0.006 mg ml" and 0.08±0.01 
mg ml-1 respectively, although a solubility limit of the oils did not allow preparation of 
higher concentrations which might result in 50% inhibition of human AChE. Thus, S. 
glutinosa oil showed 31±3.1% inhibition and S. napifolia 18±3.3% inhibition of AChE 
at final concentrations of 0.04 mg ml" and 0.008 mg ml" respectively. A solubility limit 
of S. longistyla oil also restricted preparation of its higher concentrations, which might 
result in 50% inhibition of BuChE. 
Table 4.8 shows extracts of sage which did not reach 50% inhibition of ChEs. Oil of S. 
discolor was an ineffective inhibitor for both enzymes, while oils of S. atrocyanea, S. 
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sclarea and S. verbenaca were ineffective only for BuChE. A solubility limit of the rest 
of extracts did not allow preparation of its higher concentrations, which might result in 
50% inhibition of the enzymes. Table 4.9 shows constituents with no less than 10% in 
the extracts, while Appendix 3 demonstrates their whole chemical profiles. 
Table 4.4. Salvia oils with apparent dual anti-cholinesterase activity 
IC50' mg ml' 
Oil Yield mean±SD (n=4)d 
% BuChE AChE 
S. africana-lutea 0.62 0.06±0.006 0.02±0.002 
(yellow oil with a tint of green)a (0.66) 
S. argentea 0.15 b 0.07±0.01 0.074±0.007 
(amber oil)a (0.26) 
S. divinorum 0.2 b 0.06±0.003 0.046±0.01 
(dark, thick, brawn oi1)a (0.2) 
S. involucrata 0.5 b 0.07±0.003 0.03±0.003 
(thick amber oil)a (0.5) 
S. keerlii 0.46 b 0.1±0.02 0.04±0.007 
(amber oil)a (0.46) 
S. lavandulaefolia 1.2 b 0.16±0.03 0.04±0.001 
(amber oil with a tint of green)a (2.2) 
S. microphylla var. neurepia 0.22 b 0.026±0.006 0.035±0.003 
(dark amber oil with a tint of green)a (0.3) 
S. officinalis 0.53 b 0.06±0.003 0.015±0.001 
(amber oil)a (0.53) 
Appearance of the inhibitor. 'Yield of the inhibitor based on one batch extraction. Total 
yield of the extraction, which is in some cases comprised oil and a precipitated residue, 
is shown in brackets. `Final concentration of inhibitors required for 50% enzyme 
inhibition, as calculated from the dose response-curve equations. dEach oil was tested in 
triplicate. Mean of triplicate was designated as n=1. Standard deviation (SD) was 
calculated on a basis of four sets of triplicate using a dose response equation of each 
triplicate. 
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Table 4.5. Major constituents of extracts of Salvia species with dual anti-cholinesterase 
activity 
% in oil° 
Compounds 
. 
ti CA) 
Ö 
l - e 
a-pinene 12.39 12.4 
1,8-cineole 16.59 16.6 
Camphor 21.09 37.7 16.0 
(+)-4-carene 28.41 13.6 
Caryophyllene 30.76 22.6 10.4 12.7 
y-elemene 31.17 10.0 
a-caryophyllene 31.84 30.4 
1H-Cycloprop[e]azulene 32.07 10.0 
ß-elemenone 36.35 44.1 
Unidentified 45.49 37.1 
Unidentified 47.91 23.6 
Unidentified 49.28 49.0 
Squalene 63.26 22.1 
Unidentified 70.18 70.5 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
`Constituents with no less than 10% in extracts as calculated from a total area of peaks 
on a basis of l% of a major peak. 
t1H-Cycloprop[e]azulene, decahydro-1,1,7-trimethyl -4-methylene-, (1aR-[1aa, 4aß, 7a, 
7aß, 7ba)] 
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Table 4.6. Salvia extracts with less apparent dual anti-cholinesterase activity 
IC50c mg m1" or Inhibition, 
Extract Yield b mean±SD (n=4)f 
V/o 
BuChE AChE 
S. confertiflora 
(dark amber oil)' 
S. haematodes 
(amber oil)' 
S. glutinosa 
(dark amber oil with a tint of red)' 
S. longistyla 
(brown resin with a tint of yellow)' 
S. napifolia 
(amber oil)' 
S. verticilata 
(dark amber oil)' 
0.13 9±6.7 0.03±0.005t 
(0.2) [0.05 mg ml-']$ 
0.13 29±1.5 0.09±0.03t 
(0.17) [0.05 mg ml"1]$ 
0.2 0.04±0.006t 31±3.1 
(0.2) [0.04 mg ml"1] 
0.3 40±5.5% 19±2.1% 
(0.3) [0.04 mg ml- ]l [0.01 mg ml'1]$ 
0.14 0.08±0.01]' 18±3.3% 
(0.18) [0.008 mg ml'1] 
0.12 38±2.1% 28±4.6 
(0.12) [0.045mg ml'1]$ [0.01 mg ml'1]$ 
'Appearance of the inhibitor. Yield of the inhibitor based on one batch extraction. Total 
yield of the extraction, which is in some cases comprised oil and a precipitated residue, 
is shown in brackets. °Final concentration of inhibitors required for 50% enzyme 
inhibition, as calculated from the dose response-curve equations. dInhibitory activity of 
extracts which did not reach 50% enzyme inhibition. The percent activity corresponds 
to the solubility limit of extract. fEach oil was tested in triplicate. Mean of triplicate was 
designated as n=1. Standard deviation (SD) was calculated on a basis of four sets of 
triplicate using a dose response equation of each triplicate. t -corresponded to C. $- 
corresponded to d. gExtracts tested within 30 days of extraction. hExtracts tested after 
100 days of extraction. 
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Table 4.7. Major constituents of extracts of Salvia species with less apparent dual anti- 
cholinesterase activity 
% in oil° 
s Compound 
Q r ýEý 
Z 
tj 4: L13 tI3 r vi 
Caryophyllene 30.76 28.1 23.7 23.8 28.2 24.2 10.3 
a-caryophyllene 31.84 22.8 10.2 
Germacrene D 32.69 19.0 10.7 
1H-cyclopenta[1,3]- 32.71 21.0 
cyclopropa[1,2]benzenet 
Unidentified 34.51 10.7 
Unidentified 68.64 17.9 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds , 
cConstituents with no less than 10% in extracts as calculated from a total area of peaks 
on a basis of 1% of a major peak. 
11 H-cyclopenta[ 1,3 ] -cyclopropa[ 1,2] benzene, octahydro-7-methyl-3-methylene-4-(1- 
methylethyl)-, [3aS-(3aa, 3bß, 4ß, 7a)] 
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Table 4.8. Anti-cholinesterase activity of Salvia extracts restricted by the solubility limit 
Inhibition, %C 
Extract Yield b mean±SD (n=4)d 
10 
BuChE AChE 
S. atrocyanea 0.26 25±1.3% 31±3.9% 
(dark amber oil with a tint of green)a (0.34) [0.08 mg ml-1] [0.02 mg ml"] 
S. discolor 0.7 12±3.0 11±8.5 
(amber oil)' (1.0) [0.15 mg ml''] [0.015 mg ml*'] 
S. Jamensis var. la luna 0.2 40±2.9% 34±2.6% 
(amber oil)' (0.2) [0.05 mg ml'1] [0.03 mg ml"] 
S. sclarea 0.2 22±1.9% 40±4.5% 
(dark amber resin) (0.2) [0.1 mg ml'1] [0.02 mg ml*'] 
S. stenophylla 0.12 33±2.5% 38±2.8% 
(dark amber oil)' (0.14) [0.06 mg ml'1] [0.02 mg/ml"] 
S. verbenaca 0.24 21±1.7% 31±3.6% 
(light amber oil)a (0.24) [0.05 mg ml"1] [0.02 mg/ml"] 
'Appearance of the inhibitor. Yield of the inhibitor based on one batch extraction. Total 
yield of the extraction, which is in some cases comprised oil and a precipitated residue, 
is shown in brackets. `Inhibitory activity of extracts which did not reach 50% enzyme 
inhibition. The percent activity corresponds to the solubility limit of extract. dEach oil 
was tested in triplicate. Mean of triplicate was designated as n=1. Standard deviation 
(SD) was calculated on a basis of four sets of triplicate using a dose response equation 
of each triplicate. 
107 
Supercritical fluid extraction 
Table 4.9. Major constituents of extracts of Salvia species with restricted solubility limit 
% in oil' 
Compound' 
Q 
Lý C3 Q .° 
113 
U E. ' Q O 
Unidentified 30.747 10.9 
Cary-ophyllcne 30.76 15.7 
Germacrene D 32.69 12.2 
Unidentified 46.54 123 
9,12,15-octadecat icnoic acid. 
methyl ester, (Z Z, Z)- 
48.90 33.8 
Squalene 63.26 39.7 223 
Unidentified 67.60 13.0 
Lup-20(29)cn-3-one 72.27 39.1 
Unidentified 73.24 18.0 
Unidentified 75.43 34.4 
'Identities of compounds determined from mass spectrometry analysis 
bRT retention time of the compounds 
`Constitucnts with no less than 10% in extracts as calculated from a total area of peaks 
on a basis of 1% of a major peak. 
4.2.2. Kinetic studies on inhibition of BuChE and AChE by extracts of Sah'ia 
species 
Determination of kinetic constants for inhibition of both cholinesterases is shown in 
Appendix 2. For the convenience of reading, this Chapter summarises only processed 
data on the enzymes kinetics. 
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The Michaelis constant (Kin) value and a limiting value of initial enzyme velocity 
(Vmax) for human BuChE were 0.037 mM and 13 nM min-' respectively (Table 4.10; 
Appendix 2). Oils of S. apiana, S. officinalis var. purpurea and S. fruticosa showed 
non-competitive inhibition of BuChE. The inhibition was a combination of competitive 
and un-competitive type, with the competitive inhibitor constant (Kie) being less than 
the un-competitive one (Kies). 
Table 4.10. Effect of BuChE inhibitors on Km, Vmax and Ki values 
Inhibitor Inhibitor 
concentration 
me ml's 
Km, 
mM 
Vmax, ' 
nM min' 
Kie, 
mg ml-s 
Kies, ` 
mg ml's 
Type of 
inhibition 
Control 0 0.037 1.3 
S. apiana 0.08 0.068 0.7 0.025 0.05 non-competitive, 
0.1 0.08 0.5 mixed (Kies>Kie) 
S. officinalis 0.0075 0.043 0.86 0.015 0.033 non-competitive, 
var. purpurea 0.015 0.053 0.5 Mixed (Kies>Kie) 
S. fruticosa 0.01 0.051 0.65 0.016 0.022 non-competitive, 
0.02 0.056 0.5 mixed (Kies>Kie) 
The anoarent Km and Vmax values were calcul ated by t heir respective regression 
equations using a Lineww-eaver"Burk plot (Appendix 2). bIhe competitive inhibitor 
constant was determined using Dixon's plot (Appendix 2). `The un-competitive 
inhibitor constant «-as determined using Dixon's re-plot (Appendix 2). dCharacterisation 
of a type of BuChE inhibition was made according to Engel (1981) (Appendix 2). 
The Km and Vmax values for AChE were 0.1 mM and 0.97 nM mind respectively 
(Table 4.11; Appendix 2). Oil of S. corrugata showed a non-competitive, simple type of 
inhibition, with Kies being equal to Kie. In contrast to non-competitive inhibition of 
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BuChE, oil of S. ofcinalis var. purpurea demonstrated a competitive type of inhibition 
of ACNE, i. e., the oil binds only to the enzyme but not to the substrate. Oils of S. apiana 
and S. frulicosa shored non-competitive, mixed inhibition of the enzyme, i. e., 
Kies>Kie (the oils binds both to the enzyme and the substrate). 
Table 4.11. Effect of AChE inhibitors on Km, Vmax and Ki values 
Inhibitor Inhibitor 
concentration 
me ml'1 
Km, ' 
mtii 
Vmax, ' 
nNI min' 
Kie, 
mg ml's 
Kies, ` 
mg m1'1 
Type of 
inhibition 
Control 0 0.1 0.97 
S. corrugata 0.0025 0.1 0.9 0.018 0.018 non-competitive, 
0.01 0.1 0.78 simple (Kies=Kie) 
S. apiana 0.025 0.12 0.86 0.025 0.125 non-competitive, 
0.1 0.28 0.5 mixed (Kies>Kie) 
S. officinalis 0.005 0.11 0.97 0.048 Competitive 
var. 0.02 0.2 0.97 only Kie 
purpurea 
S. fruticosa 0.02 0.12 0.78 0.043 0.093 non-competitive, 
0.08 0.14 0.51 mixed (Kies>Kie) 
The apparent tim and Vmax values were determined by their respective regression 
questions using a Lineweaver-Burk plot (Appendix 2). "The competitive inhibitor 
constant aas determined using Dixon's plot (Appendix 2). `The un-competitive 
inhibitor constant was determined using Dixon's re-plot (Appendix 2). 4Characterisation 
of different types of AChE inhibition was made according to Engel (1981) (Appendix 
2). 
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4 . 2.3. Fractionation of residues from Phs tosol A extraction 
Extraction ut' sage species %%ith Phvtosol A in some cases (4.2.1. ) provided extracts with 
two phases. i. e.. oil and a residue. The residue (hexane treated. Chapter 2) of three non- 
scented sage species were analysed for their chemical composition and screened for 
anti-ChE activity . The hexane treated residues of S. argentea. S. napilblia and 
S. 
v unnanensis comprised single peaks using GC MS analysis. Figure 4.2 shows a total ion 
count of the residue of S. ºvnnanensis. On the figure an identified single peak represents 
100° o of a total area of peaks. The retention time of the peak was 36.94 minutes. The 
fraction inhibited human BuChE and human AChE with IC:,, values of 0.07±0.005 mg 
ml" and 0.15=0.0 3 mg ml" respectively. 
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Figure 4.3 sho%%s a total ion count of the hexane treasted residue of S. urgentea. On the 
figure an identified peak. with the retention time of 68.50 minutes. represents 100% of a 
total area of peaks. This isolated fraction. at a final concentration of 0.1 mg ml-'. gave 
no inhibition of both cholinesterases. 
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Figure 41 Total ion count of hexane treated residue of S. argenteu. 
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Figure 4.4 sho%%s a total ion count of the hexane treated residue of S. napitolia. On the 
figure an identified peak. with the retention time of 68.525 minutes. also represents 
100°0 of a total area of peaks. An amount of the isolated fraction was insufficient for 
cam ing out anti-cholinesterase activity tests. 
Fiie M: \SS-OILS\SS46R. D 
Operator : p. d for s. s 
Acquired : 2Q Jan 2003 11: 11 using AcqMethod SSSCNF 
Instrument : GC/MSD 3 
Sa. ple Name: 4.6 res in 1000/lul inj ss sh scan 
Misc Info . 
Vial Number: 26 
nc S&1 0 
. 652 
smoac 
ýoooo 
eeo= 
srs= 
roooo 
IBOM 
30oooo 
rsoow 
imoýoa 
eoaaý 
soooo ý 
r, 4.. ,0 ac 's 00 ao 00 25 00 30 00 
r315 
oc .o 00 .s oo 50 00 55 00 60 00 65 ao 7000 75 00 eo 00 8500 
i: iture 4 41 otal on count of hexane treated residue of S. napif olia 
11, 
Supercritical fluid extraction 
4.2.4. Extraction of S. fru: ic osa i% ith a mixture of PhN tosol A and Z'%, ethyl acetate 
A pilot test of extraction of aerial parts oI . ti. _Irurüusa 
by a mixture of Phvtosol A and 
3° ° eth,. I acetate pro% ided a dark amber oil rich in gamma-sitosterol (42° 0) (Appendix 1 
pro% ide database of chemical constituents) and camphor (25.11o). A chemical 
composition of nma1 or constituents in the oil is sho%Nn in Table 4.12. It may be noted that 
gamma-sitosterol was not detected in the oil extracted only with Phvtosol A (4.2.1). 
Table 4.1-1. Major constituents of S. fruticosa oil extracted by Phvtosol A and 3° o ethyl 
: ý:..... .,. 1\IUCC 
. t11riýunJ nun u ýýi 1ýý1a1 
1. S-oneole 10 
. 
5y 7.1 
Camphor 
-11.09 -5.1 
Car. ophv Ilene 30.76 7.3 
( gamma-sito terol 64.30 42 
`I. ik: ntltic-,, 1 :,, Ynpoundý, dctcrn fined from mass spectrometry analysis. 
Constituents %%ith no less than 7°° in the oil as calculated from a total area of peaks on 
a basis of 1Io of a major peak. 
4.2.5. ( ro%%-contamination i.. uc. 
lt ýýas 10und that a contact of Phvtosol .\ %Nith a plastic rubber material allo%Ns 
extraction of a number of plasticizers (Table 4.13) with anti-cholinesterase activ it-%. :A 
mixture of contaminants inhibited human BuChE with an IC': (, alue of 0.01±0.001 mg 
ml ` and . 
121_-4.2°° of human AChE at a final assay concentration of 0.14 nig ml". 
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Hence. any equipment ººith plastic or rubber surfaces used not only in the extraction 
process but also to contain the gas should thus be avoided. Chapter - (Materials and 
Methods) sho%%s that the equipment used in the extraction process was plastic rubber 
free as %%eII as the c,. linder containing the solvent. Thus, a hand set extraction kit 
(Chapter 2) supplied hý . Ad% anted Phvtonics Ltd.. NN as modified by replacing a rubber 
rinn; %% ith pI tetrafluoroeth% Lene 1 PTEF 1 coated ring. 
Table 411 Contaminant< extracted hý Phv-tosol A from a plastic rubber material 
ont. if1111 an', Retention time o1 total 
Mill 
[)ihutý I phthalate I .ýý. 
] 
E3crv% I but,. I phthalate 18.19: 25.9 
1. 
_'-benzenedicartxix%lic acid. 41.5 71.8 
dii, ooctý I ester 
1dClIti ! C, ,1 : k) fltlllllll, lllt, dctcrniink: J from nlaý,, srectrometr\ anal\, ýis. 
ont, ºmrnant, %ýith in the oll as calculated frone a total area of peaks on a basis of 1 °o 
t, i ,i Ill. t r pk', 1! 
4.3. I)i%cu. * inn 
-i "; Dual anti-cholinesterase activity of extracts 
The main finding of the present studs as that using Ph\tosol A as a sol' ent enables 
effecti\e extraction of molecules with anti-BuChE and anti-: AChl: activities. 10 days 
old extracts of .S afric ap; a-lute a. 
S. argenhe'a. S. c/ivinorum. S. /ruticosa. S. invo/urrata. 
S. rm, rop/n Ila ' ar. nc"urepia. S ut>icina/is. and S. ofJicina/is var. purpurea had marked 
dual anti -cholinestera_x arti\it'. i. e.. range from 0.01 mg, mi" to 0.1 mg ml-'. This range 
.,, nýrntr. iti, 'n' nia\ lc \%ithin theraputical doses since 1 ildesle\ et al.. ("UO 3) 
11-1; 
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reported in-riti o that a dose of 50 µl of Salvia lavandulaefolia oil, which in vitro inhibits 
human (Perry et al., 2000 b) and bovine (Savelev et al., 2003) AChE with IC50 values 
of 0.03 mg ml's and 0.05-0.07 mg ml-1 respectively, significantly improved memory in a 
dose-dependent manner in healthy young volunteers. Thus, considering that an average 
human body contains five litres of blood and the oral administration of the oil (assume 
to reach the brain), 150 mg dose of Spanish sage which would give 50% inhibition of 
AChE is physiologically relevant. Hence, the single dose (50 µl) of steam distilled 
Spanish sage oil administrated by Tildesley et a1. (2003) is approximately three times 
less than the one needed for 50% inhibition of AChE in the body. Moreover, an analysis 
of a chemical profile of these extracts revealed no apparent pattern between their 
constituents and anti-cholinesterase activity, suggesting that each extract has a unique 
combination/ratio of compounds which allows synergistic interactions (Chapter 6; 
Savelev et a1., 2003). This unique combination/ratio may also be a result of adaptation 
of plants to surrounding herbivores which can involve changes in concentrations of 
terpenes (Valladares et al., 2002). 
4.3.2. Storage effects 
The activity of the extracts may vary during their storage. For instance, anti-BuChE 
activity of S. fruticosa oil was increased 5 times during 30 days of storage, i. e., from 7 
to 37 days. The profound changes in the activity of the oil which are due to chemical 
alterations during storage (Misharina et al., 2003) were apparent during the first 37 
days. After this period the activity of the oil reached its peak and remained unchanged 
for another 63 days. In contrast anti-cholinesterase activity of 70% EtOH extract of S. 
fruticosa did not significantly change during the first 37 days of storage. This may 
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indicate that non-polar compounds are subject to more rapid chemical transformations 
than polar. 
Furthermore, anti-BuChE activity of 30 days old S. apiana oil may not be regarded as 
therapeutical with an IC50 value of 0.18±0.035 mg ml'' but it may after 100 days of 
storage when the value increased six times. The peak of the maximum activity of the oil 
or its maturity may not necessary be reached in 100 days, hence, as in the case with S. 
fruticosa oil, the 37 days activity check may be warranted. Dual anti-cholinesterase 
activity S. officinalis var. purpurea oil remained within the theraputical range of 
concentrations during both check points (30 and 100 days) of the storage time however, 
less storage time activity check may be required. 
An analysis of chemical composition of the oils revealed that changes in the activity of 
the oils during the storage are likely to be due to significant alterations in concentration 
of minor constituents (Appendix 3) interacting synergistically with almost unaltered 
concentrations of major constituents. For example, 30 days old S. apiana oil had, inter 
alfa, 34.4% of 1,8-cineole, 38.6% of camphor, 5% of limonene and 0.8% of 4-carene, 
whereas after 70 days of storage the oil contained 32.6% of 1,8-cineole, 38.5% of 
camphor, no limonene or 4-carene, 2.2% and 1.7% of unidentified compounds with the 
retention time of 16.4 and 34.04 minutes respectively. Thus, six times increase in anti- 
BuChE activity of S. apiana oil may be attributed to a significant decrease in 
concentration of limonene from 5.0% in 30 days old oil to a non-detected level in 100 
days. In addition, certain molecules of plant materials, extracted at the low boiling 
temperature, may undergo an extensive thermolysis during first days of storage, which 
could lead to metabolic production of active molecule species with a minor percent. 
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Finally, this data shows that the stability test on the claimed activities of essential oils is 
an important issue to%%ards standardisation. It may have an important clinical 
application since Perry et al. (2003) reported a positive result of a clinical trial of 
Phytosol A extracted oil of S. larandulaefolia on those with AD and Tildesley et al., 
(2003) showed that steam distilled oil from the same plant enhanced memory in healthy 
young volunteers. 
433. Kinetic studies 
Kinetic studies using Lineweaver-Burk plot showed that S. officinalis var. purpurea oil, 
as galanthamine (Lilienfeld and Parys, 2000), is a competitive inhibitor of human AChE 
but non-competitive (mixed) for BuChE, i. e., a combination of competitive and 
uncompetitive inhibition. To date, there is no report showing competitive inhibition of 
AChE by any steam distilled oils. This type of inhibition may be due to the abundant 
presence (46.5%) of a-caryophyllene and/or its synergistic interaction with thujone 
(6.10/6), a non-competitive rapidly detoxified blocker of the GABAA receptor (Hold et 
al., 2000), and/or other constituents (Chapter 6; Savelev et al., 2003). The other 
extracts, with the dual activity showed a non-competitive (mixed) type of inhibition 
with Ki values corresponding to their IC50 values (Cortes et al., 2001). The non- 
competitive (mixed) type of inhibition was also found in tacrine (Alhomida et al., 
2000), a licensed drug in the treatment of AD and physostigmine (Perola et al., 1997). 
4.3.4. Differential anti-cholinesterase activity of the extracts 
Oils of S. glutinosa and S. napifolia showed a ratio preference towards inhibition of 
BuChE, as does rivastigmine (Giacobini, 2000). From a clinical point of view, this may 
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be used to treat more severe cases of AD, which show higher BuChE levels. Since 
BuChE is present in the neuritic plaques, together with AChE, a drug inhibiting BuChE 
could reduce the formation of A. This also may produce significant increase in brain 
ACh without triggering side effects (Giacobini, 2000). A solubility limit of extracts S. 
longist}"1a and S. Jamensis -*-ar. la luna did not allow preparation of their higher 
concentrations which might result in obtaining 50% inhibition of BuChE within the 
theraputical doses, i. e., less than 0.1 mg m1'1. 
In contrast S. larandulaefolia oil was four times more selective inhibitor for AChE than 
I3uChE. Six weeks treatment of subjects with mild to moderate AD with the oil, 
extracted using Phytosol A, resulted in reduction of neuropsychiatric symptoms and an 
improvement in attention (Perry et al., 2003). This suggests that if the positive effect of 
the trial is attributed to inhibition of AChE, since the enzyme is more abundant at an 
early stage of the disease (Ballard, 2001; Greig et al., 2001), then the IC50 value of the 
oil is clinically relevant. This study also suggests that active molecules of the oil reach 
the brain and inhibit AChE in select areas. 
Extracts of S. corrugata and S. confer: Wora selectively inhibited AChE with ICso 
values of 0.009 mg ml" and 0.03 mg ml'' respectively. Huperzine A and donepezil, 
licensed drugs in the treatment of AD, have also been reported (Giacobini, 2000) to be 
more selective towards inhibition of AChE. An analysis of a chemical composition of 
these extracts (Appendix 3) showed no obvious pattern between major constituents and 
acetylcholinesterase activity, suggesting that each extract evolves its own anti-herbivore 
defensive chemical profile (Schmeller et al., 1997; Valladares et al., 2002). The rest of 
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extracts, concentrations of which were also restricted by a solubility limit, had 
combinations of molecules with less apparent anti-BuChE activity. 
Extracts with preferential cholinergic activity could potentially be used therapeutically 
according to severity of AD (Giacobini, 2000). For example, extracts with dual anti- 
ChE activity, may be appropriate to patients with those forms of the disease, where the 
level of AChE has not yet significantly declined (Davies et al., 1999) but a possibility 
that BuChE could hydrolyse ACh exists (Mesulam at al., 2002 a), i. e. a moderate stage. 
In addition, people with a family history of AD, possibly at their late forties, may 
benefit from using extracts with selective anti-AChE activity. For example, reversible 
inhibitors of AChE may not only postpone a decline in a level of ACh but also 
indirectly participate in the cholinergic anti-inflammatory pathway (Chapter 1) by 
increasing a level of ACh, which is in addition a functional agonist to the nAChR a7 
subunit on a macrophage. The interaction of ACh with the subunit increases calcium 
influx in macrophage, which results in suppression of a pro-inflammatory cytokine, 
namely tumour necrosis factor (Wong et al., 2003). 
4.3.5. Extraction issues 
Extraction of sage species with Phytosol A in most cases provided extracts with two 
phases, i. e., oil and a residue. Despite being a non-polar solvent, Phytosol A may 
increase its polarity by taking (the solvent is lightly soluble in water, 0.08 %wt) some of 
the remaining water from the plant materials. The modest pressure during the extraction 
process may also be conducive for extraction of compounds which normally 
(considering only polarity of 1,2,2,2-tetrafluoroethane) do not dissolve in the solvent. 
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Hence, when Phytosol A evaporates it leaves an extract with constituents expressing 
different polarities, i. e., the extract with two phases. 
The hexane treated residues of S. argentea, S. napifolia and S. yunnanensis contained, 
in each case, an unidentified peak representing 100% of the isolated fraction. The 
isolated fraction of S. yunnanensis showed to be a potential source of isolation of single 
compounds with dual anti-cholinesterase activity. Thus, the residue of extracts should 
not be disregarded in a search for new biologically active compounds. 
Phytosol A extracts of S. atrocyanea, S. divinorum, S. Jamensis var. la luna were rich in 
squalene (Figure 4.5. ), a molecule with potential anti-cancer, anti-oxidant and 
detoxifying properties (Gregory and Kelly, 1999; Smith, 2000). The average intake of 
squalene is 30 mg per day in the United States, however, when consumption of olive oil 
containing 0.2-0.7% squalene is high the intake of it can reach 200 mg per day as 
observed in Mediterranean countries where a decreased risk for various cancers is 
associated with high olive oil consumption (Smith, 2000). To date, there is no report to 
demonstrate the presence of squalene in sage species. 
Figure 4.5. Squalene, C30H50, (2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22- 
tetracosahexaene) 
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The use of Phytosol A as a solvent permitted extraction of vitamin E, a dietary 
compound that functions as an antioxidant scavenging toxic free radicals which may 
contribute to the pathological processes in AD. Sano et al. (1997) reported that in two 
years clinical trial 2000 IU a day of vitamin E slows the progression of AD in patients 
with moderate stage, while a combination of vitamin E and donepezil had also a 
positive effect in those patients (Matte et al., 2003). Thus, the abundant presence of 
vitamin E in extracts of S. atrocyanea (4.8%) and S. argentea (0.8%) may also provide 
an additional therapeutical value to their anti-cholinesterase activity. 
Moreover, using Phytosol A in a combination with 3% ethyl acetate allowed extraction 
(42%) of y-sitosterol (Figure 4.6. ) in the S. fruticosa oil, which has not been reported in 
the oil obtained via Phytosol A alone. Such significant change in a chemical 
composition may have a profound effect on cholinergic activity of the oil and additional 
activity tests are therefore required. Nevertheless, the abundant presence of phytosterol 
may provide the oil with new theraputical values, namely cancer prevention (Li et al., 
2001) and blood lymphocyte proliferation (Bouic et al., 1997). Due to its lipophilic 
nature y-sitosterol can also act as a phytophore to other less lipophilic but active 
constituents. In addition, this is a first report of the presence of y-sitosterol in Salvia 
species despite previous reports (Ulubelen et al., 1994; Miura et al., 2001; Wu, 2001) 
on isolation of ß-sitosterol from the genus. 
Finally, due to low viscosity, Phytosol A has good penetration properties into the 
materials to be extracted (Houghton and Raman, 1998). Any contact of the solvent with 
plastic/rubber objects increases a chance of extracting contaminants, such 
plasticizers/phthalates, with anti-ChEs activity. The presence of phthalates in plant 
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extracts may change a natural chain of chemical interactions (synergistic/antagonistic) 
within plant extracts and it also can rapidly increase production of reactive oxygen 
species in vivo (Rusyn et al., 2001). To avoid this cross contamination plastic/rubber 
containing material, which are likely to be in a contact with the solvent, should be 
replaced with PTFE coated material (Chapter2). 
Et 
Pr-i 
Figure 4.6. y-Sitosterol. C29H50O, (Stigmast-5-en-3-ol, (30,24S)- (9CI)) 
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Chapter 5. Anti-cholinesterase activity of terpenoids 
present in extracts of Salvia species 
5.1. Introduction 
A diverse range of bioactivities of Salvia species (1.3.1.4.4.; Appendix 1) has warranted 
research into investigation of individual constituents that present in extracts of the 
plants. These constituents-products of metabolic pathways, known as secondary 
metabolites, are not directly involved in growth or development of plants but rather play 
a defensive role against predators and pathogens by having a toxic effect on the latter 
(Panagiotopoulos et al., 2000). 
According to Panagiotopoulos et al. (2000) there are three major groups of secondary 
products: terpenoids, phenolics and nitrogen containing compounds. Terpenoids, the 
most abundant compounds in sage species, are lipid synthesised from acety-CoA via the 
mevalonic acid pathway. The taxonomy is based on the number of five-carbon 
containing units of the terpenoids. Thus, the two five-carbon unit containing terpenoids 
are called monoterpenes (10 carbon atoms), the three five-carbon unit are sesquiterpenes 
(15 carbon atoms), four five-carbon unit are diterpenes (20carbon atoms), triterpenes 
(30 carbon atoms) and polyterpenes (more than 40 carbon atoms). 
Phenolic compounds are aromatic substances mainly formed via the shikimic acid or the 
malonic acid pathway. This group has a hydroxyl group joined to an aromatic ring. In 
addition to its defensive role, phenolics act as attractants to insects at the flowering 
period. Rosmarinic, camosic and salvianolic acids (Figure 1.15), carnosol and 
tanshinones (Figures 1.16 and 1.17) are representatives of this group of metabolites. 
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Nitrogen containing molecules, such as alkaloids and cyanogenic glycosides, are 
synthesised by common amino acids. In contrast to terpenes and phenolics, they are not 
abundant in sage. 
A variety of terpenes have been found in essential oils of Salvia species (Giannouli and 
Kintzios, 2000; Appendix 1). Some of the major compounds were analysed for their 
bioactivity on the CNS relevant to treatment of dementia (Appendix 1). Perry et at., 
(2000 b) reported that 1,8-cineole and a-pinene had human anti-AChE activity with IC5o 
values of 0.67 and 0.63 mM respectively, whereas camphor (IC50>10 mM), linalool, 
geraniol and y terpinene were inactive. Camphor and borneol were also found (Park et 
al., 2001; Park et al., 2003) to inhibit nicotinic acetylcholine receptors in a non- 
competitive way. Stimpfl et al. (1995) reported that inhalation of 1,8-cineole increases 
the cerebral blood flow in the healthy humans and in-vitro it inhibits pro-inflammatory 
cytokines, TNF-a and IL1, production (Juergens et al., 1998 a; Juergens et al., 1998 b). 
Inhalation of linalool produced a dose-dependant sedative effect in mice (Jirovetz et al., 
1991). Re et al. (2000) demonstrated that linalool may inhibit ACh release via reduction 
of the influx of calcium in the presynaptic terminal or the inhibition of the voltage-gated 
sodium and potassium channels. In addition, Elisabetsky et al. (1995) reported an 
inhibitory effect of linalool on glutamate binding activity in rat cortex. 
As there are no reports on anti-BuChE activity of compounds present in any species of 
Salvia the purpose of this study was to determine in-vitro whether the low molecular 
weight constituents of the genus contribute to inhibition of BuChE. Parallel AChE 
inhibitory activity was also investigated. 
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5.2. Results 
Anti-BuChE activity of single chemicals is shown in Table 5.1.3-carene was the only 
compound reaching 50% inhibition of the enzyme at a final concentration of 2 mM 
during the 5 minutes pre-incubation period, while the rest of the constituents showed 
little or no activity. Incubation time affected the inhibitory activity of 3-carene (Table 
5.2) with the ICso values being significantly decreased from 2 mM in 5 minutes to 0.7 
mM in 60 minutes. The activity of ß-pinene was also significantly increased from 
24±4% inhibition at a final concentration of 3.8 mM for 5 minutes to an IC50 value of 
2.3 mM in 60 minutes, whereas the activity of sabinene decreased from 28±5% in 5 
minutes to 8±5% in 60 minutes at a final concentration of 1.8 mM. The potency of 
camphor did not change with time. 
In contrast to inhibition of BuChE, human anti-AChE activity of ß-caryophyllene, 3- 
carene, 1,8-cineole, a-pinene and ß-pinene was apparent (Table 5.3). The assay 
solubility limit of ß-caryophyllene did not allow further investigation of higher 
concentrations. ß-caryophyllene, at a final concentration of 0.06 mM (0.0125 mg ml"), 
gave 32±3.0% inhibition of human AChE. To compare this activity with that of 3- 
carene, a concentration of 0.0125 mg ml-1 was substituted into the mean dose-response 
curve equation of 3-carene (y=20.8 Ln (X)+124.55) as X (concentration). Hence, Y 
(inhibition) was 33%. Thus, 3-carene at a final concentration of 0.0125 mg/ml (0.08mM) 
would give 33% inhibition of the human AChE, whereas ß-caryophyllene at a final 
concentration of (0.06 mM) provided with 32±3% inhibition of the enzyme. This 
indicates that ß-caryophyllene was a more potent inhibitor of human AChE than 3- 
carene. The remaining chemicals demonstrated modest or no activity towards inhibition 
of bovine or human AChEs. 
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Table 5.1. Anti-BuChE activity of compounds present in Salvia species 
Compound IC50, mg ml-'a Inhibition, %° 
mean±SD (n=4)° mean±SD (n=4)° 
a-pinne 0 [1.0 mg ml' (7.3 mM)] 
ß-pinene 
Limonen 
1,8-cineole 
Linalool 
3-carene 
a-thujone 
Camphor 
Borneol 
a-terpineol 
Bornyl acetate 
a-copaene 
Sabinene 
Neryl acetate 
Globulol 
Guaiol 
a-caryophyllene 
ß-caryophyllene 
Caryophyllene oxide 
Sclareol 
Manool 
24±4 [0.5 mg m1'' (3.7 mM)] 
0 [0.5 mg m1' (3.6 mM)] 
0 [1.5 mg m11(9.8 mM)] 
13±2.0 [1 mg ml'' (6.5 mM)] 
0.3±0.01 mg mrl (2 mM) 
1012.0 [0.5 mg ml-' (3.2 mM)] 
0 [1 mg m1"' (6.6 mM)] 
0 [0.25 mg mrl (1.6 mM)] 
0 [0.5 mg m11(3.2 mM)] 
0 [0.25 mg m1' (1.3 mM)] 
0 [0.06 mg m11(0.3 mM)] 
28±5 [0.25 mg m1' (1.8 mM)] 
0 [0.25 mg mr' (1.3 mM)] 
0 [0.05 mg ml"' (0.2 mM)] 
0 [0.0125 mg m1'' (0.06mM)] 
18±3.6 [0.25 mg m1' (1.2 mM)] 
0 [0.5 mg m14 (2.5 mM)] 
12±4 [0.25 mg ml"' (1.1 mM)] 
0 [0.025 mg ml-' (0.8 mM)] 
0 [0.05 mg m11(1 mM)] 
Quinidine (control) 6.8x104 mg ml"1(0.9µM) 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. bInhibitory activity of compounds which did 
not reach 50% enzyme inhibition. The percent activity corresponds to the values of 
solubility of each cEach chemical was tested in a set of four triplicates. Mean of 
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one triplicate was designated as n=1. Standard deviation (SD) was calculated on a basis 
of four sets of triplicates using a dose response equation of each triplicate. 
Incubation time for the constituents before adding the substrate was 5 minutes. 
Table 5.2. Anti-BuChE activity of compounds over a course of incubation time 
Compound IC50, mg ml"' or Inhibition, 
mean±SD (n=4)° 
5 min 30 min 60 min 
ß-pinene 24±4 (0.5 mg ml") 43±7 (0.5 mg ml") 0.3±0.004 
3-carene 0.3±0.01 t 
Sabinene 28±5 (0.25 mg m1-1)$ 
0.16±0.031 0.1±0.02t 
16±3 (0.25 mg ml'1)$ 8±5 (0.25 mg ml')$ 
Camphor 0 (1 mg m1'')ß 0 (1 mg/m1)$ 0 (1 mg m1"1)$ 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. bInhibitory activity of compounds which did 
not reach 50% enzyme inhibition. The percent activity corresponds to the values of 
solubility of each terpene. `Each chemical was tested in a set of four triplicates. Mean of 
one triplicate was designated as n=1. Standard deviation (SD) was calculated on a basis 
of four sets of triplicates using a dose response equation of each triplicate. t- 
corresponds to a. 1-corresponds to b. 
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Table 5.3 Anti-AChE activity of compounds present in species of Salvia 
Compound IC50, mg MI", Inhibition, 
mean±SD (n7-4 )d mean±SD (n=4)d 
a-pinene 0.1±0.01 (0.7mM) 
ß-pinene 0.2±0.008 (1.5mM) 
Limonene 13±4.2 [0.07 mg ml"' (0.5 mM)]t 
1,8-cineole 0.06±0.007 (0.4 mM)t 
Linalool 18±2.3 [0.5 mg m1' (3.25 mM)] 
3-carene 0.03±0.005 (0.2 mM)t 
a-thujone 37±4 [0.5 mg m1' (3.2 mM)]t 
Camphor 13±3.2 [0.09 mg m1' (0.6 mM)t 
Borneol 19±2.6 [0.25 mg m14 (1.6 mm)] 
a-terpineol 22±5.5 [0.25 mg ml" (1.6 mM)]t 
Bornyl acetate 23±4.0 [0.25 mg m1' (1.3 mM)] 
a-copaene 0 [0.06 mg ml"' (0.3 mM)] 
Sabinene 0 [0.125 mg ml"1(0.6 mM)] 
Neryl acetate 0 [0.125 mg ml-' (0.65 mM)] 
Globulol 0 [0.05 mg ml"' (0.2 mM)] 
Guaiol 0 [0.025 mg ml-' (0.1 mM)] 
a-caryophyllene 0 [0.25 mg ml"' (1.2 mM)] 
ß-caryophyllene 0.03±0.003 (0.13 mM) 32±3 [0.0125 mg ml"' (0.06 mM)]t 
Caryophyllene oxide 3 5±4.7 [0.25 mg ml'' (1.1 mM)] 
Sclareol 0 [0.025 mg ml"' (0.8 mM)] 
Manool 21±6.3 [0.05 mg ml"1(1 mM)] 
Physostigmine (control) 1.4x 10"5 mg m1' (0.04 jM) 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. bInhibitory activity of compounds which did 
not reach 50% enzyme inhibition. The percent activity corresponds to the values of 
solubility of each terpene. dEach chemical was tested in a set of four triplicates. Mean of 
one triplicate was designated as n=1. Standard deviation (SD) was calculated on a basis 
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of four sets of triplicates using a dose response equation of each triplicate. tCompounds 
tested with the human enzyme otherwise with the bovine. 
5.3. Discussion 
The study showed lack of anti-BuChE activity in the low molecular weight compounds 
tested. Nevertheless, further tests on combinations comprising these molecules for the 
activity of the enzyme may be warranted (Savelev et al., 2003). It also demonstrated 
slow onset of the inhibition of the enzyme during the incubation periods by single 
molecules such as 3-carene, which is abundant (16.5%) in oil of Salvia aurea L. 
(Serrato-Valenti et al., 1997) and ß-pinene, which is rich in oil (34.4%) of Salvia 
candidissima Vahl. (Bayrak and Attila, 1987). Volatility of the inhibitors restricted the 
course of incubation time at 30 °C, although Ogura et al. (2000) reported that 
rivastigmine, a non-volatile chemical, reached its maximum inhibition of the enzyme 
after six hours. 
Bovine and human anti-AChE activity of terpenoids has been previously described 
(Miyazawa et al., 1997; Miyazawa et al., 1998; Perry et al., 2000 b). This study 
confirmed that low molecular weight compounds readily inhibit AChE, in contrast to 
inhibition of BuChE. Anti-AChE activity of ß-caryophyllene (Figure 5.1) and 3-carene 
(Figure 5.2) has never been previously reported and to date they are the most active 
non-oxygenated plant derived inhibitors with 15 and 10 carbons respectively. A lack of 
negative charge in these molecules may not allow their passage through the aromatic 
gorge of the enzyme but rather produce a quasi-steric hindrance for the substrate at an 
entrance of the gorge (Tai et al., 2002). Moreover, their volatile nature may enable their 
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administration as inhaled vapour avoiding the alimentary system with its attendant 
denaturing of active molecular species. 
Me 
CH 2 
Figure 5.1. ß-Caryophyllene C 15 H24 
Synonyms: Bicyclo[7.2.0]undec-4-ene, 
4,11,11-trimethyl-8-methylene-, 
(1R, 4E, 9S)- (9CI) 
Figure 5.2. (+)-3-Carene; C1oH16 
Synonyms: 3,7,7-trimethyl bicyclohep-3- 
ene 
The preferential inhibition of AChE, but not BuChE, by the secondary metabolites may 
be explained via the defensive mechanism of plants against herbivores (Schmeller et al., 
1997), as the latter contains cholinesterase structurally similar to the human AChE 
(Gnagey et al., 1987; Marcel et al., 1998). Selective anti-AChE activity of the single 
molecules may restrict their use to early stages of AD, where AChE is thought to be 
responsible for the hydrolysis of the neurotransmitter (Davies et al., 1999). In addition, 
collecting Salvia species which are rich in ß-caryophyllene, 3-carene and 1,8-cineole 
may provide oils with higher anti-AChE activity. 
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Chapter 6. Synergistic and antagonistic interactions of 
anticholinesterase terpenoids in Salvia lavandulaefolia 
essential oil 
Synergy means behaviour of whole systems unpredicted 
by the behaviour of their parts taken separately. 
Buckminster Fuller, 1975 
6.1. Introduction 
Study of interactions between biologically active agents in therapeutics, toxicology, 
environment and physiology is important for several reasons (Berenbaum, 1989). Those, 
as an example, include: increased rates of survival of patients with leukaemia and 
lymphomas when the latter were treated with combinations of four to six drug agents 
rather than with single ones; among elderly, non-hospitalised individuals, around 20% 
are taking combinations of drugs with the potential for aversive interactions; individuals 
exposed to more than one human carcinogen have a greater than expected incidence of 
cancer. 
Traditionally used plants and their extracts comprise a number of chemical constituents 
whose mechanism of interactions within the human biological system is not yet fully 
understood. The presence of synergism in plant extracts was shown by Klohs et al. 
(1959) who used the root of the kawa plant (Piper methysticum). A crude oil extract and 
several isolated known sedative compounds were each tested for their effects on the 
central nervous system by determining their ability to antagonise clonic strychnine- 
induced convulsions and death in mice. The total extract was particular effective, and 
dihydromethysticin (DHM) was found to be the most potent individual compound. A 
mixture of kawain, dihydrokawain, methysticin, dihydromethysticin, yangonin and 
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dihydroyangonin, combined in the ratio they were found present in the crude extract, 
was assayed and its potency found to be similar to that of DHM. However, as DHM 
represented only 5% of the total extract, and the other constituents were known to be 
less potent than DHM, the mixture was deemed synergistic. 
Liu et al. (1992) isolated a series of flavonoids which significantly enhanced in-vitro the 
anti-malarial activity of artemisinin, the most potent active constituents of Artemisia 
annua, against Plasmodium falciparum. Thus, the authors suggested that the whole 
plant extract may be more effective than the equivalent dose of the same active principle. 
Chen et al. (1994) assayed the wound-healing properties of blood-red sap (Croton 
lechleri) from Ecuador. The authors concluded that there is no single compound for 
wound healing but that the whole sap contributes to the remedial process and synergy is 
therefore likely. 
In a double blind placebo controlled clinical trial of Chinese medicinal plants (Sheehan 
& Atherton, 1992) 37 young patients with non-exudative atopic eczema showed 
significant improvement when they were treated orally with doses of an aqueous extract 
of ten Chinese herbs. A combination of pharmacological tests and clinical treatment 
with different combinations of herbs led to the conclusion (Phillipson et al., 1994) that 
it was a ten herb mixture which was effective and that there was no single active herb or 
principle. 
Berman et al. (2003 b) reported that a combination of tetrahydrocannabinol (THC), the 
psychoactive constituent of cannabis, and cannabidol (CBD), the inert constituent of 
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cannabis, was more affective in the treatment of patients with chronic neuropathic pain 
than THC on its own. 
Miyazawa et al. (1998; 2001) have also presumed that the anti-acetylcholinesterase 
activity of essential oils of Mentha species may be superior to individual compounds 
from the plants. 
Licensed drugs aimed at enhancing the cholinergic deficit associated with the cognitive 
dysfunction of Alzheimer's disease are at present based on the inhibition of the enzyme 
acetylcholinesterase (Levy et al., 1999; Jann, 2000; Coyle and Kershaw, 2001; 
Grutzendler and Morris, 2001). 
In a double blind, randomized and placebo-controlled trial Akhondzadeh et al. (2003) 
reported that ethanol extract of S. oficinalis L. improved cognition and reduced 
agitation in patients with mild to moderate stage of Alzheimer's disease. Despite the 
positive outcome of the trial the medical application of the extract is likely to be 
restricted due to lack of standardisation, i. e., identification and control of its active 
constituents. The latter is important in order to ovoid an over dose or under dose 
prescriptions in the treatment. 
Perry et al. (2000 a) suggested that Spanish sage (Salvia lavandulaefolia, Vahl) may 
also be relevant in the treatment of dementia of the Alzheimer's type and reported 
(Perry et al., 2000 b) in-vitro inhibition of acetylcholinesterase (AChE) by Spanish sage 
oil and its constituents. It was proposed that the inhibitory activity of the natural plant 
extract is due to the synergistic nature of the oil rather than a single inhibitor. 
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An assessment of the enzyme inhibitory activity of a combination of chemicals in terms 
of zero interaction, synergy or antagonism depends on a definition of what the expected 
response of a mixture should be. The interactions of a defined combination of 
compounds can be generally described as having a zero interaction, in which the 
response of the combination is that expected from the individual dose-response curves; 
synergy, in which the response is greater than expected; and antagonism, in which it is 
less. There are a number of methods, which have been proposed to demonstrate 
synergistic interactions between agents (Gessner, 1988; Berenbaum, 1989). The critical 
point in selecting an appropriate method is an understanding of the nature of a 
combination and the shapes of the dose-response curves of the agents. A linear or close 
to linear relationship is a basic assumption of the approach based on summation 
(Berenbaum, 1989). 
Interaction effects have also been studied using the isobole approach (Loewe, 1953; 
DeJongh, 1961), which is based on the necessity of agents to produce a specified 
response, such as death in 50% of the animals, known as LD50. A complication in 
analysing chemical interactions of natural constituents in inhibiting an enzyme such as 
acetylcholinesterase is that some constituents are less potent inhibitors and therefore, 
may not reach 50% inhibition of the enzyme on a dose-response scale over the range of 
concentrations examined. An essential oil comprises many constituents and to mimic 
combinations of such constituents regardless of number, in order to analyse the 
chemical interactions, is challenging. 
The method of Berenbaum (1978; 1985) is based on an assumption of zero-interactivity 
of agents in a combination. This approach facilitates analysis of a combination of agents 
with different types of dose-response relation or dose-scale and permits combinations of 
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any number of agents. This method was adopted in this study to explore the chemical 
interactions of principal constituents of Spanish sage essential oil. 
The aim of this work was to investigate the hypothesis that the activity of the natural 
plant extract is greater than the combined activity of individual components in their 
naturally occurring ratios. Because of the declining activity of AChE in AD (Davies and 
Maloney, 1976; Perry et al., 1977; Davies et al., 1999) a low enzyme concentration, 
relative to Ellman et al. (1961) was selected to ascertain the anticholinesterase activity 
of the natural plant oil and terpenoid combinations. 
6.2. Results 
IC50 values 
The oil and component terpenoids were tested for their anticholinesterase activity within 
their solubility limits. The compounds were divided into (i) those which reached 50% 
inhibition of AChE, and (ii) those which were less potent (Table 6.1. ). 
The IC50 value of the oil did not significantly differ from that of 1,8-cineole and was 
marginally less than the IC50 value of a-pinene. Other constituents showed significantly 
less anticholinesterase activity. 
Interactions 
The terpenoids were assessed in combinations for their AChE inhibitory activity on a 
basis of their naturally occurring concentrations in the oil (Table 6.2. ). The 
anticholinesterase contribution of 1,8-cineole accounted for half the activity of the 
natural plant extract (Table 6.2. ) and therefore was considered as the main agent, which 
could show synergy with other constituents. The reported chemical composition of 
Spanish sage oil is variable (Giannouli and Kintzios, 2000; Perry et al., 2000 b) and for 
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this reason the combinations of the terpenoids, investigated in the present study, 
reflected the average naturally occurring composition in the plant extract. 
Table 6.1. Anticholinesterase activity of essential oil and its constituents 
Inhibitor (i) IC50 (mg ml-1)' (ii) Activity", % 
X ±SD (n=4) X ±SD (n=4) 
Spanish sage oil 0.05±0.01 
1,8-cineole 0.06±0.01 
a-pinene 0.09±0.01 
ß-pinene 0.2±0.03 
Camphor 
Linalool 
Bomyl acetate 
Caryophyllene oxide 
Bomeol 
39±4.0 (0.5 mg ml") 
18±2.3 (0.5 mg ml") 
23±4.0 (0.25 mg ml»') 
35±4.7 (0.25 mg ml'') 
19±2.6 (0.25 mg ml"') 
'Final concentration of inhibitors required for 50% enzyme inhibition, as calculated 
from the dose response-curve equations. bInhibitory activity of compounds, which did 
not reach 50% enzyme inhibition, as calculated from the dose-response curves equations. 
The percent activity was obtained from the dose-response curve equations of the agents 
and corresponds to the values of solubility of each terpene. A concentration of each 
inhibitor was substituted into the dose-response curve equation of each inhibitor as X 
(concentration). Hence Y would represent inhibition, i. e., the activity of an inhibitor at 
its particular concentration. 
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Table 6.2. Inhibition of AChE by the essential oil and its constituents at concentrations 
based on ratios occurring in the oil 
Compound % in oils Concentration % Inhibitionc 
mg ml-1 bX ±SD (n=4) 
Spanish Sage 100 0.05 50±1.7 
1,8-cineole 26.8 0.013 26±1.6 
camphor 24.7 0.012 0 
a-pinene 6.6 0.003 0 
ß-pinene 5.4 0.0027 0 
Borneol 3.2 0.0016 0 
Caryophyllene oxide 1.2 6x 10-4 0 
Linalool 0.8 4x 104 0 
Bornyl acetate 0.7 3.5x104 0 
'Chemical composition of Spanish Sage obtained by GC-MS analysis. bFinal assay 
concentration of compounds, which corresponds to their chemical composition in the oil 
and was calculated from the IC50 value of the whole oil. The whole oil of 0.05 mg/ml, 
which gave 50% inhibition of the enzyme (IC50 value of the oil) was taken as 100%, 
for the convenience of calculations. Hence, the concentration of the agents was 
calculated on a basis of their percentage composition in the oil. `Percentage inhibition 
was calculated from the dose-response curve equations of each chemical at the 
concentrations in column 3. 
J 
In all combinations it was considered that the expected inhibition would be within the 
response scale of individual constituents, so that the iso-effective line intersects the 
dose-response curves of all agents. The inhibitory activity of 1,8-cineole and a-pinene 
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exceeded 50% inhibition of AChE (Table 6.1. ) and this allowed five concentrations of 
this combination, based on the typical ratio, to be tested (Table 6.3. ) (the number of 
concentrations of a combination depended on the inhibitory activity of the compounds 
and of their aqueous solubility in that combination). Caryophyllene oxide and camphor 
did not exceed 50% inhibition of the enzyme. As the result, only three concentrations of 
1,8-cineole/caryophyllene oxide and two of 1,8-cineole/camphor were analysed (Table 
6.3. ). In a combination of eight terpenes (Table 6.3. ) there was only one concentration, 
which allowed the isoeffective line intersecting the dose-response curves of all agents 
within their response scales and solubility limits. The interaction index (Table 6.3. ) was 
calculated to estimate the significance of these chemical interactions. 
Combinations of two compounds 
A minor synergy was apparent in 1,8-cineole/a-pinene and 1,8-cineole/caryophyllene 
oxide combinations at its higher concentrations, whereas at the lower concentration the 
interaction index expressed a zero-interactive response. Antagonism was found in 1,8- 
cineole/camphor combinations with the interaction index of 2. 
Figure 6.1 illustrates synergism in the combination of 1,8-cineole and a-pinene, 
whereas Figure 6.2 shows antagonism in the combination of 1,8-cineole and camphor. 
The dose-response curves of the agents are the mean of four dose-response estimations. 
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Table 6.3. Inhibition of AChE by combinations of terpenoids 
Combination Concentration 
mg m1 
Total 
mg ml'I b 
Inhibition, % 
Xt SD (n=4) 
observed ° expected d 
Interaction index of 
combination f 
X± SD (n=4) 
1,8-cineole/ 0.45 0.59±0.11 
a-pinene 0.04 0.5 92±1.4 84±2.7 synergy 
1,8-cineole/ 0.225 0.50±0.08 
a-pinene 0.02 0.245 84.5±1.7 73±2.1 synergy 
1,8-cineole/ 0.09 0.71±0.06 
a-pinene 0.008 0.1 63.5±0.6 58±1.4 synergy 
1,8-cineole/ 0.045 0.83±0.08 
a-pinene 0.004 0.05 50±1.3 47±1.0 synergy 
1,8-cineole/ 0.009 1.1±0.11 
a-pinene 8x104 0.01 20±1.3 21±2.0 zero- interaction 
1,8-cineole/ 0.045 
caryophyllene 0.003 0.048 56±2.4 46±1.2 0.55±0.05 
oxide synergy 
1,8-cineole/ 0.0225 
caryophyllene 0.0015 0.024 40±1.6 35±1.3 0.73±0.04 
oxide synergy 
1,8-cineole/ 0.009 
caryophyllene 0.0006 0.01 23±4.0 21±2.5 0.91±0.1 
oxide zero-interaction 
1,8-cineole/ 0.045 antagonism 
camphor 0.065 0.1 33±3.4 47±1.5 2.4±0.21 
1,8-cineole/ 0.009 2.08±0.39 
camphor 0.013 0.02 10±4.8 21±2.0 antagonism 
1,8-cineole 0.007 
camphor 0.01 
a-pinene 6x 10-4 0.96±0.7 
b-pinene 5x10-4 zero 
caryophyllene 0.02 19±2.8 18±2.3 interaction 
oxide 5.0x 10-4 
borneol 0.0013 
bornyl acetate 2.5x10-4 
linalool 4.0x 104 
'Final concentrations of individual compounds in the assay. bFinal concentrations of the 
combinations. °Inhibition of the combination obtained experimentally. dCalculated zero- 
interactive response of the combinations. 11f the observed inhibition is significantly 
more (P<0.05) than expected, with the interaction index less than 1, synergy is the result 
140 
Chemical interactions 
If the observed inhibition is significantly less (P<0.05) than expected, with the 
interaction index more than 1-antagonism is inferred, if not significant (P>0.05) with 
the interaction index of 1-zero-interaction. 
100 
------------ --------ý-------- clr>E ed inhibition, 84.5% 
75 
-- ----------------- speed inhibitor, 731/o -0 
50 
25 
0, 
0 0.5 1 1.5 2 
Concentration, mg/ml 
Figure 6.1. Calculation of expected response of 1,8-cineole (da; 0.225 mg ml*') and a- 
pinene (db; 0.02 mg m1'') combination. ", dose-response curve of 1,8-cineole; f, dose- 
response curve for a-pinene. A horizontal line of the expected inhibition of 73±2.1% 
intersects the two dose-response curves at points where concentrations of 1,8-cineole 
(Da) and a-pinene (Db), on the X-axis, are iso-effective with the combination (da; db) 
and, therefore satisfies equation 2, namely 0.225/0.236+0.02/0.304=1. Both of these 
compounds would produce 73±2.1% inhibition, so this is the response of the 
combination to be expected from the concentration-response curves of the compounds. 
The observed inhibition was 84.5±1.7%, i. e., more than expected, indicating synergism. 
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Figure 6.2. Calculation of the expected response of 1,8-cineole (da; 0.009 mg ml'') 
and camphor (db; 0.013 mg ml'') combination. ", dose-response curve of 1,8-cineole; 
A, dose-response curve of camphor. A horizontal line of the expected inhibition of 
21±2.0% intersects the two dose-response curves at points where concentrations of 1,8- 
cineole (Da) and camphor (Db), on the X-axis, are iso-effective with the combination 
(da; db) and, therefore satisfies equation 2, namely 0.009/0.0094+0.013/0.23=1. Both of 
these compounds would produce 21±2.0% inhibition, so this is the response of the 
combination to be expected from the concentration-response curves of the compounds. 
The observed inhibition was 10±4.8%, i. e., less than expected, indicating antagonism. 
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Combinations of more than two compounds 
The eight compounds mixture was zero-interactive (Table 6.3. ) and its inhibitory 
activity did not exceed that of the oil (Table 6.1. ). The inhibitory activity of a 
combination, excluding 1,8-cineole, as the most potent inhibitor, and camphor, which is 
the antagonist to 1,8-cineole, comprising minor constituents was analysed. In the 
combinations of the remaining six terpenes (Table 6.4. ) the additive inhibition was 
significantly less than observed, indicating synergism, when the method of summation 
was applied. In contrast there were zero-interaction responses according to the approach 
of Berenbaum. 
Table 6.4 Assessment of inhibition of AChE by combinations of six terpenoids on 
the basis of two methods 
Combination Concentration Inhibition, % ° Inhibition. %. X ±SD (n=4) 
mg m1"1 X ±SD (n=4) observed d expected f additive 9 
a-pinene 0.008 4±4.8 
ß-pinene 0.007 0 
caryophyllene oxide 0.006 0 
borneol 0.016 0 
bornyl acetate 0.0034 0 
linalool 0.004 0 
TOTAL: 0.044 b 
a-pinene 0.004 0 
ß-pinene 0.0035 0 
caryophyllene oxide 0.003 0 
borneol 0.008 0 
bomyl acetate 0.0017 0 
linalool 0.002 0 
TOTAL: 0.022 
14±2.4 16±2.5 4±4.8 
(1.22 ±0.3) 
6.5±2.6 5.5±1.6 0 
(0.95±0.13) 
'Final concentrations of individual compounds in the assay. bA sum of individual 
concentrations. cExpected inhibition of individual compounds, calculated from its dose- 
response curve equations accordingly to their final concentrations in the combination. 
dInhibition obtained experimentally and compared with the expected one (column 5), 
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with the interaction index shown in the brackets. The inhibition was not significantly 
more (P>0.05) than expected, with the interaction index of 1, indicating the zero- 
interactive response. fCalculated zero-interactive response of the combination. gConsists 
of a sum of the expected inhibitions of individual compounds. The additive inhibition 
was significantly less (P<0.05) than observed, indicating synergism. 
The inhibitory activity of the tested combinations of terpenes was summarised on a 
basis of IC50 values (Table 6.5. ). The presence of camphor significantly decreased the 
inhibitory activity of 1,8-cineole raising the IC50 value of 0.06±0.01 mg ml" (Table 6.1. ) 
to 0.18±0.2 mg ml''. When combined with a-pinene and caryophyllene oxide 1,8- 
cineole showed marginal synergistic responses. The inhibitory activity of eight and six 
compound combinations did not exceed that of the oil (Table 6.1. ). 
Table 6.5 Assessment of inhibition of AChE by combinations of terpenoids on a basis 
of IC50 values 
Combination Mass IC50, mg ml-la 
ratio X ±SD (n=4) 
1,8-cineole/a-pinene 0.7: 0.06 0.05±0.005 
1,8-cineole/caryophyllene oxide 0.7: 0.05 0.043±0.003 
1,8-cineole/camphor 0.7: 1 0.18±0.02 
Six compounds b 0.18±0.01 
Eight compounds ° 0.11±0.01 
'Concentration of combinations required for 50% inhibition of enzyme AChE, as 
calculated from the dose-response curve equations of the combinations. bCombination 
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comprising a-pinene, ß-pinene, caryophyllene oxide, borneol, bornyl acetate and 
linalool in the ratio as 0.06: 0.05: 0.05: 0.1: 0.03: 0.03. `Combination comprising 1,8- 
cineole, camphor, a-pinene, ß-pinene, caryophyllene oxide, borneol, bornyl acetate and 
linalool in the ratio as 0.7: 1: 0.06: 0.05: 0.05: 0.1: 0.03: 0.03. 
6.3. Discussion 
6.3.1. Inhibition of AChE 
The anticholinesterase activity of 1,8-cineole was almost the same as the natural plant 
oil (Table 6.1. ). A similar result was reported by Miyazawa et al. (1998) who found that 
an IC50 value of 0.026 mg ml-1 of Mentha aquatica (water mint) oil, for inhibition of 
bovine AChE at a final concentration of 0.0065 U ml-1, was equivalent to that of 0.025 
mg ml-1 of viridiflorol, a major terpene constituent of the oil. Their IC50 value of 1,8- 
cineole of 0.04 mg m1"1 was close to that obtained in the present study, namely 
0.06±0.01 mg ml-1. 
It was also reported (Perry et al., 2002) that essential oil of S. lavandulaefolia inhibits 
the rat brain AChE in-vivo. There was a decrease in AChE activity in the striatum and 
hippocampus, though not in the cortex, at doses of 20 µ1 and 50 pl suggesting that 
constituents of the oil or their metabolites reach the brain and inhibit AChE in select 
areas. The anti-AChE activity of the oil for bovine AChE, namely 0.05±0.01 mg ml" 
was similar to the one obtained in-vitro with human AChE, i. e., 0.03 µl m1' (Perry et al., 
2000 b). The oil and its constituents showed uncompetitive type of inhibition. 
\ ,[ 
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This was more potent than IC50 values of 0.09 mg ml" for a-pinene, 0.1 mg ml" for 
1,8-cineole and 0.72 mg ml-1 for camphor and also for a combination of major 
constituents as a "mimic oil" of 0.3 mg ml". On a basis of these data synergy in the oil 
was proposed. Variables in the assays, such as final concentrations of reactants and total 
volume of the reaction mixture, which are surface related to adsorption of these 
sparingly-soluble compounds, are likely to produce a variation in the inhibitory activity 
in independent investigations. 
6.3.2. Evidence of synergy 
Evidence of synergy was apparent when the inhibitory activity of the individual 
terpenes, measured at the same concentrations as existed in the oil at its ICso value, was 
not as great as the whole oil (Table 6.2. ). In the original plant extract the potency of 1,8- 
cineole is likely to be different due to the presence of other constituents, which could 
interact with 1,8-cineole therefore, it may not account for the half of the activity of the 
oil. 
The inhibitory activity of 1,8-cineole, with oxido-p-menthane structure, was the most 
potent amongst the constituents, containing in addition the (+), (-)-isomer hydrocarbons, 
ketone, deoxy-and-hydroxy hydrocarbon structures (Figure 6.3. ). Synergistic 
interactions, which were found in the mixtures of 1,8-cineole/a-pinene and 1,8- 
cineole/caryophyllene oxide varied in their interaction indexes and gradually declined to 
the zero-interactive responses at the lower concentrations (Table 6.3. ). This may be due 
to effects of dilution reducing an ability of the inhibitors (weak aqueous system), which 
may be responsible for inhibition of a peripheral site of the enzyme, to block an 
entrance for the substrate to pass through to the narrow aromatic gorge of the enzyme. 
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This demonstrates that interactions in a combination vary depending on the 
concentrations and ratios between the agents. It should also be noted that the isomeric 
forms of the commercially available compounds may also contribute to anti-AChE 
activity of their combinations in comparison with the activity of the extract. Potential 
effects of the iso-forms on the enzyme were not assessed in this study. 
Results, obtained more recently (personal communication with Dr E. Okello, School of 
Biology), indicate that Spanish sage oil and 1,8-cineole are rapidly reversible inhibitors 
and there was a decrease in AChE inhibitory activity of approximately 40% during the 
incubation time of 30 minutes at 30 °C with the enzyme final concentration of 0.008 U 
ml-1. In contrast Perola et al. (1997) reported that physostigmine, a slowly reversible 
inhibitor, increased its inhibitory activity within this period. The incubation time 
employed in this study could reduce the synergistic and antagonistic interactions of the 
terpenoid combinations. The period of incubation may be an important variable, 
considering that there is no incubation time in-vivo, in an investigation of chemical 
interactions of rapidly reversible inhibitors. 
The possible clinical importance of relatively small deviations from zero-interaction, 
indicating the presence of minor synergy or antagonism in a combination has been 
previously discussed (Berenbaum, 1987; Hall et al., 1983). It was observed (Atherton et 
al., 1981; Berenbuam 1987), in antibacterial studies, that minor interactions in-vitro 
may not only result in significant synergism in-vivo but also make a difference to the 
duration of effective drug level in-vivo. Such interactions could also be relevant to 
patients with AD where a concentration of AChE in hippocampus and cerebral cortex 
decreases to 10 to 15 % of its normal values at advanced stages of the disease (Perry et 
147 
Chemical interactions 
al., 1978 a). Further experiments in-vivo are needed to ascertain the effects of these 
interactions on the CNS. 
Because such responses are likely to occur to the natural plant extract, it is important to 
select an active synergistic mixture with the optimum therapeutical properties. There is 
preliminary evidence, from our studies, indicating that 1,8-cineole is a selective 
inhibitor for AChE but not for butyrylcholinesterase, another therapeutical target in the 
treatment of Alzheimer's disease (Yu et al., 1999) and if caryophyllene oxide or a- 
pinene, which showed synergistic properties in the combinations with 1,8-cineole, 
inhibit butyrylcholinesterase such mixtures may be called synergistically selective. 
The further complexity of interactions in the natural plant extract was apparent from 
significant antagonism, with the interaction index of 2, which appeared in the 
combination of 1,8-cineole and camphor (Table 6.3. ). This suggests that the "mimic oil" 
composed by Perry et al. (2000 b), as described above, may have had antagonistic 
properties because of the presence of camphor that would influence the degree of 
proposed synergy in S. lavandulaefolia oil. 
6.3.3. Methodological issues 
The present analysis has also demonstrated how two methods may be used in exploring 
the interactions between agents and how this may give different results when applied to 
the same set of data, so that a mixture may appear zero-interactive according to one and 
synergistic to another method (Table 6.4. ). 
The method of summation was included as an example of how an inappropriately 
selected approach can lead to a misleading interpretation. The terpenes used in this 
study had non-linear dose-response curves and therefore a sum of their inhibitory 
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activity would not reflect a response of a zero-interactive combination (Berenbaum, 
1989). Figures 6.1 and 6.2 illustrate examples of such non-linearity for 1,8-cineole in 
combinations with camphor and a-pinene. As the result, the synergistic response, 
evaluated by the method of summation, in the combination of six terpene compounds 
(Table 6.4. ) was disregarded and the combination was deemed as zero-interactive 
according to the method of Berenbaum (1978; 1989). 
The comparative analysis of mixtures on a basis of IC50 values (Table 6.5. ) cannot 
reveal a true interaction within the combinations. For example, in the combination of 
1,8-cineole and camphor there are two roles, which could express either synergy or 
antagonism. It could be said, comparing Tables 6.1 and 6.5, that camphor is the 
antagonist to 1,8-cineole, because it increased the IC50 value of the latter from 
0.06±0.01 mg ml"' (Table 6.1. ) to 0.18±0.02 mg ml" (Table 6.5. ) but on the other hand, 
1,8-cineole is synergistic to camphor, because it decreased the inhibitory activity of the 
latter from 39±4.0% at 0.5 mg ml-1 (Table 6.1. ) to the IC50 value of 0.18±0.02 mg ml" 
(Table 6.5. ). On the other hand, applying the method of expected inhibition, based on 
the zero-interactive response, allowed evaluation of antagonistic interactions of these 
combinations. The IC50 value of the whole oil (Table 6.1. ) was similar to the 
combination of 1,8-cineole/a-pinene and less potent than the combination of 1,8- 
cineole/caryophyllene oxide (Table 6.5. ). The IC50 values of eight and six compound 
combinations, based on the typical chemical composition of Spanish sage essential oil, 
were significantly less potent than that of the whole oil. The zero-interactive responses 
of these two combinations suggest that minor constituents are more likely involved in 
the anticholinesterase activity of the essential oil. 
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It has to be pointed out that, because of a decreased level of AChE in the brain during 
AD (Perry et al., 1978), the analysis of the chemical interactions were carried out at the 
low concentration of the enzyme, compared to a typical of 0.08 U ml" (Ellman et al., 
1961). Therefore, minor synergy and antagonism in the natural plant extract may only 
occur under these particular experimental conditions. 
Chemical compositions of S. lavandulaefolia vary (Perry et al., 1999; Giannouli and 
Kintzios, 2000; Karousou et al., 2000) and as a result, identifying plants with desirable 
chemical contents may help to extract oils with maximum therapeutical properties. This 
study shows that high 1,8-cineole and low camphor contents in the oil may increase its 
anticholinesterase activity. S. fruticosa may be ideal for AChE inhibition with a high 
level of 1,8-cineole up to 75% and low camphor in a range of 0.8-30.3% (Byarak and 
Akgul, 1987; Karousou et al., 1998; Karousou et al., 2000; Langer et al., 1996). Other 
properties of sage species, such as anxiolytic, antioxidant, oestrogenic, antidepressive 
and anti-inflammatory (Perry et al., 2000 a) could equally be monitored for optimum in 
a chemical composition of oils by analysing the activity of chemical components and 
interactions between them. 
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Caryophellene oxide: C15H240 (220.4) Camphor: C1OH160 (152.2) 
a-pinene: ClOH16 (136.2) ß-pinene: ClOH16 (136.2) 
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Linalool: C10H180 (154.3) Borneole: C10HI8O (154.3) 
ýý 
Bornyl acetate: C12H2002 (196.3) 1,8-cineole: C10H180 (154.3) 
Figure 6.3. Terpenoid components of S. lavandulaefolia essential oil. Molecular 
weights are shown in the brackets. 
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Chapter 7. Phytosol extracts of Salvia species in relation to ß- 
secretase, interleukin 8 and cholinergic receptor activities 
7.1. Introduction 
Selkoe (2001) reviewed the principal steps in the AD cascade that lead to the loss of 
synapses and glia cell somata, the dentritic dystrophy, and the neurotransmitter deficits 
that are the basis for the dementia. In brief, these steps include mutation in APP 
(presenilin (PS) 1 and PS2 genes); increased production, accumulation and aggregation 
of A 342 (Aß3943) peptides that lead to a progressive neuritic injury within amyloid 
plaques followed by inflammatory responses (i. e., microglial activation and cytokine 
release); disruption of neuronal metabolic and ionic homeostasis (oxidative injury); 
phosphatase activities (hyperphosphorylated tau, paired helical filaments), widespread 
neuronal and neuritic dysfunction and neurodegeneration in hippocampus and cerebral 
cortex with progressive neurotransmitter deficits. Thus, it is of interest to test an agent 
such as Salvia for some of these non-transmitter related activities. 
7.1.1. ß-secretase as a target for the treatment of AD 
APP is a single transmembrane polypeptide that is trans-located into the endoplasmic 
reticulum, a network of tubules and vesicles which is involved in the synthesis of 
proteins and proteins membrane insertion, via its signal peptide and then post- 
translationally modified through the secretory pathway (Selkoe, 2001). Its half-life is 
relatively brief, 45-60 minutes in most cells tested (Weidemann et al., 1989). Reports by 
Haass et al. (1992), Seubert et al. (1992) and Shoji et al. (1992) demonstrated that Aß is 
generated and secreted by all cells that express APP and it can be measured in the brain, 
plasma and cerebrospinal fluid (CSF). Games et al. (1995) showed that over expression 
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of APP in transgenic mice leads not only to increased Aß levels but to development of 
the pathological hallmarks of AD, including numerous extracellular Aß deposits, 
neuritic plaques, synaptic loss. 
Both during and after the trafficking of APP through the secretory pathway, it can 
undergo a variety of proteolytic cleavages to release secreted derivatives into vesicle 
lumens and the extracellular space. There are three proteolytic activities, a, 0 and y- 
secretases, involved in the cleavage of APP (Selkoe, 2001) (Figure 7.1. ). The first 
proteolytic cleavage is made by a-secretase and it results in the release of the large 
soluble fragment (a-APPs) into the lumen/extracellular space and retention of an 83- 
residue COOH-terminal fragment (CFT or C83) in the membrane. Some APP molecules, 
not subjected to a-secretase cleavage, can be cleaved by ß-secretase (a beta-site APP- 
cleaving enzyme, BACE1 or memapsin2) generating a smaller derivative (ß-APPs) and 
retaining a 99-residue CFT (C99). The C83 and C99 fragments may be cleaved by a 
protease(s) called y-secretase (also called presenilins) to release the Aß-peptides. 
Presenilins, unstable holoproteins, produce fragments which are the principal 
biologically functional form of presenilins. However, Kume et al. (2003) suggested that 
y-secretase may cleave APP independently of a-and ß-secretase pre-cutting. 
It could be argued that blocking Aß generation would affect other metabolites that may 
have an important physiological function; however ß-secretase inhibition would not 
affect the vast majority of APP molecules that are processed by the a-secretase pathway, 
and in contrast to y-secretase inhibition, it would not interfere with the Notch signalling 
pathway (receptors that mediate cells interaction) (Selkoe, 2001, Citron, 2002). 
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Figure 7.1. Overview of possible pathways for Aß biogenesis, clearance and 
fibrillisation (Source: Ling et al., 2003). The a-cleavage pathway is the major route for 
APP processing. Aß is derived from APP through two sequential cleavages by (3- and y- 
secretases. The Swedish APP mutation enhances (3-cleavage causing increased 
formation of Aß. All other C-terminal A(3 mutations and PS mutations increase the ratio 
of A1342 40 without increasing total Aß. A1342 can aggregate in a concentration-dependent 
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manner or associate with Aß fibril promoting proteins. The clearance of'excessive A(3 is 
either through uptake mechanisms involving LRP, A2M, APOF and uPA or by direct 
degradation by IDE, NEP, A2M-serine protease complex and the PA/plasmin system. 
Activation of PA/plasmin in return enhances the a-secretase pathway. 
The crystal structure of the BACE-1 (13-secretase) ectodornain demonstrates that the 
enzyme is very similar to other known aspartic proteases. However, there are 
differences in details of the active site, with 0 secretase being more open and less 
hydrophobic than in other aspartic proteases (Hong et al., 2000). The relatively large 
active site of (3-secretase may make the development of small molecule inhibitors 
difficult, unless they act in a synergistic manner. 
A lysine (Lys) °-asparagine (Asn)/Methionine (Met) -leucine (Leu) double mutation 
near the (3-secretase cleavage site found in Swedish familial AD produces 
approximately 6-8-fold more A(3 (A1340 and A(3 42) compared with cells expressing 
normal (3-APP resulting in early onset of AD (Citron et id., 1992). 
Luo et al. (2001) demonstrated that the BACEI knockout mice lack brain A(3 and 1- 
secretase-cleaved APP CTFs. Moreover the mice were healthy and fertile. Cai et al. 
(2001) showed that the BACE 1 knockout mice abolish cortical A(3 without observed 
side-effects and concluded that BACE-1 is the principal neuronal protease required for 
the cleavage of APP to generate A(3 peptides. Roberts el al. (2001) also reported that 
BACEI knockout mice lack the major ß-secretase in brain and have a significantly 
reduced level of A(3 peptide production, yet these mice have no deficiencies in 
physiology or basic behaviours. In addition, Horn ei ul. (2003) demonstrated in-vitro 
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that selective inhibition of BACE-1 by a synthetic compound suppresses A(3 secretion in 
human embryonic kidney cells. 
The BACE1 knockout data published to date encourage the development of (3-secretase 
inhibitors as a therapeutic strategy in the treatment of AD because it suggests that, at 
least in mice, other ß-secretase substrates and products are not very important or are 
provided by compensatory mechanisms, whereas no compensatory mechanism allows 
A(3 production. Because the BACEI knockout mice do not have a clinically relevant 
phenotype. they have not led to the identification of functional 13-secretase substrates yet 
(Citron. 2002). 
To date, there are no reports available on anti-secretase activity of any species of plants. 
Oils of S. apiana, S., fruticosa and S. officinalis var. purpurea had not only marked dual 
anti-ChEs activity but also high yield and thus were selected for the screening. 
7.1.2. Neuroinflammation as a target in the treatment of AI) 
A role of inflammation in the development of AD has recently been reviewed (Aisen, 
2000, Akiyma et al., 2000; Cooper et al., 2000; Selkoe, 2001; Weiner and Selkoe, 
2002). In addition, Neurobiology of Aging (2001: volume 22, issue 6) provided a 
special issue dealing with inflammatory processes in AD. The cholinergic anti- 
inflammatory pathway involving the nAChR 0 subunit and pro-inflammatory 
cytokines has also been discussed (1.3.1.3. ). 
As noted in these reviews, the appropriate targets for anti-inflammatory therapy remain 
to be clarified. Cytokine activities in the brain appear to be complex, with both pro- 
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inflammatory and anti-inflammatory roles. Meda et al. (2001) and Bales et al. (2000) 
reviewed evidence suggesting that deposition of AD represent a triggering factor in glial 
activation leading to inflammatory responses in the brain. Thus, studying a mechanism 
of such responses may provide a significant insight into the pathophysiology of AD, and 
may also lead to the identification of new strategies for AD treatment. 
Etanercept, a protein antagonist of the TNF-a receptor, is a newly approved treatment 
for arthritis (Aisen, 2000). Cooper et al. (2000) noted that inflammation in arthritis, like 
the inflammation in AD, is highly complex and involves multiple inflammatory 
responses. If treating a single inflammatory mediator such as TNF-a, is effective in 
arthritis, then there is a possibility that a similar strategy may also be beneficial in AD. 
Chemokines belongs to a rapidly expanding family of cytokines with the primary 
function of recruitment of leukocytes to the site of inflammation (Selkoe, 2001). IL-8 is 
a 72-amino-acid peptide expressed in many cell types and is released in response to 
proinflammatory stimuli. It is a potent inflammatory mediator that belongs to a family 
of CXC (the first cysteine pair is separated by an intervening amino acid) 
proinflammatory chemotactic cytokines (Xiong et al., 2003). Accumulating evidence 
(MacDermott, 1999; Frangogiannis et al., 2002; Xiong et al., 2003) implicates 
interleukin 8 (IL-8) as a major mediator of acute macrophage-mediated inflammation. 
Horuk et al. (1997) and Xia et al. (1997) demonstrated that one of the receptors 
(CXCR2) of IL-8 is expressed in the neuritic portion of plaques surrounding deposits of 
amyloid. The authors suggested that IL-8 may participate not only in reactive processes 
of normal neuronal function but also in the neurodegenerative process. Moreover, Lue 
et al. (2001) and Walker et al. (2001) demonstrated a significant dose dependent 
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increase (up to 11.7-fold) of secreted pro-inflammatory IL-8 in human post-mortem 
brain microglia when the latter was exposed to increasingt doses of A. 
Kelder et al. (1998) reported an increased level of IL-8 in patients with human 
immunodeficiency virus-associated dementia (HAD), whereas Zheng et al. (2001) and 
Xiong et al. (2003) showed that IL-8 inhibit long-term potentiation, a neural response 
linked closely to learning and memory via CXCR2 activation in the hippocampus and 
suggest this also may contribute to the cognitive dysfunction associated with HAD. 
Plants reputed anti-inflammatory activities may be a source of therapeutics with anti- 
inflammatory properties. Mudanpi, the root cortex of Paeonia suffruticosa Andrews 
(Ranunculaceae), is an important crude drug used in Chinese traditional medicine as an 
anti-inflammatory agent (Oh et al., 2003). Oh et al. (2003) demonstrated that in-vitro 
95% methanol extract of root of Paeonia suffruticosa (mudanpi) suppresses IL-8 
secretion. These authors also reported that dimethyl sulfoxide (DMSO) has been used in 
the preparation of plant extracts. Poliakova et al. (1993) showed that in vivo DMSO 
may reduce inflammation of external and middle ear, while Smirnova et al. (2002 a; 
2002 b) described a meditative role of IL-8 in inflammation of the middle ear cleft. In 
addition, Nakamuta et al. (2001) demonstrated that in vitro DMSO inhibits TNF-a 
production, one of the primary pro-inflammatory cytokines. Thus, the use of DMSO 
may complicate the results reported by Oh et al. (2003). 
Extracts of neem tree (Azadirachta indica Juss. Meliaceae), East-Indian globe-thistle 
(Sphaeranthus indicus Linn. Asteraceae) and also myrrh oil (Commiphora molmol) 
have been shown to inhibit secretion of IL-8. (Jain and Basal, 2003; Tipton et al., 2003). 
Hart et al. (2000) reported that the main component of essential oil of Melaleuca 
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alternifolia (tea tree) terpinen-4-ol suppresses inflammatory activity of IL-8, while a- 
terpineol and 1,8-cineole are inactive. 
Salvia apiana and Salvia fruticosa have historically been reputed as plants with anti- 
inflammatory properties (1.3.1.4.2. ). To date, there is no data available on the 
suppression of IL-8 secretion by any species of Salvia. 
7.1.3. Cholinergic receptors as a target in the treatment AD 
A role of nicotinic and muscarinic receptors in development of AD has been described 
in Chapter 1 (1.2.1.3; 1.2.2. ). Chapter 1 also describes interaction of current licensed 
ChEI drugs and the cholinergic receptors (1.3.1.1. ). 
Plant extracts have been shown to have both cholinergic nicotinic and muscarinic 
human receptor binding activities (Wake, 2001). Wake (2001) reported that one of 80% 
EtOH extracts of Melissa officinalis, exhausted of water-soluble quaternary ammonium 
compounds, has [3H]-nicotinic displacement activity with an IC50 value of 0.7 mg ml", 
whereas the crude EtOH extract of the same plant is less active, with an IC50 value of 
3.6 mg ml''. In contrast an 80% EtOH extract of Salvia verticillata ssp. verticillata, also 
exhausted of water-soluble quaternary ammonium compounds, had less nicotinic 
activity with an IC50 0.5 mg ml-1 compared with the crude EtOH extract with an IC50 1.0 
mg m1'. Wake noted that the extracts prepared from autumn-harvested leaves are 
relatively inactive compared to the summer-harvested leaves. 
Wake (2001) also showed, using [N-methyl-3H]-scopolamine displacement assay, that 
one of fresh leaf 80% EtOH extracts of Melissa officinalis has muscarinic activity with 
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an IC50 value of 0.06 mg ml". In addition, the EtOH extract of Salvia elegans Vahl., 
'Scarlet Pineapple' exhibited a total displacement of [N-methyl-3H]-scopolamine at a 
concentration of 1.4 mg of dried plant per ml (Wake et al., 2000). Lewis et al. (1999) 
reported that 80% EtOH extract of Panax ginseng, CA Meyer, (Araliaceae) has 
relatively low affinity for nicotinic and even less for muscarinic receptors, with IC50 
values of 2.12 mg ml-1 and 5.25 mg ml" respectively. There are also reports indicating 
that camphor and borneol specifically inhibit nAChRs in a non-competitive way (Park 
et al., 2001; Park et al., 2003). 
The objective of the present section of this research project was to test extracts of Salvia 
species for (3-secretase inhibition, suppressive activity of IL-8, and nicotinic and 
muscarinic receptor activities. 
7.2. Results 
7.2.1. Essential oils of sage and their chemical constituents in relation to ß 
secretase 
8% EtOH in the assay did not inhibit 0 secretase (Table 7.1. ). Although, EtOH showed 
some tendency towards the inhibition of the enzyme over the course of the incubation 
time, the student t-test analysis indicated that such inhibition was insignificant with the 
confidence interval exceeding 5% (P>0.05). 
Neither oils of S. apiana, S. fruticosa, S. officinalis var. purpurea nor their single 
compounds 1,8-cineole and 3-carene had anti-ß secretase activity at tested 
concentrations (Table 7.2. ). A tendency of 1,8-cineole to inhibit the protease was 
statistically insignificant, with the confidence interval exceeding 5% (P>0.05). 
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Table 7.1. Anti-ß secretase activity of EtOH 
Inhibitor ß-Secretase activity, mean±SD (n=3)a 
30 min 1 60 min 1 90 min 1 120 min 
8% EtOH 32615±3743 36237±4685 38221±4620 42158±4870 
(P=0.09, P>0.05) b (P=0.17, P>0.05)b (P=0.32, P>0.05)b (P=0.4, P>0.05)b 
H2O 39630±3336 42026±3128 42327±3690 45721±4076 
aActivity is expressed in fluorescence units. Mean of triplicate was designated as n=1. 
Standard deviation (SD) was calculated on a basis of three sets of triplicate. 
bStatistical significance. If P value is more than 0.05, the inhibition is not significant. 
During the four intervals of incubation time P values exceeded 0.05. 
Table 7.2. Anti-ß secretase activity of oils and their single constituents 
Inhibitor Concentration ß-Secretase inhibition, % 
mg ml"' b mean±SD (n=3)a 
30 min 1 60 min 1 90 min 1 120 min 
S. fruticosa 1 0.4 10101010 
S. officinalis 
var purpurea 0.1 0 0 0 0 
S. apiana 0.3 0 0 0 0 
1,8-cineole 0.5 5.5±8.3 5±8.7 4±6.9 5±8.7 
3-carene 0.2 0 0 0 0 
'Agents were tested in triplicate. Mean of triplicate was designated as n=1. Standard 
deviation (SD) was calculated on a basis of three sets of triplicate. 
bConcentration of test solutions were close to their solubility limit in the assay. 
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7.2.2. Oils of S. apiana and S. fruticosa in relation to interleukin 8 
There was 18±2.1% inhibition of the IL-8 secretion by S. apiana oil in the HT29-MXT 
cells after 24h of incubation, while oil of S. fruticosa was inactive (Figure 7.2. ). In both 
cases, the first four hours of incubation produced no inhibition. 
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Figure 7.2. IL-8 suppressive activity of oils of S. apiana (a) and S. frulicosa (b) 
Each proposed inhibitor and control was tested in triplicate over the period of 
incubation time. Standard deviation was calculated on a basis of three sets of triplicate 
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The computer software allowed conversion of rates of secretion of IL-8 into values of 
concentrations, i. e., pg ml-1. 
7.2.3. Oil of Salvia apiana in relation to nicotinic and muscarinic receptors 
Oil of S. apiana displaced [3H]-(N)-methyl nicotine from human nicotinic acetylcholine 
receptors and [3H]-(N)-methyl scopolamine from muscarinic receptors in a dose 
dependent manner with IC50 values of 0.02 mg ml-1 and IC50 0.1 mg ml" respectively 
(Figure 7.3. ). 
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Figure 7.3. Nicotinic and muscarinic receptors binding activity of S. apiana oil 
a. [3H]-(N)-methyl nicotine displacement curve of S. apiana oil 
b. [3H]-(N)-methyl scopolamine displacement curve of S. apiana oil 
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In both cases there was more than 90% displacement of the radioligands by the oil at a 
concentration of 0.5 mg ml-1. As calculated from the dose-response curve equations 
(Figure 7.3. ) IC50 values of the oil for [3H] nicotine and [3H] scopolamine displacement 
were 0.02±0.024 mg ml" and 0.1±0.015 mg ml-1 respectively. 
7.3. Discussion 
7.3.1. Anti-ß secretase activity of oils of sage and their constituents 
The present study shows that neither oils of S. apiana, S. fruticosa or S. officinalis var 
purpurea nor 1,8-cineole and 3-carene inhibited 0 secretase over the course of 
incubation time. The relatively large active site of ß-secretase (Hong et al., 2000) may 
help to prevent its inhibition by small molecules. Even the essential oil, with their 
recognised synergistic mode of action, did not react with the active site, although this 
may not be a case for other plant extracts. Interestingly, 1,8-cineole showed a steady but 
an insignificant trend towards reduction of 0 secretase activity over the periods of 
incubation time. The fact that 8% EtOH does not inhibit the protease may permit 
analyses of other hydrophilic compounds. 
Ghosh et al. (2001) reported syntheses of several human ß-secretase (memapsin-2) 
inhibitors. OM99-2 (Figure 7.4) has a K; value of 1.6 nM and it is more potent than 
inhibitor OM99-1 (Figure 7.4), K; of 36 nM. The therapeutic potential of inhibitor 
OM99-2 may be limited because of its high molecular weight and numerous peptide 
bonds. However, its structure may serve as an important molecular template for 
structure-based design of memapsin-2 inhibitor drugs and may help to identify other 
plant derived inhibitors. 
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7.3.2. Oils of S. apiana and S. fruticosa in relation to interleukin 8 
The present study demonstrates that the oil of S. apiana has a modest suppressive effect 
on IL-8 secretion in the human mucin- and IL-8 cytokine secreting cells HT29-MTX, 
while the oil of S. fruticosa has not. The suppressive effect of the S. apiana oil was not 
apparent before 24 hours of incubation and the longer time may be needed to observe a 
greater inhibitory effect. For instance, Hart et al. (2000) reported that terpinen-4-ol, a 
main constituent of tea tree oil, suppresses IL-8 production after 40 hours of incubation. 
Nevertheless, the inhibitory effect (18%) of S. apiana oil may be relevant 
therapeutically in the context of suppression of acute inflammation, as a certain level of 
expression of IL-8 is required in order to antagonise transmembrane G-protein-coupled 
receptors, a signalling inflammatory pathway of IL-8 (Wells et al., 1996; personal 
communication with Dr Smirnova, department of Physiological Sciences, the Medical 
School, University of Newcastle), hence the profound inhibition of the cytokine may 
destabilise a natural defensive mechanism of the immune system towards inflammation. 
It should also be noted that the HT29-MTX culture cells contain more than 90% of 
goblet cells, a source of IL-8 secretion (Dr Smirnova, personal communication). There 
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are no reports suggesting presence of goblet cells in the brain. Production of IL-8 (other 
cytokines) in the brain is attributed mainly to macrophages. Further experiments, 
involving macrophage-containing cells line, are therefore warranted. 
1,8-cineole, one of the main constituents of S. fruticosa oil (Chapter 4), has been 
reported to have no suppressive activity on IL-8 secretion (Hart et al., 2000) and 
therefore may contribute to the lack of activity in whole oil. The modest activity of S. 
apiana oil may indicate that camphor, major constituent of the oil (Chapter 4), also does 
not have suppressive IL-8 activity. Thus, essential oils of sage with major constituents 
other than 1,8-cineole and camphor but terpineol-4-ol (Hart et al., 2000) may worth 
further investigation for inhibition of IL-8 secretion. 
7.3.3. Oil of S. apiana in relation to nicotinic and muscarinic receptors 
The current study shows that oil of S. apiana contains a compound, or a combination of 
compounds acting synergistically, that displaces [3H]-nicotine from human nAChR and 
[3H]-scopolamine from human mAChR in a dose-dependent manner with IC50 values of 
0.02±0.024 mg ml" and IC50 0.1±0.015 mg ml" respectively. The shape of a dose- 
response curve for scopolamine displacement may indicate some degree of non-specific 
interference within the oil at its low concentration, although for nicotinic displacement 
such interference was less apparent. Further study on kinetics of these displacements 
may evaluate receptor-specific activities. 
In both cases, the oil, a final concentration of 0.5 mg ml", displaced more than 90% of 
[3H]-nicotine and [3H]-scopolamine from human membrane. In contrast, Wake (2001) 
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reported that 80% EtOH extract of Salvia elegans, a final concentration of 1.2 mg ml-1, 
displaced 85% of [3H]-nicotine and 100% of [3H]-scopolamine. 
The preliminary results indicate that oil of S. apiana contains constituent(s) with 
nicotinic and muscarinic binding properties. Further fractionation of the oil therefore is 
warranted. Finally, if a positive effect of EtOH extract of S. officinalis (Akhondzadeh et 
al., 2003) and Phytosol A extracted oil of S. lavandulaefolia (Perry et al., 2003) on 
those with AD is attributed not only to inhibition of ChEs but also to its nicotinic and 
muscarinic binding activities than the IC50 values of the oil may become clinically 
relevant. 
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Chapter 8. General discussion 
8.1. Salvia species as a source of agents with activities relevant to dementia 
treatment 
8.1.1. Clinical relevance 
The ethnobotanical reputation of sage as a plant with memory enhancing properties 
(Chapter 1) has recently been corroborated with positive results from in vivo studies. A 
single dose of 50µl of steam distilled oil of S. lavandulaefolia enhanced memory, 
compared to placebo, in a dose-dependent manner in healthy young adults (Tildesley et 
al., 2003), while clinical administration of the plant oil obtained by Phytosol A 
extraction improved behaviour and attention in an open label trail in subjects with mild 
to moderate AD (Perry et al., 2003). Further, Akhondzadeh et al. (2003) reported, in a 
double blind placebo controlled clinical trail, that administration of 60 drops a day (16 
weeks) of a 45% EtOH extract of S. officinalis during four months significantly 
enhanced cognition and reduced agitation in patients with mild to moderate AD. An 
EtOH extract of S. officinalis inhibited human AChE with an IC50 value of 0.03 mg ml" 
(personal communication with Dr. Wake, medicinal plant research centre University of 
Newcastle). This IC50 value is similar to those obtained by most of the extracts in this 
study (Chapter 3 and 4). Thus, if the effect of the trial is attributed to inhibition of 
cholinesterases then the IC50 values of the active extracts may become clinically 
relevant. These positive results not only indicate that sage species are the source of 
molecules with activities relevant for dementia treatment, but also provide information 
to clinical significance of an IC50 value of extract. 
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Moreover, the positive outcome of the trials may indicate that active molecule species 
penetrate the blood brain barrier and interact, inter alia, with a cholinergic system 
within the brain which is responsible for cognition (Bartus et al., 1982; Perry et al., 
1986 b). In addition, previous in vitro reports (Chapter 1) showed that extracts of sage 
species inhibit the major enzyme of human AChE and have affinity for human 
cholinergic acetylcholine receptors. The present study further contributes to improving 
the efficacy of non-polar extracts of Salvia species in the treatment of dementia. 
8.1.2. Evidence of synergy 
One of the novel findings of this study (Chapter 5) was that none of the twenty one low 
molecular weight compounds tested had marked anti-BuChE activity, although the 
whole extracts invoked slow onset of a non-competitive type of inhibition of the 
enzyme within a therapeutically relevant range of concentrations, i. e., 0.01 mg ml" 
1<IC50<0.1 mg ml''. Non-competitive inhibition of BuChE was also reported (Chapter! ) 
in tacrine and donepezil, licensed drugs in the treatment of AD, and physostigmine. An 
abundant presence, in some cases more than 50%, of the inactive constituents in the 
extracts provides no obvious explanation for variations in anti-BuChE activity of the 
species in terms of the chemical composition of their extracts, although major 
synergistic interactions among certain minor and major constituents within the latter 
may explain these differences. 
In contrast inhibition of human AChE by those twenty one terpenoids was more 
apparent. Moreover, the screening of these compounds resulted in another new finding. 
Thus, ß-caryophyllene (caryophyllene) and 3-carene (Chapter 5) were the most active 
non-oxygenated terpenoids ever reported with IC50 values of 0.1 and 0.2 mM 
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respectively, although the most active oxygenated terpene viridiflorol inhibited bovine 
AChE with the same value as ß-caryophyllene (Miyazawa et al., 1998). A lack of 
negative charges in ß-caryophyllene and 3-carene molecules may not allow their 
passage to the active site via the aromatic gorge of the enzyme but rather produce a 
quasi-steric hindrance for the substrate at the entrance of the gorge (Tai et al., 2002). 
Interestingly, all extracts, such as S. argentea, S. keerlii, S. microphylla var. neurepia, S 
S. confertiflora, S. haematodes, S. glutinosa, S. longistyla, S. napifolia, S. verticilata 
and S. Jamensis var. la luna which are rich in ß-caryophyllene (more than 10%) 
expressed anti-AChE activity (Chapter 4), although the solubility limit did not allow 
preparation of higher concentrations which might result in 50% inhibition of AChE 
within a range of theraputical concentrations. This may be explained via synergistic 
interactions of certain constituents with ß-caryophyllene. Evidence of such interactions 
was apparent when the inhibitory activity of ß-caryophyllene, the only major compound 
with more than 10% in S. microphylla var. neurepia oil, did not account for the activity 
of the whole oil (Table 8.1). It can be noted that the inhibitory contribution of ß- 
caryophyllene alone is only 29% and the rest of the activity may be attributed to minor 
synergistic interactions between ß-caryophyllene and other constituents of the oil. As 
another example, the amount of 1,8-cineole in steam distilled oil of S. fruticosa (8/02) 
(Chapter 3) is 21.5%. If the oil, which gave 50% inhibition of AChE at a final 
concentration of 0.04 mg m1' at incubation time of 5 minutes is taken as a mixture of 
100% then a final concentration of 21.5% 1,8-cineole in the oil would be 0.0086 mg ml' 
1 or 0.05 mM. As calculated from a mean dose-response curve of 1,8-cineole a final 
concentration of 0.0086 mg ml" would give 20% inhibition of the enzyme, hence the 
compound alone would not also account for the IC50 value of the oil and nor would the 
other tested constituents. 
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Table 8.1. Inhibition of AChE by essential oil of S. microphylla var. neurepia and ß- 
caryophyllene at the concentration occurring in the oil 
Inhibitor % in oils Concentration % Inhibition` 
mg ml'1 b mean±SD (n=4) 
S. microphylla 
var. neurepia oil 100 0.035 50±0.003 
ß-caryophyllene 12.7 0.006 29±1.6 
(caryophyllene) 
'Percent inhibitor in the oil obtained by GC/MS analysis. bAn IC50 value of the whole 
oil of 0.035 mg ml'', which gave 50% inhibition of the enzyme was taken as 100%, for 
the convenience of calculations. Hence, the concentration of ß-caryophyllene was 
calculated on a basis of its percentage in the oil. `Percentage inhibition was calculated 
from the dose-response curve equations of each inhibitor. Thus, 0.035 mg ml" was 
substituted into the equations of the oil to calculate expected percent of AChE inhibition, 
while 0.006 mg ml" was substituted into the equations of ß-caryophyllene to calculate 
expected percent of inhibition. 
Anti-AChE activity of the extracts is mainly due to the activity of the principal chemical 
constituents, with a minor degree of synergy, whereas anti-BuChE activity cannot be 
accounted for in terms of the principle constituents indicating major synergy. Indeed, 
the presence of minor synergy in inhibition of bovine AChE between 1,8-cineole/a- 
pinene and 1,8-cineole/caryophyllene oxide (Savelev et al., 2003; Chapter 6) may 
support this speculation. In addition, despite the abundant presence (46.5%) of inactive 
a-caryophyllene in S. officinalis var. purpurea oil inhibition of AChE was competitive. 
This shows that synergistic interactions of constitutes within Salvia extracts may result 
in two ways of inhibition of the enzyme, i. e., competitive and non-competitive. 
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Further, regardless of differences between the supercritical extraction and steam 
distillation both methods allowed extraction of molecules with dual anti-cholinesterase 
activity. Most inhibitors presently used in AD therapy are not selective for AChE, 
however they all show significant clinical efficacy (Giacobini, 2000). Considering the 
pronounced decrease in AChE activity in certain brain areas (Chapter 1) of patients with 
advanced AD and the large pool of BuChE available in glia, neurons and neuritic 
plaques (Chapter 1), it may be an advantage for a ChE inhibitor to be non-selective 
rather than AChE selective. A balance between AChE and BuChE inhibition may result 
in optimal theraputical efficacy if a non-selective ChE inhibitor is used in mild to 
moderate forms of AD. An observation of Costa et al. (1999) showed that inhibition of 
BuChE activity in the cerebral spinal fluid correlates more strongly with cognitive 
improvement than inhibition of AChE during rivastigmine trail. 
8.1.3. Antiinflammatory and neuroprotective roles of dual anti-cholinesterase 
inhibitors 
Dual anti-cholinesterase activity of the extracts may also be therapeutically relevant for 
those with mild cognitive impairment, since Mesulam et al. (2002) reported that widely 
spread BuChE can hydrolyse ACh in the normal brain. Although this contradicts to a 
theory (Giacobini, 2000; Chapter 1), based on the differences in the enzymatic affinity 
constant (Km), that in the normal brain AChE is the main enzyme responsible for ACh 
hydrolysis with BuChE playing a supportive role and that selective AChE inhibitors 
may be more desirable for those with mild and moderate stages of AD (Davis et al., 
1999), familial AD and mild cognitive impairment. 
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Further, inhibitors with dual anti-cholinesterase activity may be involved in the 
cholinergic anti-inflammatory pathway (Chapter 1) by increasing a level of ACh, which 
is a functional ligand for the a7 nAChR on the macrophage (Wang et al., 2003). Upon 
binding of ACh to the receptor subunit suppression of pro-inflammatory cytokine TNF 
synthesis occurs via an increase in Ca2+ influx within a macrophage (Wang et al., 2003). 
Neumann et al. (1998) reported that glial-derived TNF interacts with neurons as part of 
an injury or inflammatory process, while later Zassler et al. (2003) showed in-vivo that 
such interaction induces axonal damage of cholinergic nerve terminals and nerve fibers, 
suggesting that this can lead to subsequent retrograde cell death of cholinergic neurons 
in the basal nucleus of Meynert. Thus, glial and neuronal inhibition of BuChE and 
AChE by the extracts with dual activity may increase the level of ACh which apart from 
neurotransmission can have an indirect neuroprotective role via controlling 
overexpression of TNF. 
8.1.4. Extracts with multiple activities 
Evidence (Court et al., 2001; ONei11 et al., 2002; Perry and Piggott, 2003; Piggott et al., 
2003; Chapter 1) of early stage nicotinic and muscarinic abnormalities in AD and DLB 
supports the use of cholinergic agonists in prospective treatment of the diseases. 
Galanthamine, one of the most successful plant-derived licensed drugs in the treatment 
of AD, apart from dual anti-cholinesterase activity, has affinity for nAChRs (Chapter 1). 
This study showed that using Phytosol A as a solvent allows extraction of S. apiana oil 
not only with dual anti-ChE activity but also with marked human nicotinic and 
muscarinic ligand binding properties. Development of non-toxic cholinergic ligands for 
therapeutical purposes may enable treatment of cholinergic receptor/transmitter related 
cognitive problems to be carried out with less risk of undesirable side-effects. In 
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addition, the oil expressed modest suppression of a pro-inflammatory cytokine IL-8. 
Thus, in-vitro multiple activity of the oil makes it a first choice candidate for a clinical 
trial on those with AD and DLB. A theory of a multiple drug therapy towards AD 
(Prasad et al., 2002) may find one of its solutions in herbal standardised extracts. 
Finally, Salvia extracts with dual anti-ChEs activity and/or cholinergic receptors 
binding properties may have a synergistic effect together with the licensed drugs 
currently used in the treatment of AD. Such an effect may reduce administrative doses 
of these drugs and consequently could result in reduction of undesirable side-effects 
caused by the latter. The lipophilic nature of the extracts, as a phytophore, may also 
enable faster delivery of the drugs to the brain. 
8.2. Species variation 
This study also demonstrated a lack of correlation between geographical distribution of 
the species (Appendix 1) and a chemical profile of their extracts, which may be due to 
adaptation of the plants to particular enviromental conditions. For example, Bellomaria 
et al. (1992) reported, as confirmed in this study, that oil of S. fruticosa may contain 
42% camphor and 20% 1,8-cineole if collected in the Troodos area of Cyprus but 55% 
1,8-cineole and 6% camphor if harvested in the Anglisidhes and Stavros areas. Oils of 
sage species from western Crete and northern parts of Greece also contain low amounts 
of camphor and high of 1,8-cineole (Karousou et al., 2000). 
In-vitro a naturally occurring combination of camphor and 1,8-cineole was antagonistic 
in inhibiting bovine AChE with an interaction index of 2 (Savelev et al., 2003). 
Collecting Salvia species rich in 1,8-cineole but not camphor may therefore provide oils 
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with more potent cholinergic activities, as it may also plants which are abundant in ß- 
caryophyllene and 3-carene. 
It was reported (Park et al., 2001; Park et al., 2003) that camphor and borneol are 
specific, non-competitive antagonists to nicotinic acetylcholine receptors and as the 
level of ACh decreases with the progression of the disease (Chapter 1) these two 
molecules may become competitive with the neurotransmitter. It could also accentuate, 
especially to non-smokers, the loss of nicotinic receptors during ageing (Court et al., 
1997). Extracts with dual anti-cholinesterase activity and lower camphor and borneol 
content may thus be the most appropriate for clinical trials among the species so far 
investigated. 
8.3. Methodological issues 
A comparative analysis of oils of S. fruticosa (8/02) and S. officinalis obtained via 
Phytosol A extraction and steam distillation revealed not only differences in their 
chemical composition but also significant variations in the ratio of major and minor 
constituents, which resulted in favour of cold extracted oils in terms of their anti-ChEs 
activity. Thus, anti-AChE activity of Phytosol A oil of S. officinalis, with an IC50 value 
of 0.015±0.001 mg ml'', was 5 times more potent than the steam distilled oil, while anti- 
BuChE activity, with an IC50 value of 0.06f0.003mg ml'', was only apparent in the cold 
extracted oil. 
In contrast, variations in a ratio of major and minor constituents of S. fruticosa (8/02) oil 
resulted once again in favour of Phytosol A oil. Thus, the steam distilled oil did not 
inhibit human BuChE, whereas the Phytosol extracted oil had an IC50 value within the 
175 
General discussion 
theraputical rage of concentrations. In addition, anti-AChE activity of the latter was two 
times more potent. 
These examples demonstrate that the low boiling temperature of Phytosol A may 
prevent hydrolysis and thermolysis of active molecular species during the extraction 
process. It should also be pointed out that there is a possible artefact which can occur 
from the modification of labile materials undergoing chemical changes as a result of the 
drying or extraction processes (Tyler, 1994). These changes may be brought about by 
the mechanical disruption of the plant tissues freeing enzymes, normally existing within 
strictly defined, often membrane bound regions of the cytoplasm (Stryer, 1988), which 
can act upon various substrates in a random fashion. This may produce materials not 
normally present in the living plant. Furthermore, a slight change in the extraction 
process could result in an extract containing novel or batch-exclusive molecules which 
may alter the extract's behaviour when assayed for biological activity. 
Extraction of Salvia species with Phytosol A provided extracts with major chemicals 
which have never been reported to be present in the genus (Chapter 4). The study also 
showed that these extracts are a potential source of isolation of single unknown 
compounds with activities relevant to treatment of dementia. 
176 
General discussion 
8.4. Recommendations for further research 
Further research into Salvia species as a source of materials for dementia therapy would 
need to take the following points into consideration. 
1. Prospective treatment of dementia is likely to be based on a multiple drug therapy, 
hence screening and standardisation of extracts with activities relevant to dementia 
therapy is vital. Standardised active fractions/extracts targeting both cholinesterases, 
cholinergic acetylcholine receptors, pro-inflammatory cytokines, secretases, protein 
phosphatase 1 and reactive oxygen species may be amalgamated in order to study a 
synergetic effect of its combination(s). For example, a standardised fraction with anti- 
BuChE activity, comprising a known number of synergistically interactive molecules, 
may be combined with a standardised fraction expressing nicotinic receptor ligand 
binding properties. If such combination remains synergistically interactive further 
fractionation (standardisation) of the latter may thus be warranted. 
2. In vitro and in vivo experiments are needed to ascertain potential synergistic effect of 
extracts with anti-cholinesterase activity and the licensed drugs (cholinesterase 
inhibitors) used in the treatment of AD. A positive interaction within these 
combinations may reduce doses of the prescribed drugs needed and therefore their 
undesirable side-effects. 
3. It would be interesting to conduct in vivo experiments designed to monitor TNF-a 
secreting activity after administration of extracts with dual anti-cholinesterase activity in 
healthy and demented subjects. A reduced level of the pro-inflammatory cytokine would 
indicate at a possible neuroprotective effect of such inhibitors. This may be achieved by 
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measuring a level of cytokines in the blood before and after administration of the 
extracts. 
4. Phytosol A may be recommended for isolation of single compounds from non- 
scented plants. The solvent can also be used for isolation of polar plant constituents if 
combined with a polar co-solvent. The extraction of polar compounds (fractions) may 
proceed this way; 
1. Plant material (PM) + Phytosol A »> PM1 + extract (extract for analysis) 
2. PM1 + Phytosol A in a combination with a polar solvent (PS) »> PM2 + extract 
(extract for analysis) 
3. PM2 + Phytosol A and PS »> PM3 + extract (extract for analysis) 
4. PM4 + extract 
Changing physical parameters, such as temperature, percentage of co-solvent and the 
intensity of vortex, during the extraction process may also be recommended for the 
purpose of better process standardisation. A residue which appears to be a part of the 
most extracts may be used as a source of isolation of new single molecules. 
6. Phytosol A extracts showed to be more superior to steam distilled oils for anti-ChEs 
activity, especially towards inhibition of BuChE. A comparative analysis of a chemical 
composition of these extracts and their anti-ChEs activity did not allow identification of 
a chemical fingerprint which would explain such superiority. Hence, more comparative 
analyses of these two methods are needed in order to evaluate a link between the 
bioactivity and a chemical profile of the extracts. 
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8. As a ratio of G1 and G4 forms of AChE changes during AD it is of an interest to 
analyse Salvia extracts for their selectivity. Preferentiality towards inhibition of the Gl 
form (remains unchanged in AD) thus would be more desirable, although galanthamine 
and donepezil are not selective for any forms. 
9. The ethnopharmacological approach to screening plants for useful therapies for 
dementia is supported in this study and could be extended to other plant species. 
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Appendix 1. 
Salvia database 
The database is recorded on the attached CD disk. It includes botanical descriptions of 
the species. plant images, and abstracts/articles on their reported bioactivities and/or 
chemical compositions. (nss64; Velevas3 1) or visit w, ýkw. ncl. ac. uk/meclplant 
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Database of active principals of Salvia species 
The database is recorded on the attached CD disk. It includes a chemical structure of 
molecules (or a link to a website for identification of' a chemical structure) and 
abstracts/articles on their bioactivities. 
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Appendix 2. Kinetic Studies 
2.1. Determination of kinetic constants for the inhibition of butyrylcholinesterase 
by oils of sage 
In order to determine a limiting value of initial enzyme velocity (Vmax) and the 
equilibrium constant of the reversible combination of' ßuChl? with its substrate, 
Michaelis constant (Km), a Lineweaver-Burk plot (l, ineweavcr and Burk, 1914) was 
used (Figure 2.1). 
Control (BuChE) 
80 
c 60 y0.8012x+21.425 
N" R2 = 0.9963 
40 
20 
0 
-30 -15 0 15 30 45 60 75 
1/S(MM) 
Figure 2.1. Lineweaver-Burk plot shows a reciprocal of the change in absorbance per 
minute versus acetylcholine concentration in the absence of inhibitor. Fach point on the 
graph is a mean of eight experimental values (n=8). 
To calculate Km and Vmax of the enzyme a following equation was used, i. e., 
Y=0.8012X+21.425 (Figure 2.1. ) where Y is IN and X is 1/S. The intercept on the 
ordinate (Y) is the reciprocal of 1/Vmax, whereas the intercept on the abscissa (X) gives 
the reciprocal of -I/Km. It may be noticed that the intercept on the ordinate would only 
take place when X=0 and the intercept on the abscissa when Y 0. 
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Hence, 
if Y=O, X=-26.74 or X=-1/-26.74=0.037 or Km=0.037 mM. 
if X=O, Y=21.425 or Y=1/21.425 or Vmax=0.047 abs mini 1. 
Since the extinction coefficient of the yellow anion is known (Ellman, 1959), Vmax 
value of 0.047 abs min' may be converted into internationally recognised units of 
enzyme velocity, namely molar per minute (M min 1) (Lowry and Passonneau, 1972). 
Equation 1.1, derived from the Beer-Lambert law, has been used for calculation of the 
rates of hydrolysis (Ellman et al., 1961). 
AAminlxVt 
Rates (M min-) = (1.1) 
ext 
Where 
Rates = amount of substrate hydrolyse per minute, velocity 
AA min 1= absorbance per minute = 0.047 
Vt = total volume of reaction mixture, L=0.00022 
e= extinction coefficient = 13600 M"1 cm -1 (Ellman, 1959) 
C= path length, cm = 0.6 (a distance that the light travel through the reaction mixture 
with a total volume of 0.00022 litre) 
0.047x0.00022 
Rates (M min )==0.0000000013 
13600x0.6 
1.3x109Mmin'= 1.3 nMminl 
Thus, the dissociation constants Km and Vmax for BuChE are 0.037 mM and 1.3 nM 
miri-1 respectively. 
xxv 
Appendix 2. Kinetics 
Lineweaver-Burk plot was also used to determine the dissociation constants (Km and 
Vmax) and a type of inhibition of oils of S. apiana, S. officinalis var. purpurea and S. 
fruticosa, while Dixon's plot (Dixon, 1953) and its re-plot described by Dixon and 
Webb (1979) were adopted for the determination of competitive and un-competitive 
enzyme inhibitor constants respectively. 
Two concentrations of S. apiana oil were used to analyse changes in Km and Vmax 
values of the enzyme-substrate complex (Figure 2.1. ). Table 2.1 demonstrates an 
increase in Km values but a decrease in Vmax values when a concentration of the 
inhibitor rises, while Figure 2.1 shows that convergence of the reciprocals is above 
abscissa. According to Engel (1981) and Cornish-Bowden and Wharton (1988) these 
facts characterise general non-competitive (mixed) type of inhibition of BuChE by the 
oil, which is simultaneous occurrence of competitive and un-competitive inhibition. A 
non-competitive inhibitor (i) can bind to both enzyme (e) and enzyme-substrate (es) 
complex. Figure 2.1 reflects a case when the inhibitor-enzyme-substrate constant (Kies) 
of un-competitive binding is more than the inhibitor-enzyme constant (Kie) of 
competitive binding, Le., Kies>Kie. 
Figure 2.3 shows a graphical method for determination of Kie value (Dixon, 1953) of S. 
apiana oil. The value of 0.025 mg ml"' was read off directly of the plot. In the case of 
mixed inhibition, Dixon's plot can not be used for determination of Kies, whereas a plot 
of S (substrate concentration)xV"1 (absorbance per minute) against inhibitor 
concentrations (I) is appropriate (Dixon and Webb, 1979). Figure 2.4 demonstrates a 
graphical method for determination of Kies value. The value of 0.05 mg ml" was 
obtained directly from the graph. Thus, the un-competitive inhibitor constant of the oil 
is more than the competitive one, i. e., 0.05 mg ml-1 > 0.025 mg ml4. 
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S. apiana oil 
400 
350 
y=4.382x+54.97 
2 300 
E 250 
200 y=2.6812x+39.194 
150 " II]=0 
100 
50   [I]=0.08 
mg/ml 
-20 0 20 40 60 80 A [I=0.1 
1/S (MM) mg/ml 
Figure 2.2. Lineweaver-Burk plot shows reciprocals of the change in absorbance per 
minute versus butyrylcholine concentration in the absence and presence of two inhibitor 
concentrations of S. apiana oil. Each point on the graph is a mean of eight experimental 
values (n=8). 
Table 2.1. Effect of S. apiana oil on the dissociation constants 
Inhibitor, 
mg ml'1 Km, mM Vmax, nM min 
[I]=0 (control) 0.037 1.3 
[I]=0.08 0.068 0.7 
[I]=0.1 0.08 0.5 
aThe apparent constants were calculated using linear equations of reciprocals from 
Figure 2.1 Km values increase but Vmax decrease when the inhibitor concentrations 
rise. 
Dissociation constants a 
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Determination of the kinetic constants of oils of S. officinalis var. purpurea (Figure 2.5; 
Table 2.2) and S. fruticosa (Figure 2.6; Table 2.3) were carried out in the same way as 
described in the example of S. apiana oil. 
Determination of Kie for S. apiana oil 
c 
N 
m 
fC 
" [S]=0.5 mM 
[S]=0.06mM 
I, mg/ml 
Figure 2.3. Dixon's plot. Determination of competitive inhibition constant for S. apiana 
oil. If the absorbance per minute"' is plotted against inhibitor concentrations, at two 
constant substrate concentrations, two straight lines are obtained with a point of 
intersection on the left of the vertical axis above abscissa. Projection of this point on the 
horizontal axis provides Kie value, which can therefore be read off directly. Each point 
on the graph is a mean of eight experimental values (n=8). 
Determination of Kies for S. apiana oil 
25 
C 20 
15 " 
[S]=0.5 mM 
A 
f [S]=0.06 mM 
/5 
-0.05 -0.025 _5 
9 0.025 0.05 0.075 
I, mg/ml 
Figure 2.4. Determination of un-competitive inhibition constant for S. apiana oil. At 
two constant substrate concentrations, two straight lines intersects at a point below the 
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abscissa, if Kies>Kie. Projection of this point on the abscissa provides Kies value, 
which can therefore be read off directly. Each point on the graph is a mean of eight 
experimental values (n=8). 
S. officinalis var. purpurea oil 
300 
250 Y=2.9467x + 55.786 
C 
E 200 
150 
y=1.313l x+ 30.592 
100- 
59,00 f [I]=0 
[I]=0.015 mg/ml 
-25 -10 5 20 35 50 65 80 
1/S (MM)   
[I]=0.0075 mg/ml 
a. Lineweaver-Burk plot shows reciprocals of the change in absorbance per minute versus 
butyrylcholine concentration in the absence and presence of two inhibitor concentrations. 
Determination of Kie for S. officinalis var. 
purpurea oil 
Determination of Kies for S. officinalis var. purpurea 
oil 
100 
75 
9 
50 4 
IS]=0.5 mm 
  [S]=0.06 mM 
-0.03 -0.015 0 0.015 0.03 
I. mg/ml 
b. Determination of a competitive inhibitor 
constant 
25 
20 
15 
:, " (S) 0.5 mM 
" (S1 0.06 mM 
E 
-0 "0.02 5 0.02 
I, mg/ml 
c. Determination of an un-competitive inhibitor 
constant 
Figure 2.5. Determination of the dissociation and inhibitor constants for S. officinalis 
var. purpurea oil. Each point on the graphs is a mean of eight experimental values (n=8). 
a). Lineweaver-Burk plot shows a non-competitive type of inhibition of BuChE by the 
oil, Le., Kies>Kie. Km values increase but Vmax values decrease when the inhibitor 
concentrations rise (Table 2.2). Intersection of the reciprocals is above abscissa. b). The 
competitive inhibitor constant (Kie) of 0.015 mg ml" was read directly off the graph. c). 
xxix 
Appendix 2. Kinetics 
The un-competitive inhibitor constant (Kies) of 0.033 mg ml" was also obtained 
directly off the graph. 
Table 2.2. Effect of S. officinalis var. purpurea oil on the dissociation constants 
Inhibitor, Dissociation constants a 
mg m-1 Km, mM Vmax, nM min 
[I]=0 (control) 0.037 1.3 
[I]=0.0075 0.043 0.86 
[I]=0.015 1 0.053 1 0.5 
aThe apparent constants were calculated using linear equations of reciprocals from 
Figure 2.5(a) and Equation I. I. Km values increase but Vmax decrease when the 
inhibitor concentrations rise. 
S. fruticosa oil 
Cc E 
Cl) 
.n m 
3.0231x + 54,348 
2.123x + 41.418 
0 (Ij=) 
[Ij=0.02 
mg/ml 
[i=0.01 
mg/ml 
a. Lineweaver-Burk plot shows reciprocals of the change in absorbance per minute versus 
butyrylcholine concentration in the absence and presence of two inhibitor concentrations 
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Determination of Kie for S. fruticosa oil 
.. 100- 
75-   [SI=0.5 
50 mM 
[S]=0.06 
mm 
-0.02 -0.01 0 0.01 0.02 0.03 
(mg/ml) 
b. Determination of a competitive inhibitor 
constant 
Figure 2.6. Determination of the dissociation and inhibitor constants for S. fruticosa 
oil. Each point on the graphs is a mean of eight experimental values (n=8). a). 
Lineweaver-Burk plot shows a non-competitive type of inhibition of BuChE by the oil, 
Le., Kies>Kie. Km values increase but Vmax values decrease when the inhibitor 
concentrations rise (Table 2.3). Intersection of reciprocals is above abscissa. b). The 
competitive inhibitor constant (Kie) of 0.016 mg ml" was read directly off the graph. c). 
The un-competitive inhibitor constant (Kies) of 0.022 mg ml'' was also obtained 
directly off the graph. 
Table 2.3. Effect of S. fruticosa oil on the dissociation constants 
Determination of Kies for S. fru icosa oil 
30 
25 
20 " (S]=0.5 mM 
15 
>  [S]=0.06 mM 
5 
-0.25 -0.0125 -5 0.0125 0.025 
I, mg/ml 
c. Determination of an un-competitive inhibitor 
constant 
Inhibitor, Dissociation constants a 
mg ml', Km, mM Vmax, nM min 
[I]=O (control) 1 0.037 1 1.3 
[I]=0.01 0.051 0.65 
[I]=0.02 0.056 0.5 
apparent constants were calculated using linear equations of reciprocals from 
Figure 2.6(a) and Equation 1.1. Km values increase but Vmax decrease when the 
inhibitor concentrations rise. 
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2.2. Determination of kinetic constants for the inhibition of acetyicholinesterase 
by oils of sage 
Determination of the kinetic constants of oils of S. apiana, S. corrugate, S. officinalis 
var. purpurea and S. fruticosa were carried out as described above, section 2.1. 
S. apiana oil 
1200 
1000 
800 
600 
400 
200 
4.722x + 52.995 
[I]=o 
[I]=0.1 mg/ml 
[I]=0.025 mg/ml 
3.6073x + 31.08 
2.8188x + 28.139 
a. Lineweaver-Burk plot shows reciprocals of the change in absorbance per minute 
versus acetylcholine concentration in the absence and presence of two inhibitor 
concentrations 
Determination of Kie for S. apiana oil 
200 
S 
N 150 
f [S]=0.06 mM 
100 
" [S]=0.5 mM 
> 50 
-0.05 0 0.05 0.1 
I, mg/ml 
b. Determination of a competitive inhibitor 
constant 
Determination of Kies for S. aplana oil 
40 
30 
" (Sj 0. b 
> 20 mm 
2" 
m]=0.08 M 
CO 
-0.2i-0.1 _10 0.1 
I, mg/ml 
c. Determination of an un-competitive 
inhibitor constant 
Figure 2.7. Determination of the dissociation and inhibitor constants for S. apiana oil. 
Each point on the graphs is a mean of eight experimental values (n=8). 
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a). Lineweaver-Burk plot shows a non-competitive type of inhibition of AChE by the 
oil, i. e., Kies>Kie. Km values increase but Vmax values decrease when the inhibitor 
concentrations rise (Table 2.4. ). Intersection of the reciprocals is above abscissa. b). The 
competitive inhibitor constant (Kie) of 0.025 mg ml-1 was read directly off the graph. c). 
The un-competitive inhibitor constant (Kies) of 0.125 mg ml" was also obtained 
directly off the graph. 
Table 2.4. Effect of S. apiana oil on the dissociation constants 
Inhibitor, Dissociation constants a 
mg MI" Km, mM Vmax, nM min 
[I]=0 (control) 1 0.1 1 0.97 
[I]=0.025 0.12 0.86 
[I]=0.1 0.28 0.5 
aThe apparent constants were calculated using linear equations of reciprocals from 
Figure 2.7(a) and Equation I. I. Km values increase but Vmax decrease when the 
inhibitor concentrations rise. 
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S, corrugata oil 
300 1 y=3.5x + 34.52 
c 250 y=3.14x + 29.51 
E 
U) 
200 - " [9=0 150- 
100 - A [I]=0.01 
Ir- 50 - mg/ml 
  [f]=0.0025 
-10 10 30 50 70 mg/ml 
1/S (mM) 
a 
Determination of Kie for S. corrugata 
oil 
1001 
c 80 
60 " [S]=0.5 mM 
" S=006mM 
-0.02 -0.01 0 0.01 0.02 
b 
i, mg/rd 
Figure 2.8. Determination of the dissociation and inhibitor constants for S. corrugata oil. 
Each point on the graphs is a mean of eight experimental values (n=8). 
a). Lineweaver-Burk plot shows a non-competitive (simple) type of inhibition of AChE 
by the oil, i. e., Kies=lie (Engel, 1981). Km values are unchanged but Vmax values 
decrease when the inhibitor concentrations rise (Table 2.5). Convergence of the 
reciprocals is on abscissa. b). The competitive inhibitor constant (Kie) of 0.018 mg ml" 
was read directly off the graph. 
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Table 2.5. Effect of S. corrugata oil on the dissociation constants 
Inhibitor, Dissociation constants 8 
mg ml'1 Km, mM 1 Vmax, nM miii 
[I]=0 (control) 1 0.1 0.97 
[I]=0.0025 1 0.1 1 0.9 
[I]=o. o 1 0.1 1 0.78 
apparent constants were calculated using linear equations of reciprocals from 
Figure 2.8(a) and Equation I. I. Km values are unchanged but Vmax values decrease 
when the inhibitor concentrations rise. 
According to Engel (1981) oil of S. corrugate showed a non-competitive (simple) type 
of inhibition of AChE, namely the competitive inhibitor constant is equal to the un- 
competitive one (Figure 2.8. ). Oil of S. officinalis var. purpurea showed a competitive 
type of inhibition of AChE, i. e., the inhibitor combines only with the enzyme but not 
with the enzyme-substrate complex (Figure 2.9. ). Oils of S. apiana (Figure 2.7. ) and S. 
fruticosa (Figure 2.10. ) had a non-competitive (mixed) type of inhibition, i. e., Kies>Kie. 
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S. officinalis var. purpurea oil 
400 - 
C 
E N 
.0' f0 
a 
v=4.9x+27.5 
f=3.22x + 27.97 
  [U=0.02 mg/ml 
" [q=0 
" [IJ=0.005 mg/ml 
Determination of Kie for S. officinalis var. purpurea oil 
100 1 
C 
E 
U) 
ca 
" [S]=0.06 mM 
" [S]=0.5 mM 
-0.05 -0.04 -0.03 -0.01 0 0.013 0.025 
I, mg/ml 
b 
Figure 2.9. Determination of the dissociation and inhibitor constants for S. officinalis 
var. purpurea oil. Each point on the graphs is a mean of eight experimental values (n=8). 
a). Lineweaver-Burk plot shows a competitive type of inhibition of AChE by the oil 
(Engel, 1981). Km values increase but Vmax values are unchanged when the inhibitor 
concentrations rise (Table 2.6. ). Convergence of the reciprocals is on ordinate axis. b). 
The competitive inhibitor constant (Kie) of 0.048 mg ml" was read directly off the 
graph. 
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Table 2.6. Effect of S. officinalis var. purpurea oil on the dissociation constants 
Inhibitor, Dissociation constants a 
mg m1'' Km, mM Vmax, nM miri 
[I]=0 (control) 0.1 0.97 
[I]=0.005 0.11 0.97 
[I]=0.02 0.2 0.97 
aThe apparent constants were calculated using linear equations of reciprocals from 
Figure 2.9(a) and Equation I. I. Km values increase but Vmax values are unchanged 
when the inhibitor concentrations rise. 
S. frvticosa 
600 
500 
C 
E 400 
to 300 
> 200 
100 
-10 10 30 50 
1/S (MM) 
y=7.42x + 53.02 
y=4.2x + 33.945 
" [I]=0 
  [I]=0.08 
mg/ml 
70 
A [[]=0.02 
mg/ml 
a. Lineweaver-Burk plot shows reciprocals of the change in absorbance per minute versus 
acetylcholine concentration in the absence and presence of two inhibitor concentrations 
Determination of Kie for S. fruticosa Determination of Kies for S. fruticosa oil 
200- 
150- 
[S]=0.5 
100 mM 
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mM 
-0.1 -0.05 0 0.05 0.1 
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b Determination of a competitive inhibitor 
constant 
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35 
" [S]=0.5 
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c Determination of an un-competitive 
inhibitor constant 
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Figure 2.10. Determination of the dissociation and inhibitor constants for S. fruticosa oil. 
Each point on the graphs is a mean of eight experimental values (n=8). 
a). Lineweaver-Burk plot shows a non-competitive type of inhibition of AChE by the 
oil, i. e., Kies>Kie. Km values increase but Vmax values decrease when the inhibitor 
concentrations rise (Table 2.7. ). Intersection of the reciprocals is above abscissa. b). The 
competitive inhibitor constant (Kie) of 0.043 mg ml"' was read directly off the graph. c). 
The un-competitive inhibitor constant (Kies) of 0.093 mg ml" was also obtained 
directly off the graph. 
Table 2.7. Effect of S. fruticosa oil on the dissociation constants 
Inhibitor, 
mg ml'1 
Dissociation constants a 
Km, mM Vmax, nM min 
[I]=O (control) 1 0.1 1 0.97 
[I]=0.02 0.12 0.78 
[I]=0.08 0.14 0.51 
apparent constants were calculated using linear equations of reciprocals from 
Figure 2.10(a) and Equation 1.1. Km values increase but Vmax values decrease when 
the inhibitor concentrations rise. 
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Appendix 3. Chemical composition of Salvia species extracted via Phytosol A 
Appendix 3 consists of a chemical composition of extracts of Salvia species obtained 
via the supercritical cold extraction process using Phytosol A. 
Table 3.1. Chemical composition of extracts of Salvia species within thirty and one 
hundred days of storage time 
S. apiana, S. fruticosa, S. officinalis S. corrugata 
% in oils % in oil" var. purpurea, % in oil° 
%inoil' 
Compounda Eý "a N u) d d 30 days 30 days 
0ö 0 ö 
a-pinene 12.39 2.7 0.8 0.8 0.8 --- --- 
Camphene 13.01 2.2 1.5 3.4 2.2 1.8 --- 
ß-pinene 14.24 3.5 2.7 --- 0.7 4.2 --- 
3-carene 15.63 2.3 1.9 --- --- --- --- 
Benzene, 1-methyl-2-(1- 16.32 1.4 0.4 1.0 --- --- --- 
methylethyl) 
Unidentified 16.4 --- 2.2 --- --- --- --- 
D-Limonene 16.46 5.0 --- 3.8 2.5 --- 
1,8-Cineole 16.59 34.4 32.6 12.5 13.6 --- --- 
1,4-Cyclohexadiene, 1- 17.73 0.6 0.5 --- --- --- 
methyl-4-(1-methylethyl) 
Terpineol, 2 beta 18.04 -- 0.5 
(+)-4-carene 18.92 0.8 --- --- --- --- 
Cyclohexene, 1-methyl-4- 18.95 --- 0.5 1.5 1.4 --- --- 
(1-methylethylidene) 
Thujone 19.23 --- --- --- --- 6.1 --- 
Camphor 21.09 38.6 38.5 60.8 58.5 4.4 --- 
Bicyclo[3.3.1]heptan-3- 21.74 --- --- --- --- 1.6 --- 
one, 2,6,6-trimethyl 
Borneol 21.93 0.6 2.3 1.6 1.8 --- --- 
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Bicyclo[2.2.1]heptan-2-ol 26.27 0.9 1.2 1.9 2.3 2.0 --- 
1,7,7-trimethyl, acetate 
(1 S-endo) 
Copaene 29.33 -- --- --- -- 1.4 --- 
1H-Cycloprop[e]azulene, 30.44 --- --- --- --- 1.2 
I a, 2,3,4,4a, 5,6,7b-octa- 
hydro- 1,1,4,7-tetramethyl, 
[laR-(laa, 4a, 4aß, 7ba)] 
Caryophyllene 30.76 0.5 0.7 7.4 9.8 4.1 --- 
[+]-Epi-bicyclosesqui- 31.1 --- --- --- --- 1.7 
phellandrene 
1H-Cycloprop[e]azulene, 31.39 -- --- 1.5 1.8 2.8 --- 
decahydro-1,1,7-trimethyl 
-4-methylene-, (1 a, a) 
a-caryophyllene 31.84 --- --- --- --- 46.5 
1H-Cycloprop[e]azulene, 32.07 --- --- --- --- 1.1 --- 
decahydro-1,1,7-trimethyl 
4-methylene-, (1 aR-[ I aa, 
4aß, 7a, 7aß, 7ba)] 
Naphthalene, 1,2,3,4,4a, 5, 32.54 --- --- --- --- 3.6 --- 
6,8a-octahydro-7-methyl- 
4-methylene-l-(1-methyl- 
ethyl)-, (la, 4aa, 8aa)- 
1H-Cycloprop[e]azulene, 33.13 --- --- 0.8 1.0 3.2 --- 
1 a2,3,5,6,7,7a, 7b octa- 
hydro -1,1,4,7-tetramethyl 
[1 aR-(1 a. a, 7a, 7aß, 7b. a)] 
a-muurolene 33.3 --- --- --- --- 2.0 --- 
Cyclohexene, 1-methyl-4- 33.45 0.6 0.8 --- --- 
(5-methyl-l-methylene-4- 
hexenyl)-, (S) 
Naphthalene, 1,2,3,4,4a, 5, 33.69 -- -- --- --- 1.6 --- 
6,8 a, octahydro-7-methyl- 
4-methylene-l-(1-methyl 
ethyl)-, (Ia, 4aß, 8aa) 
Cyclohexanol, 3-ethenyl- 33.86 2.1 2.3 --- --- --- --- 
3-methyl-2-(1-methyleth- 
enyl)-6-(1-methylethyl)-, 
[IR-(la, 2a, 3ß, 6a)] 
Naphthalene, 1,2,3,5,6,8a- 33.96 0.8 0.6 0.6 0.8 5.1 --- 
hexahydro-4,7-dimethyl- 
1-(methylethyl)-, (1 S-cis) 
Unidentified 34.04 -- 1.7 --- --- --- --- 
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Caryophyllene oxide 35.78 --- --- --- 1.1 --- --- 
Guaiol 36.16 --- --- 1.0 1.2 --- --- 
a-bisabolol 38.61 --- 0.9 --- --- --- --- 
Unidentified 38.82 --- 3.8 --- --- --- 
Unidentified 54.89 -- -- --- --- 2.9 
Squalene 63.26 --- --- --- --- --- 2.3 
Unidentified 63.97 --- --- --- --- --- 0.8 
Unidentified 71.15 --- -- --- --- --- 20.6 
Unidentified 71.32 --- --- --- --- --- 4.1 
4,4,6a, 6b, 8a, 11,11,14a, - 
octamethyl-14,4a, 5,6,6a, 
6 b, 7,8,8 a, 9,10,11,12,12 a, 
1,14a14b; octadecahydro 
2H-picen-3-one 
71.44 --- --- --- --- 1.7 
Unidentified 71.64 -- -- --- --- --- 1.0 
Unidentified 71.93 --- --- --- --- --- 0.7 
Unidentified 72.28 --- --- --- --- --- 66.7 
Unidentified 73.97 --- --- --- --- --- 1.0 
Unidentified 74.2 --- --- --- --- --- 1.0 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
`Relative percentage as calculated from a total area of peaks on a basis of 1% of a 
major peak 
dExtracts with no more than 30 days shelf-life. 
fExtracts with 100 days shelf-life 
--- not detected 
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Table 3.2. Chemical composition of extracts of Salvia species with dual anti- 
cholinesterase activity 
% in oilc 
ö ° 
Compounds E 
E t "Z t k. -Z 113 Z 
a-pinene 12.39 2.2 --- --- --- --- 12.4 1.1 2.3 
Camphene 13.01 --- -- --- --- --- 2.5 3.2 4.2 
ß-pinene 14.24 --- --- --- --- --- 1.0 --- 7.8 
Unidentified 14.27 --- 0.7 ___ 
ß-myrcene 14.97 17.6 --- --- --- --- 1.2 __ 
Benzene, 1-methyl- 2-(1- 16.32 --- --- --- --- --- 3.3 --- 
methylethyl) 
D-limonene 16.46 --- --- --- --- --- 6.3 -- 1.6 
Unidentified 16.48 --- --- --- --- --- --- 1.9 --- 
1,8-cineole 16.59 --- --- --- --- --- 16.6 4.6 4.0 
1,4-Cyclohexadiene, 1- 17.73 --- --- --- --- --- 0.7 --- --- 
methyl-4-(1-methylethyl) 
Terpineol, Z-beta 18.1 --- --- --- --- --- 0.6 --- --- 
Cyclohexene, 1-methyl-4- 18.95 --- --- --- --- --- 0.7 
(1-methylethylidene) 
Thujone 19.23 --- --- --- --- --- --- --- 8.0 
Unidentified 20.94 --- --- --- --- --- 3.5 --- 
Camphor 21.09 --- --- --- --- --- 37.7 8.9 16.0 
Bicyclo[3.3.1]heptan-3-one, 21.74 --- --- -- --- --- --- --- 1.1 
2,6,6-trimethyl 
Borneol 21.93 --- --- --- --- --- 1.1 --- -- 
Bicyclo[2.2.1]heptan-2-ol 26.27 --- --- -- --- 1.0 --- 7.4 --- 
1,7,7-trimethyl, acetate (1S- 
endo) 
Bornyl acetate 26.28 --- --- --- --- --- 1.1 --- 2.1 
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Unidentified 26.49 --- --- --- --- --- 5.0 --- --- 
1,5,5-trimethyl-6- 28.02 --- --- --- --- 3.2 --- 1.0 --- 
methylene-cyclohexene 
(+)-4-carene 28.41 --- --- --- --- --- 13.6 --- --- 
a-cubebene 29.32 4.3 4.5 --- --- --- ___ ___ 
Copaene 29.33 --- --- --- --- --- --- 3.5 --- 
Cyclohexane, 1-ethenyl-l- 29.85 --- 1.3 --- --- 2.3 --- 1.5 --- 
methyl-2,4-bis(I -methyl 
ethenyl)-, [1 S-(1 a, 2ß, 4ß)] 
1H-Cycloprop[e]azulene, 30.44 --- --- --- --- --- --- --- 1.1 1 a, 2,3,4,4a, 5,6,7b-octa- 
hydro- 1,1,4,7-tetramethyl, 
[laR-(laa, 4a, 4aß, 7ba)] 
Caryophyllene 30.76 6.6 22.6 --- --- 10.4 1.5 12.7 2.9 
Unidentified 31.00 --- --- --- 2.5 . __ ___ 
1H-cyclopenta(1,3)cyclo- 31.06 --- 2.2 --- --- --- --- 0.3 1.3 
propa[1,2]benzene, 
octahydro-7-methyl-3- 
methylene-4-(1- 
methylethyl)-, [3aS- 
(3aa, 3bß, 4ß, 7a 
y-elemene 31.17 --- --- --- --- 10.0 --- 4.7 --- 
IH-Cycloprop[e]azulene, 31.39 4.6 --- --- --- --- --- 2.0 2.7 decahydro- 1,1,7-trimethyl - 
4-methylene-, (1 a, a) 
a-caryophyllene 31.84 2.9 5.1 --- --- 2.9 0.6 1.2 30.4 
1H-Cycloprop[e]azulene, 32.07 9.7 --- --- --- ___ --- 0.2 _-_ decahydro-1,1,7-trimethyl - 
4-methylene-, (1 aR-[ 1 aa, 
4aß, 7a, 7aß, 7ba)] 
Naphthalene, 1,2,3,4,4a, 5, 32.54 1.4 --- --- --- --- --- 1.4 2.8 6,8a-octahydro-7-methyl-4- 
methylene-l-(1-methyl- 
ethyl)-, (la, 4aa, 8aa)- 
Germacrene D 32.69 --- --- --- --- --- --- 0.4 --- 
1H-cyclopenta[1,3]- 32.71 --- 6.4 --- --- --- --- ___ ___ 
cyclopropa[1,2]benzene, 
octahydro-7-methyl-3- 
methylene-4-(1- 
methylethyl)-, [3aS- 
(3aa, 3bß, 4ß, 7a 
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Eudesma-4(14), 11 diene 32.87 2.4 --- --- --- --- --- 3.1 --- 
lH-Cycloprop[e]azulene, 33.13 --- --- --- --- --- --- --- 2.4 
1 a2,3,5,6,7,7a, 7b octa- 
hydro -1,1,4,7-tetramethyl 
[1 aR (1 a. a, 7a, 7aß, 7b. a)] 
Naphthalene, 1,2,3,4,4a, 5, 33.14 5.8 --- --- --- --- --- 5.7 
6,8a, octahydro-4a, 8-di 
methyl-2-(1 methylethenyl 
[2R-(2a, 4aa, 8aß)] 
Unidentified 33.17 --- --- --- --- 4.6 --- --- 
Unidentified 33.23 --- 1.4 --- --- --- --- --- --- 
Azulene, 1,2,3,5,6,7,8,8a, - 33.44 --- --- --- --- --- --- 0.5 --- 
octahydro-1 , 4-dimethyl-7- (1-methylethenyl)-, [I S- 
1 a, 7a, 8a 
Naphthalene, 1,2,3,4,4a, 5, 33.69 6.0 --- --- --- --- 0.9 1.1 
6,8a, octahydro-7-methyl-4- 
methylene-l-(1-methyl 
ethyl)-, (1a, 4aß, 8aa) 
Cyclohexanol, 3-ethenyl-3- 33.87 4.6 --- --- --- --- --- . -- . -- 
methyl-2-(1-methyleth- 
enyl)-6-(1-methylethyl)-, 
[1R-(la, 2a, 3ß, 6a)] 
Naphthalene, 1,2,3,5,6,8a- 33.96 7.6_ 6.7 --- --- 1.4 3.7 
hexahydro-4,7-dimethyl-l- 
(methylethyl)-, (1 S-cis) 
Unidentified 34.04 2.1 --- --- --- --- --- --- 
Unidentified 34.33 --- --- --- --- --- . -_ 0.8 
Naphthalene, 1,2,4a, 5,6, 34.39 2.0 --- --- --- --- 8a-hexahydro-4,7-dimeth- 
yl-1-(1-methylethyl)-, 
(la, 4a, a, 8a a) 
Unidentified 34.54 --- --- --- --- --- --- 0.8 
Cyclohexanemethanol, 4- 34.72 --- --- --- --- --- --- 1.3 --- 
ethenyl-a, a, 4-trimethyl-3- 
(1-methylethenyl)-, [1 R-(1 a, 
3a, 4 - 
Germacrene B 35.0 --- --- --- --- 0.8 --- 1.0 --- 
Unidentified 35.77 --- --- --. --- --- 1.2 0.8 
Guaiol 36.16 -- --- --- --- --- -- 5.5 --- 
Unidentified 36.22 --- --- --- --- 3.0 --- --- --- 
(3-elemenone 36.35 -- --- --- --- 44.1 --- --- --- 
2-naphthalenemethanol, 37.16 1.7 --- --- --- --- --- --- --- 
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1,2,3,4,4a, 5,6,7-octahydro 
a, a, 4a, 8-tetramethyl-, (2R- 
cis) 
Unidentified 37.4 8.2 --- --- --- --- --- --- 
2-naphthalenemethanol, 
decahydro-a, a, 4a- 
trimethyl-8-methylene, [2R- 
(2a, 4aa, 8ap)] 
37.69 3.7 --- --- --- --- --- --- --- 
2-naphthalenemethanol, 
1,2,3,4,4a, 5,6,8a; 
octahydro-a, a, 4a, 8- 
tetramethyl-, [2R- 
(2a, 4aa, 8aß)] 
37.78 4.6 --- --- --- --- --- 5.8 --- 
Unidentified 38.14 --- --- --- --- 0.8 --- 0.6 --- 
3,7-cyclodecadien-l-one, 
3,7-dimethyl-10-(1- 
methylethylidene)-, (EE)- 
38.96 --- -- --- --- 9.1 --- --- 
Unidentified 41.86 -- --- --- --- --- --- --- 1.6 
Unidentified 42.59 -- 1.3 1.0 --- --- --- 0.3 
Unidentified 43.55 --- --- --- --- --- --- 0.5 --- 
Unidentified 44.14 -- -- --- --- --- --- 0.2 --- 
Unidentified 44.46 --- --- --- --- --- --- 0.3 --- 
IOS, 11S-Himachala-3(12), 
4-diene 
44.59 --- -- --- --- --- --- 0.3 --- 
(E, E)-7,11,15, -trimethyl- 
3-methylene-hexadeca-1, 
6,10,14-tetraene 
44.61 --- 1.2 --- --- __- . __ __. 
Unidentified 45.49 --- 37.1 --- --- --- --- 9.0 --- 
Unidentified 45.85 --- 2.4 --- --- --- --- 
Unidentified 46.21 --- 2.1 --- --- --- --- --- 
Unidentified 47.46 --- --- --- 4.3 --- --- --- 
Unidentified 47.69 --- --- --- 0.6 . -- 
Unidentified 47.91 --- --- --- 23.6 --- --- --- 
Unidentified 48.01 --- --- -- -- --- --- 0.2 --- 
Unidentified 48.29 7.0 --- --- -_ 
Unidentified 48.37 --- --- --- 5.9 --- --- --- --- 
Unidentified 48.62 -- --- --- 2.8 --- 
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Unidentified 49.28 --- --- --- 49.0 --- --- --- 
Unidentified 50.45 -- --- --- --- --- --- 0.2 --- 
Unidentified 53.84 --- --- --- --- --- --- 0.3 --- 
Unidentified 54.89 --- --- --- --- --- --- --- 2.8 
Unidentified 56.46 --- --- --- 3.1 --- --- --- --- 
Heptacosane 60.96 -- --- 2.4 --- --- --- --- --- 
Unidentified 63.25 2.0 --0.8- -- -- --- 0.6 
Squalene 63.26 -- --- 22.1 --- --- --- --- --- 
2,6,10,14,18,22-tetracosa- 
Hexaene, 2,6,10,15,19,23- 
Hexamethyl-, (all-E)- 
63.27 --- --- --- --- 2.7 --- --- --- 
Unidentified 63.30 --- --- --- 1.9 --- --- --- 
Vitamin E 68.32 -- 0.8 --- --- --- --- --- --- 
Unidentified 70.18 -- -- 70.5 --- --- --- --- --- 
Unidentified 70.9 --- -- 1.1 --- --- -- --- --- 
Unidentified 71.47 -- --- 3.1 --- --- -- --- --- 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
`Relative percentage as calculated from a total area of peaks on a basis of 1% of a 
major peak 
--- not detected 
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Table 3.3. Chemical composition of extracts of Salvia species with less apparent dual 
anti-cholinesterase activity 
% in oil' ' 
Compounds ö 
ff Eý ;3 1z ö s ° EI) 1 
S. * ? 
, C13 
Camphene 13.01 --- --- --- 2.0 --- 
Unidentified 15.50 --- --- 0.3 --- --- 0.3 
Unidentified 16.51 --- --- 0.4 --- --- 0.3 
Unidentified 16.62 --- --- 0.5 --- --- --- 
Unidentified 16.92 --- --- 0.3 --- --- 
Unidentified 19.36 -- -- --- --- 1.0 --- 
Unidentified 21.157 --- --- 0.4 --- --- --- 
Unidentified 21.648 --- --- 0.3 -- --- --- 
Bicyclo[2.2.1]heptan-2-ol 26.27 --- --- --- 6.4 
1,7,7-trimethyl, acetate (1 S-endo) 
1,5,5-trimethyl-6-methylene- 28.02 --- --- --- 0.7 --- 
cyclohexene 
Unidentified 27.71 0.8 3.4 --- --- --- --- 
Unidentified 27.73 --- --- 0.7 --- 0.3 0.5 
1,5,5-trimethyl-6-methylene- 28.02 5.3 --- --- --- 1.3 0.8 
cyclohexene 
a-cubebene 29.32 3.2 --- --- 0.3 --- --- 
Copaene 29.33 --- --- --- --- 0.5 --- 
Unidentified 29.62 0.4 --- --- -- 1.6 
Unidentified 29.63 --- --- 1.3 --- 0.7 --- 
Cyclohexane, 1-ethenyl-l-methyl-2, 29.85 3.3 --- 1.8 0.6 1.2 1.0 
4-bis(1-methyl ethenyl)-, [1 S- 
(1 a, 2p, 4R)] 
Caryophyllene 30.76 28.1 23.7 23.8 28.2 24.2 10.3 
xlvii 
Appendix 3. GC/MS analysis 
Unidentified 31.05 --- 1.8 1.2 --- --- --- 
1H-cyclopenta(1,3)cyclo- 
propa[1,2]benzene, octahydro-7- 
methyl-3 -methylene-4-(1- 
methylethyl)-, [3 aS-(3 aa, 3 bß, 4ß, 7a 
31.06 5.8 --- --- 2.4 7.3 3.6 
Unidentified 31.16 --- --- 1.0 --- --- --- 
y-elemene 31.17 -- --- --- 1.8 --- 
Unidentified 31.23 --- --- --- --- 0.8 
Unidentified 31.54 --- --- 0.5 --- --- --- 
Bicyclo[4.4.0]dec-l-ene, 2-isopropyl 
-5-methyl-9-methylene 
31.546 --- --- --- 0.9 3.0 --- 
Unidentified 31.552 2.4 --- --- ._ --- 1.4 
Humulen-(vl) 31.71 --- --- --- 0.3 --- 
a-caryophyllene 31.84 6.5 --- 22.8 7.5 10.2 3.7 
Unidentified 31.843 -- 3.2 --- --- ___ ___ 
1H-Cycloprop[e]azulene, decahydro- 
1,1,7-trimethyl -4-methylene-, (1 aR- 
[laa, 4aß, 7a, 7aß, 7ba)] 
32.07 1.1 --- --- --- --- --- 
Unidentified 32.13 --- --- --- --- . __ 0.7 
Unidentified 32.14 1.1 --- --- 0.5 1.6 --- 
Unidentified 32.322 --- --- --- --- 1.1 
Unidentified 32.56 1.1 --- --- 0.4 -_ 
Germacrene D 32.69 19.0 --- 2.2 --- --- 10.7 
Unidentified 32.699 --- 3.8 --- --- --- --- 
1H-cyclopenta[1,3]- 
cyclopropa[1,2]benzene, octahydro- 
7-methyl-3-methylene-4-(1- 
methylethyl)-, [3aS-(3aa, 3bß, 4p, 7a 
32.71 --- --- --- 6.3 21.0 
Unidentified 33.04 --- --- --- 0.5 0.9 0.8 
Unidentified 33.18 7.1 --- --- --- --- 
Unidentified 33.213 --- 8.7 2.3 1.8 5.2 3.4 
Unidentified 33.442 -- --- 1.6 --- -- 
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Unidentified 33.50 --- --- --- --- 1.1 3.9 
Unidentified 33.603 0.5 
Unidentified 33.683 --- --- --- 0.4 --- 0.6 
Naphthalene, 1,2,3,4,4a, 5, 
6,8a, octahydro-7-methyl-4- 
methylene-l -(1-methyl ethyl)-, 
(1a, 4a(3,8aa) 
33.69 0.5 --- --- 0.4 0.6 --- 
Unidentified 33.943 --- --- 0.4 --- --- 
Unidentified 33.957 --- --- -- --- --- 1.6 
Naphthalene, 1,2,3,5,6,8a- 
hexahydro-4,7-dimethyl-l- 
(methylethyl)-, (1 S-cis) 
33.96 6.8 --- --- --- --- --- 
Naphthalene, 1,2,3,4-tetrahydro-1, 
6-dimethyl-4-(1-methylethyl)-, 
(1 S-cis) 
33.963 --- --- --- 1.1 5.0 --- 
Unidentified 34.51 0.5 1.3 2.1 10.7 
Unidentified 34.54 --- --- --- --- 0.7 --- 
Unidentified 34.96 --- --- --- 0.7 --- 0.6 
Unidentified 35.0 --- -- 0.3 --- --- 
Unidentified 35.79 --- --- 1.9 0.4 --- 1.0 
Unidentified 36.09 --- 1.7 0.5 0.6 0.9 1.1 
Unidentified 36.535 --- --- 1.7 --- --- --- 
Unidentified 37.01 --- --- --- -- -- 0.3 
Unidentified 37.29 --- --- --- 0.9 --- 0.9 
Unidentified 37.55 --- --- --- --- --- 0.3 
Unidentified 37.99 --- --- --- 0.3 --- 0.4 
Unidentified 38.133 --- 6.6 1.1 --- --- 1.4 
Unidentified 38.14 0.5 --- --- --- --- --- 
Naphthalene, 1,6-dimethyl-4-(1- 
methylethyl)- 
38.36 1.6 --- --- 0.6 --- 0.6 
Unidentified 38.365 --- --- --- --- 1.6 --- 
Unidentified 39.424 --- --- 0.6 
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Unidentified 39.75 --- --- --- --- --- 0.3 
Unidentified 41.182 --- -- 0.3 --- --- --- 
Unidentified 41.513 --- --- 0.4 --- --- --- 
Unidentified 42.40 --- --- 0.4 --- --- --- 
Unidentified 42.42 --- 2.1 --- --- --- 0.7 
Unidentified 42.59 -- 8.2 1.7 --- 1.2 --- 
Unidentified 42.734 --- 1.3 --- --- --- --- 
Unidentified 43.20 --- --- 0.7 --- --- 
Unidentified 43.214 --- 3.2 -- --- 0.4 -- 
Unidentified 43.66 -- --- 1.0 --- --- --- 
Unidentified 43.671 --- 5.6 --- -- 0.7 --- 
Unidentified 44.655 --- --- 0.4 0.4 --- --- 
Unidentified 44.78 --- --- 0.7 --- 
Unidentified 45.89 --- 0.4 --- --- 
Unidentified 46.23 -- --- 0.4 --- --- 
Unidentified 47.130 --- 1.6 --- --- --- --- 
Unidentified 48.023 --- --- 0.3 --- --- 
Unidentified 48.751 --- 0.4 --- --- --- 
Unidentified 48.911 -- 5.9 2.5 --- --- --- 
Unidentified 48.92 0.6 --- --- 0.3 0.4 --- 
Unidentified 51.745 --- --- 5.3 --- --- --- 
Unidentified 51.96 --- -- 2.3 
Unidentified 54.69 --- --- 0.5 --- --- --- 
Unidentified 55.78 --- --- 0.9 --- 
Unidentified 57.211 --- 2.1 --- 
Unidentified 58.24 --- --- --- --- 0.3 --- 
Unidentified 58.638 --- 1.9 --- --- --- --- 
Unidentified 60.956 --- 3.0 --- --- --- --- 
Unidentified 63.250 --- 4.1 1.9 --- --- --- 
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Squalene 63.26 _-- 8.8 
Unidentified 63.264 4.8 __ 
Unidentified 66.265 -- --- --- 0.3 --- 
Unidentified 67.71 --- --- 7.2 --- --- --- 
Unidentified 68.19 --- -- --- 0.5 --- 
Unidentified 68.308 --- --- --- 0.4 --- 
Unidentified 68.64 --- --- --- 17.9 --- 
Unidentified 70.355 --- --- 3.3 
Unidentified 72.258 --- 8.0 --- --- "-- --- 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
`Relative percentage as calculated from a total area of peaks on a basis of 1% of a 
major peak 
--- not detected 
Table 3.4. Chemical composition of extracts of Salvia species which did not reach* 
50% inhibition of cholinesterases 
%inoil' 
Compound' 42 Z 
Unidentified 12.39 --- --- 0.3 --- --- 
Unidentified 14.09 --- --- --- --- --- 2.6 
Unidentified 15.484 -- --- --- --- --- 1.1 
Unidentified 15.53 0.5 --- --- --- --- 
Unidentified 16.3 --- -- 0.3 --- -- --- 
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Unidentified 16.04 --- --- --- --- --- 0.6 
D-limonene 16.46 --- --- 1.0 --- --- 0.7 
Unidentified 16.604 --- --- 0.8 --- --- --- 
Unidentified 19.115 --- --- --- --- --- 0.5 
Unidentified 20.68 --- --- --- --- --- 0.7 
Unidentified 21.14 --- --- 1.4 --- --- --- 
Unidentified 21.16 0.4 --- 1.4 --- --- --- 
Unidentified 21.18 --- --- --- --- 0.4 2.2 
Unidentified 21.65 --- --- --- --- --- 2.0 
Unidentified 22.972 --- --- --- --- -- 0.7 
Unidentified 25.187 --- --- --- 7.9 --- --- 
Unidentified 27.23 --- --- --- --- --- 1.5 
Unidentified 27.72 2.0 --- 0.4 --- 0.5 2.8 
Unidentified 28.032 --- --- 1.1 --- 0.8 --- 
Unidentified 28.17 0.8 
Copaene 29.33 --- --- 3.2 2.1 --- --- 
Cyclobuta[1,2: 3,4]dicyclopentene, 
decahydro-3 a-methyl-6-methylene-l- 
(1-methylethyl)-, [1 S-(1 a. 3aa, 3bß, 
6a(3,6b. a) 
29.63 --- --- 3.4 --- 0.4 --- 
Cyclohexane, 1-ethenyl-l-methyl-2, 
4-bis(1-methyl ethenyl)-, [1 S- 
(la, 2R, 4p)] 
29.85 --- 4.5 --- --- 2.0 --- 
Unidentified 30.74 --- --- --- --- 7.5 --- 
Unidentified 30.747 --- --- --- 10.9 --- 
Caryophyllene 30.76 -- 3.4 15.7 --- --- 2.5 
1H-cyclopenta(1,3)cyclo- 
propa[1,2]benzene, octahydro-7- 
methyl-3-methylene-4-(1- 
methylethyl)-, [3 aS-(3 aa, 3 bp, 4p, 7a 
31.06 --- -- 1.3 4.0 3.0 --- 
y-elemene 31.17 --- 0.4 --- --- 
Unidentified 31.55 --- --- 0.9 --- 1.3 --- 
Unidentified 31.83 --- --- --- --- 1.9 --- 
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Unidentified 31.838 --- --- 1.3 2.1 
a-caryophyllene 31.84 --- 0.7 --- --- --- --- 
Unidentified 32.07 0.6 --- --- --- 
IH-Cycloprop[e]azulene, decahydro- 
1,1,7-trimethyl -4-methylene-, (1aR- 
[laa, 4aß, 7a, 7aß, 7ba)] 
32.072 --- --- 0.9 --- _-- 
Unidentified 32.13 --- --- --- --- 0.7 --- 
Naphthalene, 1,2,3,4,4a, 5, 
6,8a-octahydro-7-methyl-4- 
methylene-l-(1-methyl- 
ethyl)-, (la, 4aa, 8aa)- 
32.54 --- --- 4.8 --- --- -- 
Germacrene D 32.69 --- 0.6 2.8 12.2 --- --- 
1H-cyclopenta[1,3]- 
cyclopropa[1,2]benzene, octahydro- 
7-methyl-3-methylene-4-(1- 
methylethyl)-, [3aS-(3aa, 3bß, 4ß, 7a 
32.71 -- --- --- --- 7.9 --- 
Unidentified 33.10 --- --- --- -- 0.8 
Unidentified 31.854 -- --- --- --- --- 2.4 
Unidentified 33.213 3.9 0.8 --- 4.6 --- 4.7 
Unidentif ied 33.227 -- -- 3.0 --- 3.1 --- 
Unidentified 33.501 --- 0.3 --- --- --- 
Unidentified 33.61 --- --- --- --- --- 2.4 
Unidentified 33.695 -- --- 0.3 --- --- 
Unidentified 33.958 -- --- 1.5 1.7 --- 
Naphthalene, 1,2,3,5,6,8a- 
hexahydro-4,7-dimethyl-l- 
(methylethyl)-, (1 S-cis) 
33.96 -- --- --- -_- 1.1 --- 
Unidentified 35.556 --- --- 0.3 --- --- --- 
Unidentified 35.784 --- --- 1.8 -- --- --- 
Unidentified 36.09 --- --- --- --- 0.7 4.4 
Unidentified 36.64 --- -- --- --- --- 1.3 
Unidentified 38.134 3.3 0.4 0.5 --- --- 4.5 
Unidentified 38.145 --- --- --- --- 0.7 --- 
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Unidentified 38.29 --- --- --- --- --- 0.8 
Unidentified 38.373 --- --- --- --- 0.5 --- 
Unidentified 41.39 --- ---- --- --- --- 0.7 
Unidentified 42.40 2.0 --- --- --- --- 1.5 
Unidentified 42.415 --- --- --- --- 0.4 --- 
Unidentified 42.59 1.2 --- 1.5 --- 5.3 6.4 
Unidentified 42.75 1.0 --- --- --- 0.7 
Unidentified 43.09 --- --- --- --- --- 0.5 
Unidentified 43.217 --- --- 0.5 --- 1.8 --- 
Unidentified 43.225 --- --- --- --- --- 2.4 
Unidentified 43.362 ___ ___ 0.6 
Unidentified 43.673 --- --- 0.7 -- 3.1 2.6 
1H-naphthol[2,1-b]pyran, 4a, 5,6, 
6a, 7,8,9,10,1 Oa, 1 Ob-decahydro- 
3,4a, 7,7,10a-pentamethyl-, [4aR 
(4aa, 6a[3,10aa, 10bp)] 
43.88 --- --- --- 2.0 -- 
Hexadecanoic acid, methyl ester 44.78 --- --- --- -- 2.6 0.9 
Unidentified 44.815 --- --- 0.8 --- -_ -- 
Unidentified 45.03 --- --- --- 5.7 --- --- 
Unidentified 45.212 --- --- --- 3.8 --- 
Unidentified 45.489 --- --- 0.3 --- 
Unidentified 45.54 --- --- --- 3.1 --- --- 
Unidentified 45.89 --- --- --- 3.4 --- --- 
Unidentified 46.05 --- --- --- 4.6 --- --- 
Unidentified 46.217 0.9 --- --- --- 
Unidentified 46.38 --- --- --- 5.3 --- --- 
Unidentified 46.54 --- --- --- 12.3 --- 
Unidentified 46.61 --- --- --- --- --- 0.7 
Unidentified 46.99 --- --- --- 4.2 --- --- 
Unidentified 47.062 --- --- --- 5.4 --- --- 
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Unidentified 47.393 --- --- --- 2.8 --- --- 
Unidentified 47.64 1.1 --- --- --- --- 
Unidentified 47.815 --- --- --- --- --- 0.5 
Unidentified 48.12 --- --- --- --- --- 0.5 
Unidentified 48.23 --- --- --- --- --- 0.6 
Unidentified 48.75 1.1 --- 0.9 --- --- --- 
9,15; octadecadienoic acid, methyl 
ester, (Z, Z)- 
48.752 --- --- --- --- 4.4 --- 
Unidentified 48.79 --- --- --- --- --- 1.5 
9,12,15-octadecatrienoic acid, 
methyl ester, (Z, Z, Z)- 
48.90 6.4 --- 7.1 --- 33.8 
Unidentified 48.934 --- --- --- --- --- 7.4 
Unidentified 49.482 --- --- --- --- 0.7 --- 
Unidentified 49.73 0.5 --- --- --- --- --- 
Unidentified 49.85 0.4 --- 
Unidentified 50.26 --- --- --- --- 0.4 --- 
Unidentified 50.41 1.5 --- --- --- --- 
Unidentified 50.43 --- --- --- --- 3.1 --- 
Unidentified 50.48 --- -- 1.8 --- --- 
Unidentified 51.33 --- --- 0.3 --- --- --- 
Unidentified 52.92 0.5 --- --- --- --- --- 
Unidentified 53.22 0.5 -- 0.5 ---- --- 0.7 
Unidentified 53.82 -- --- --- --- 0.4 --- 
Unidentified 54.69 --- --- 0.8 -- --- --- 
Unidentified 56.52 --- --- --- --- --- 1.0 
Unidentified 57.22 1.0 --- 0.9 --- 0.9 2.5 
Unidentified 57.611 --- --- --- 1.7 --- --- 
Unidentified 58.13 0.4 --- -- --- --- --- 
Unidentified 58.170 --- --- --- --- 0.5 0.7 
Unidentified 58.62 --- --- 1.2 --- --- 2.4 
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Unidentified 60.27 -- --- -- --- 0.4 1.7 
Unidentified 60.944 --- --- --- --- 1.4 4.9 
Heptacosane 60.96 3.9 --- 1.0 --- --- --- 
Unidentified 61.79 1.5 --- --- --- --- --- 
Unidentified 62.26 --- -- 2.4 --- --- 
Unidentified 63.06 -- --- 5.8 --- --- --- 
Squalene 63.26 39.7 --- 22.3 --- --- 4.6 
Unidentified 63.264 -- 2.0 --- --- 3.7 -- 
Unidentified 65.64 0.7 --- 0.3 --- --- --- 
Unidentified 67.41 -- 3.4 --- --- --- 
Unidentified 67.60 --- --- --- --- --- 13.0 
Vitamin E 68.32 4.8 --- --- --- --_ -- 
Unidentified 68.37 -- 0.7 --- 
Lup-20(29)-en-3-one 72.27 --- 39.1 --- --- --- --- 
Unidentified 73.24 18.0 --- --- --- . __ --- 
Unidentified 75.43 -- 34.4 
'Identities of compounds determined from mass spectrometry analysis 
bRT-retention time of the compounds 
`Relative percentage as calculated from a total area of peaks on a basis of 1% of a 
major peak 
--- not detected 
*-due to the solubility limit of the extracts 
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Appendix 4. Calculations of concentrations 
I. I. Preparation of inhibitor solutions with any number of agents in a 
combination 
1,8-cineole and camphor combination was taken as an example of how final 
concentrations of individual compounds in a combination may be calculated. The 
calculation was made on a basis of an IC50 value for the whole oil, i. e., 0.05 mg ml" 
and percentage contents of each compound in the whole oil (Chapter 6, Table 6.2. ) 
There are 26.8% of 1,8-cineole and 24.7% of camphor in the S. lavandulaefolia 
essential oil (Chapter 6, Table 6.2. ) 
0.05 mg ml-1 (whole oil IC50 value) - 100% (as a mixture containing all compounds) 
X mg ml'' (camphor) - 24.7% 0.05x24.7/100=0.012 
Y mg ml" (cineole) - 26.8% 0.05 x26.8/100=0.013 
X=0.012 mg ml" (camphor final concentration) 
Y=0.013 mg m1" (1,8-cineole final concentration) 
Thus, final concentrations of 0.012 mg ml-1 camphor and 0.013 mg ml" 1,8-cineole are 
in the naturally occurring ratio. The total final concentration of camphor/cineole mixture 
is 0.025 mg ml-1. To prepare a mixture with an assay final concentration of 0.025 mg 
ml" each of the individual compound stock solutions is needed to be calculated. 
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I. I. I. Calculation of a stock solution for 1,8-cineole (example) 
1 0.013 mg (WO - l000µ1(1,8-cineole final concentration in lml, Vs) 
X mg (Wm) - 220 µl (total volume of the assay mixture, Vt) 
X=0.00286 mg (amount of 1,8-cineole in the assay mixture, Wm) 
Where, 
Wf- amount of inhibitor in the assay final concentration, mg 
Vs-volume of 1 ml to express the amount of inhibitor in the assay final concentration, µl 
Wm-amount of one inhibitor in the reaction mixture, mg 
Vt-total volume of the reaction mixture, µl 
2 0.00286 mg (Wm) -5 µl (volume of 1,8-cineole transferring into the reaction 
mixture, Vp) 
X mg (Wfs) - 300 µl (150 pl of 1,8-cineole and 150 pl of camphor to make the 
final stock solution, V 1, n) 
X=0.1716 mg (amount of 1,8-cineole in 150 µl when taken from its stock 
solution; or amount of 1,8-cineole in the final stock solution of 300 µl, Ws) 
Where, 
Vp- amount of inhibitor transferring into the reaction mixture, µl 
Wfs-amount of inhibitor in the final stock solution of 300 µl, or in 150 µl taken from 
cineole stock solution, mg 
V1-volume of both inhibitors in the final stock solution, µl 
Ws-amount of cineole required to prepare the stock solution in 1 ml, mg 
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3 0.172 mg (Wfs) - 150 µl (volume taken from cineole stock, V1) 
X mg (Ws) - 1000 µl (volume of cineole to make a stock solution, Vs) 
X=1.14 mg (amount of 1,8-cineole needed to make a stock solution of 1 ml) 
Thus, 1.14 mg of 1,8-cineole need to be dissolved within 1 ml 86% EtOH to make a 
stock solution of 1.13 mg ml-1. This would give 1,8-cineole assay final concentration of 
0.013 mg ml-1. This has been calculated for 300 µl of 1,8-cineole/campor stock solution. 
The same principal of calculations may be applied to camphor. Alternatively, the 
calculations of 1,8-cineole final concentration and its stock solution may be simplified 
into mathematical equations; 
(i) Wm=WfxVt/Vs 
Where, 
Wm-amount of 1,8-cineole in the reaction mixture, mg 
Wf- amount of cineole in the assay final concentration, mg 
Vt-total volume of the reaction mixture, µl 
Vs-volume of 1 ml to express the amount of cineole in the assay final concentration, µ1 
(ii) Wfs=WmxVlxn/Vp 
Where, 
Wfs-amount of cineole in the final stock solution of 300 µl, or in 150 µl taken from 
cineole stock solution, mg 
V 1-volume of both inhibitors in the final stock solution, µl 
n-amount of inhibitors in the final stock solution 
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Vp-volume of the final stock solution (cineole/camphor) going into the reaction mixture, 
µl 
(iii) Ws=WfsxVs/V1 
Where, 
Ws-amount of cineole required to prepare the stock solution in 1 ml, mg 
Vs-volume of 1 ml to prepare cineole stock solution, µl 
V1 -volume of one inhibitor taken from the stock into the final stock solution, µl 
Since, Wfs (ii) and Wm (i) are known, amount of 1,8-cineole to make the stock solution 
(Ws) and the final assay concentration (Wf) may be calculated as; 
(iv) Ws=WfxVt/VsxVlxn/VpxVs/V1 
or 
(v) Ws=WfxVtxn/Vp (for stock) 
From (v) Wf is 
(vi) Wf--WsxVp/Vtxn (for final concentration) 
To calculate a stock or a final concentration of a combination comprising any number of 
inhibitors equation (v) and (vi) may be applied respectively. 
Example: cineole final concentration is 0.013 mg ml", Wf 
The assay total volume is 220 ml, Vt 
n=2, two chemicals are needed to make the final stock solution. 
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5 µl from the final stock solution (cineole/camphor) were pipetted into the assay 
reaction mixture, Vp 
The amount of cineole (Ws) required for the stock of 1 ml solution may be calculated as 
in (v): 
Ws=WfxVtxn / Vp, 
Ws=0.013x220x2 / 5=1.14 mg 
1.14 mg of 1,8-cineole is needed to make the stock solution of 1 ml, which would give a 
final assay concentration of 0.013 mg ml-1. 
The same calculations can be applied to camphor. 
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Appendix 5. Calculation of expected inhibition 
An IC50 value of the individual compounds and their standard deviations were 
calculated on a basis of equations (Table V. 1. ) obtained from the dose-response curves 
of these compounds. 
Table V. I. Dose-response curve equations for the monoterpenoids 
Compound 
Cineole 
y=17.429Ln(x)+99.755 y=14.823Ln(x)+90.668 
Camphor 
r 12.31 OLn(x)+36.115 y=15.448Ln(x)+48.176 
a-pinene 
y=20.756Ln(x)+94.952 y=19.891 Ln(x)+96.783 
ß-pinene 
y=19.675Ln(x)+82.108 y=20.976Ln(x)+86.61 
Car. oxide 
n 4d 
y=15.481Ln(x)+95.398 y=15.911Ln(x) 95.366 
y=13.313Ln(x)+39.71 y=12.407Ln(x) 39.282 
y=17.562Ln(x)+93.965 y=18.254Ln(x)+96.282 
y=18.383Ln(x)+76.531 y=19.457Ln(x)+81.564 
y=11.777Ln(x)+56.846 y=11.573Ln(x)+55.552 y=11.8Ln(x)+53.7 y= 12.3 1 Ln(x)+61.8 
Bomeole 
y--6.285Ln(x)+25.251 y=7.31 Ln(x)+23.574 
Bornyl acetate 
y=9.444Ln(x)+36.354 y=10.202Ln(x)+34.911 
Linalool 
y=8.3895Ln(x)+21.125 y=7.56ILn(x)+18.73 
y=8.05Ln(x)+22.544 y=7.822Ln(x)+26.170 
}r9.353Ln(x)+35.112 y=8.234Ln(x)+30.781 
y=8.425Ln(x)+19.172 y=8.117Ln(x)+18.983 
a Equation obtained from a dose response curve produced in triplicate test 1 
b Equation obtained from a dose response curve produced in triplicate test 2 
`Equation obtained from a dose response curve produced in triplicate test 3 
d Equation obtained from a dose response curve produced in triplicate in test 4. 
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The calculation of the expected and observed inhibitions is shown, as an example, using 
the data of 1,8-cineole and a-pinene mixture of 0.245 mg ml"' with 1,8-cineole (da) of 
0.225 mg m1-' and a-pinene (db) of 0.02 mg ml-' (Chapter 6, Table 6.3. ). Figure V. 1 
shows a dose-response curve, as a mean of four (Table V. 1), of each of the compounds. 
100- 
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Figure V. 1. Dose-response curves of 1,8-cineole and a-pinene 
-1,8 cineole dose-response curve, -a-pinene dose-response curve. 
Expected inhibition of the mixture 0.245 mg ml-' (Synergy 6, Table 6.3. ) was 73±2.1%; 
observed 84.5±1.7%, i. e., more than expected, indicating synergy. 
The expected inhibition of AChE by the combination has been calculated as follow, 
For one set of triplicate 
Equations obtained from the dose-response curves of 1,8-cineole and a-pinene are 
Y= 15.481Ln(X)+95.398 and Y=17.562Ln(X)+93.96 respectively (Table V. 1, n3). 
Equation I (Chapter 2) stipulates the zero-interactive respond of the mixture 
da/Da +db/Db= 1 (1) 
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where, 
da- final concentration of 1,8-cineole in the mixture (as one of the compounds of the 
mixture) 
db- final concentration of a-pinene in the mixture (as one of the compounds of the 
mixture) 
Da- individual concentration of 1,8 cineole, which was calculated from its dose- 
response curve equation to satisfy equation 1 
Db- individual concentration a-pinene, which was calculated from its dose-response 
curve equation to satisfy equation 1 
The object of the procedure is to calculate concentrations of 1,8-cineole (Da) and a- 
pinene (Db) that would be isoeffective with the combination (da, db) if the combination 
is zero-interactive. To approximately estimate the expected inhibition of AChE by the 
mixture, 0.225 mg ml-' (da) was substituted as X (concentration) into the cineole 
equation to find Y (inhibition) 
Y=15.481 Ln(O. 225)+95.398 
Y=72, or 72% inhibition 
72% inhibition is a rough estimate of what the combination would be expected to 
produce. This is based on the data (Chapter 6, Table 6.1. ) that camphor showed little 
anti-AChe activity in comparison with 1,8-cineole. 
From now, it is a matter of time to find the expected inhibition of the mixture which 
would satisfy equation 1. 
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Expected inhibition of 73% was randomly chosen as a close figure to 72. Because the 
expected inhibition has an isoeffective quality (Equation 1) it has to intersect both of the 
dose-response inhibition curves (Figure V. 1). 
73% was substituted as Y (inhibition) into 1,8-cineole dose-response equation to find 
corresponding to it 1,8-cineole individual concentration (Da); 
73=15.481 Ln(X)+95.398 
X=0.24 (concentration) or 0.24 mg m1"1 
Now, 73% of expected inhibition was substituted as Y (inhibition) into a-pinene dose- 
response equation to find corresponding to it a-pinene individual concentration (Db); 
73=1 7.5 62 Ln(x)+93.965 
X=0.303 (concentration) or 0.303 mg m1"1 
For 73% of preliminary expected inhibition Da and Db were 0.24 and 0.303 mg ml" 
respectively. If Da and Db are isoeffective (Equation 1), intersecting the two dose- 
response curves with the same horizontal line (Figure V. 1), they would satisfy equation 
(1) namely, 
0.225/Da + 0.02/Db =1 
0.225/0.24 + 0.02/0.303 = 0.937 + 0.066=1 
As Da and Db satisfy equation 1,73% inhibition is accepted as the expected response of 
the combination. 
For the mixture 0.245 mg m1' the expected inhibition is 73% and corresponds to one set 
of triplicates (Table V. 1, n3). 
In the same manner, as described above, equations of three remaining set of triplicates 
nl, n2 and n4 (Table V. 1. ) were used to calculated the mean ±SD of the expected 
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inhibition. For the four sets of triplicates the expected inhibition is 73±2.1% (Chapter 6, 
Table 6.3. ). The observed inhibition of the combination was 84.5±1.7% (Chapter 6, 
Table 6.3. ), i. e., more than we expected (synergy). To calculate Da and Db for the 
observed inhibition in order to show the interaction index of the mixture, 84.5% was 
substituted as Y (inhibition) into 1,8-cineole and a-pinene dose-response curve 
equations. 
Cineole 
Y=15.481 Ln(X)+95.398 
84.5=15.481 Ln(X)+95.398 
X=0.49 or 0.49 mg/ml 
Da=0.49 mg/ml 
a-pinene 
Y=17.562Ln(X)+93.96 
84.5=17.562Ln(X)+93.96 
X=0.58 or 0.58 mg/ml 
Db=0.58 mg/ml 
The interaction index for the observed effect of the combination was calculated as; 
da/Db + db/Db <1 
0.225/Da + 0.02/Db <1 (synergy effect) 
0.225/0.49 + 0.02/0.58 = 0.46 + 0.034 = 0.5 
0.5 <1 (indicating synergy) 
The interaction index of 0.5 was calculated only for one set of triplicates (n3). For all of 
n's (n=4) the interaction index of the combination was 
0.225/0.52+0.02/0.56=0.47 i. e., less than 1, indicating synergy. 
The same approach of calculation of the expected inhibition was applied to the rest of 
the combinations used in this study. 
i 
__ýý. 
Y 
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The calculation of expected inhibition along with results of the observed inhibition may 
be expressed graphically. 
Da, 
1,8-cineole mg m14 
0.52 
0.24 
0.225 
Db, a-pinene, mg ml"' 
Figure V. 2 The isobole for the observed effect of 1,8-cineole/a-pinene 
combination 
The iso-effective linear of the mixture of 0.245 mg m1'1 (cineole 0.225 mg m1" (da) and 
a-pinene 0.02 mg ml-' (db)) is drawn through the point representing the combination 
and it ends on the individual concentration axes, which satisfied Equation 1 for the 
expected inhibition of 73±2.1% (n=4) with Da of 0.24±0.005 mg ml" and Db of 
0.304±0.05 mg ml-1, namely 
0.225/0.240+0.02/0.304=1 
Thus, 0.24 and 0.304 are the points for the iso-effective linear. 
The isobole is drawn through the point representing the combination of 0.245 mg ml" 
and its ends on the individual concentration axes. The individual concentrations for both 
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ends were calculated using 1,8-cineole and a-pinene dose-response curve equations 
(Table V. 1), where observed inhibition of 84.5±1.7% (n=4, ) was assumed as Y and 
substituted into the equations of both chemicals at 0.245 mg ml-1 mixture combination. 
Hence, for cineole X (Da) was 0.52±0.1 mg ml-1 (n=4) and a-pinene (Db) 0.56±0.04 mg 
ml"1(n=4). 
The isobole for the observed effect of inhibition is concave-up and the interaction index 
for the mixture is 0.225/0.52+0.02/0.56=0.47, i. e., less than 1, indicating synergy. 
The values of 0.304±0.05 (representing the iso-effective linear) and 0.56±0.04 
(representing one of the ends of the isobole) locating on camphor concentration axes are 
significantly different (P<0.05), without overlapping itself. The same is refer to the 
values locating on 1,8-cineole concentration axes, namely 0.52±0.1 and0.24±0.005 
(P<0.05). 
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